<!DOCTYPE html>
<html lang="en"     class="pb-page"  data-request-id="774e771c-f9cd-4ad5-9947-cd9a1b9a6d15"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";ctype:string:Journal Content;csubtype:string:Volume Supplement;journal:journal:annonc;pageGroup:string:Article View;article:article:pii\:S0923753419471846;wgroup:string:Migrated Websites;page:string:Show Full Text;issue:issue:pii\:S0923753415X68001;subPage:string:Full Text;website:website:annonc-site;product:product:elsevier\:product\:ha;requestedJournal:journal:annonc"/>




<!-- if there is any customization for Responsive Project widget  -->


























    
    







    
            
        



        
                <meta name="robots" content="noarchive,nocache" />
            
    






    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=1, user-scalable=1"/>











        <meta property="og:title" content="Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†" />
    


        <meta property="og:type" content="Article" />
    


        <meta property="og:url" content="https://www.annalsofoncology.org/article/S0923-7534(19)47184-6/abstract" />
    



        <meta property="og:site_name" content="Annals of Oncology" />
    




        <meta property="og:description" content="Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases
with age and varies considerably across Europe. A family history of lymphoma, autoimmune
disease, human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) seropositivity,
a high body mass as a young adult and some occupational exposures have been identified
as risk factors of DLBCL [2]. In recent years, there have been important survival
improvements for DLBCL in all European regions [3]." />
    











        <meta name="twitter:title" content="Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†" />
    






        <meta name="twitter:description" content="Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases
with age and varies considerably across Europe. A family history of lymphoma, autoimmune
disease, human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) seropositivity,
a high body mass as a young adult and some occupational exposures have been identified
as risk factors of DLBCL [2]. In recent years, there have been important survival
improvements for DLBCL in all European regions [3]." />
    

        <meta name="twitter:card" content="summary_large_image">
    











    
    
            
            
        <link rel="canonical" href="https://www.annalsofoncology.org/article/S0923-7534(19)47184-6/fulltext">
    


<title>Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology</title><meta name="citation_journal_title" content="Annals of Oncology"/> <meta name="citation_journal_abbrev" content="Annals of Oncology"/> <meta name="citation_publisher" content="Elsevier"/> <meta name="citation_title" content="Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†"/> <meta name="citation_date" content="2015/09/01"/> <meta name="citation_volume" content="26"/> <meta name="citation_firstpage" content="v116"/> <meta name="citation_lastpage" content="v125"/> <meta name="citation_pmid" content="26314773"/> <meta name="citation_abstract_html_url" content="http://www.annalsofoncology.org/article/S0923753419471846/abstract"/> <meta name="citation_fulltext_html_url" content="http://www.annalsofoncology.org/article/S0923753419471846/fulltext"/> <meta name="citation_pdf_url" content="http://www.annalsofoncology.org/article/S0923753419471846/pdf"/> <meta name="citation_issn" content="0923-7534"/> <meta name="citation_issn" content="1569-8041"/> <meta name="citation_language" content="English"/> <meta name="citation_doi" content="10.1093/annonc/mdv304"/> <meta name="citation_pmid" content="26314773"/> <meta name="citation_author" content="H. Tilly"></meta><meta name="citation_author_institution" content="Centre Henri-Becquerel, Université de Rouen, Rouen, France"></meta><meta name="citation_author" content="M. Gomes da Silva"></meta><meta name="citation_author_institution" content="Portuguese Institute of Oncology, Lisbon, Portugal"></meta><meta name="citation_author" content="U. Vitolo"></meta><meta name="citation_author_institution" content="A.O. Città della Salute e della Scienza di Torino, Turin, Italy"></meta><meta name="citation_author" content="A. Jack"></meta><meta name="citation_author_institution" content="St James's University Hospital, Leeds, UK"></meta><meta name="citation_author" content="M. Meignan"></meta><meta name="citation_author_institution" content="Henri Mondor University Hospital, Créteil, France"></meta><meta name="citation_author" content="A. Lopez-Guillermo"></meta><meta name="citation_author_institution" content="Hospital Clinic, Barcelona, Spain"></meta><meta name="citation_author" content="J. Walewski"></meta><meta name="citation_author_institution" content="Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland"></meta><meta name="citation_author" content="M. André"></meta><meta name="citation_author_institution" content="CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium"></meta><meta name="citation_author" content="P.W. Johnson"></meta><meta name="citation_author_institution" content="Cancer Research UK, University of Southampton, Southampton, UK"></meta><meta name="citation_author" content="M. Pfreundschuh"></meta><meta name="citation_author_institution" content="Innere Medizin I, Universität des Saarlandes, Hamburg, Germany"></meta><meta name="citation_author" content="M. Ladetto"></meta><meta name="citation_author_institution" content="Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy"></meta><meta name="citation_reference" content="citation_title=Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project; citation_author=M. Sant; citation_author=C. Allemani; citation_author=C. Tereanu; citation_author=et al.; citation_journal_title=Blood; citation_volume=116; citation_firstpage=3724; citation_lastpage=3734; citation_publication_date=2010; "></meta><meta name="citation_reference" content="citation_title=Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project; citation_author=L.M. Morton; citation_author=S.L. Slager; citation_author=J.R. Cerhan; citation_author=et al.; citation_journal_title=J Natl Cancer Inst Monogr; citation_firstpage=130; citation_lastpage=144; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study; citation_author=M. Sant; citation_author=P. Minicozzi; citation_author=M. Mounier; citation_author=et al.; citation_journal_title=Lancet Oncol; citation_volume=15; citation_firstpage=931; citation_lastpage=942; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL; citation_author=G. Ott; citation_author=M. Ziepert; citation_author=W. Klapper; citation_author=et al.; citation_journal_title=Blood; citation_volume=116; citation_firstpage=4916; citation_lastpage=4925; citation_publication_date=2010; "></meta><meta name="citation_reference" content="citation_title=World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues; citation_author=S.H. Swerdlow; citation_author=E. Campo; citation_author=N.L. Harris; citation_author=et al.; citation_publication_date=2008; citation_publisher=IARC, Lyon, France; "></meta><meta name="citation_reference" content="citation_title=EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations; citation_author=A.W. Langerak; citation_author=P.J. Groenen; citation_author=M. Brüggemann; citation_author=et al.; citation_journal_title=Leukemia; citation_volume=26; citation_firstpage=2159; citation_lastpage=2171; citation_publication_date=2012; "></meta><meta name="citation_reference" content="citation_title=A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma; citation_author=G. Wright; citation_author=B. Tan; citation_author=A. Rosenwald; citation_author=et al.; citation_journal_title=Proc Natl Acad Sci USA; citation_volume=100; citation_firstpage=9991; citation_lastpage=9996; citation_publication_date=2003; "></meta><meta name="citation_reference" content="citation_title=Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways; citation_author=G. Lenz; citation_author=G.W. Wright; citation_author=N.C. Emre; citation_author=et al.; citation_journal_title=Proc Natl Acad Sci USA; citation_volume=105; citation_firstpage=13520; citation_lastpage=13525; citation_publication_date=2008; "></meta><meta name="citation_reference" content="citation_title=Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue; citation_author=D.W. Scott; citation_author=G.W. Wright; citation_author=P.M. Williams; citation_author=et al.; citation_journal_title=Blood; citation_volume=123; citation_firstpage=1214; citation_lastpage=1217; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Accurate classification of germinal center b-cell-like/activated b-cell-like diffuse large b-cell lymphoma using a simple and rapid reverse transcriptase-multiplex ligation-dependent probe amplification assay: a CALYM study; citation_author=S. Mareschal; citation_author=P. Ruminy; citation_author=C. Bagacean; citation_author=et al.; citation_journal_title=Mol Diagn; citation_publication_date=2015; "></meta><meta name="citation_reference" content="citation_title=Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray; citation_author=C.P. Hans; citation_author=D.D. Weisenburger; citation_author=T.C. Greiner; citation_author=et al.; citation_journal_title=Blood; citation_volume=103; citation_firstpage=275; citation_lastpage=282; citation_publication_date=2004; "></meta><meta name="citation_reference" content="citation_title=A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy; citation_author=W.W. Choi; citation_author=D.D. Weisenburger; citation_author=T.C. Greiner; citation_author=et al.; citation_journal_title=Clin Cancer Res; citation_volume=15; citation_firstpage=5494; citation_lastpage=5502; citation_publication_date=2009; "></meta><meta name="citation_reference" content="citation_title=Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg Lymphoma Biomarker Consortium; citation_author=D. de Jong; citation_author=A. Rosenwald; citation_author=M. Chhanabhai; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=25; citation_firstpage=805; citation_lastpage=812; citation_publication_date=2007; "></meta><meta name="citation_reference" content="citation_title=MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy; citation_author=K.J. Savage; citation_author=N.A. Johnson; citation_author=S. Ben-Neriah; citation_author=et al.; citation_journal_title=Blood; citation_volume=114; citation_firstpage=3533; citation_lastpage=3537; citation_publication_date=2009; "></meta><meta name="citation_reference" content="citation_title=Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab; citation_author=S. Barrans; citation_author=S. Crouch; citation_author=A. Smith; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=28; citation_firstpage=3360; citation_lastpage=3365; citation_publication_date=2010; "></meta><meta name="citation_reference" content="citation_title=Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma; citation_author=P. Lin; citation_author=T.J. Dickason; citation_author=L.E. Fayad; citation_author=et al.; citation_journal_title=Cancer; citation_volume=118; citation_firstpage=1566; citation_lastpage=1573; citation_publication_date=2012; "></meta><meta name="citation_reference" content="citation_title=Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; citation_author=T.M. Green; citation_author=K.H. Young; citation_author=C. Visco; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=30; citation_firstpage=3460; citation_lastpage=3467; citation_publication_date=2012; "></meta><meta name="citation_reference" content="citation_title=Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; citation_author=N.A. Johnson; citation_author=G.W. Slack; citation_author=K.J. Savage; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=30; citation_firstpage=3452; citation_lastpage=3459; citation_publication_date=2012; "></meta><meta name="citation_reference" content="citation_title=MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma; citation_author=H. Horn; citation_author=M. Ziepert; citation_author=C. Becher; citation_author=et al.; citation_journal_title=Blood; citation_volume=121; citation_firstpage=2253; citation_lastpage=2263; citation_publication_date=2013; "></meta><meta name="citation_reference" content="citation_title=Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification; citation_author=B.D. Cheson; citation_author=R.I. Fisher; citation_author=S.F. Barrington; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=32; citation_firstpage=3059; citation_lastpage=3068; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group; citation_author=S.F. Barrington; citation_author=N.G. Mikhaeel; citation_author=L. Kostakoglu; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=32; citation_firstpage=3048; citation_lastpage=3058; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement; citation_author=A.B. Khan; citation_author=S.F. Barrington; citation_author=N.G. Mikhaeel; citation_author=et al.; citation_journal_title=Blood; citation_volume=122; citation_firstpage=61; citation_lastpage=67; citation_publication_date=2013; "></meta><meta name="citation_reference" content="citation_title=Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study; citation_author=E. Pelosi; citation_author=D. Penna; citation_author=A. Douroukas; citation_author=et al.; citation_journal_title=Q J Nucl Med Mol Imaging; citation_volume=55; citation_firstpage=469; citation_lastpage=475; citation_publication_date=2011; "></meta><meta name="citation_reference" content="citation_title=Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination; citation_author=G. Benevolo; citation_author=A. Stacchini; citation_author=M. Spina; citation_author=et al.; citation_journal_title=Blood; citation_volume=120; citation_firstpage=3222; citation_lastpage=3228; citation_publication_date=2012; "></meta><meta name="citation_reference" content="citation_title=A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project; citation_journal_title=N Engl J Med; citation_volume=329; citation_firstpage=987; citation_lastpage=994; citation_publication_date=1993; "></meta><meta name="citation_reference" content="citation_title=Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial; citation_author=C. Récher; citation_author=B. Coiffier; citation_author=C. Haioun; citation_author=et al.; citation_journal_title=Lancet; citation_volume=378; citation_firstpage=1858; citation_lastpage=1867; citation_publication_date=2011; "></meta><meta name="citation_reference" content="citation_title=Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA; citation_author=O. Fitoussi; citation_author=K. Belhadj; citation_author=N. Mounier; citation_author=et al.; citation_journal_title=Haematologica; citation_volume=96; citation_firstpage=1136; citation_lastpage=1143; citation_publication_date=2011; "></meta><meta name="citation_reference" content="citation_title=Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era; citation_author=M. Ziepert; citation_author=D. Hasenclever; citation_author=E. Kuhnt; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=28; citation_firstpage=2373; citation_lastpage=2380; citation_publication_date=2010; "></meta><meta name="citation_reference" content="citation_title=Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03–1B); citation_author=N. Ketterer; citation_author=B. Coiffier; citation_author=C. Thieblemont; citation_author=et al.; citation_journal_title=Ann Oncol; citation_volume=24; citation_firstpage=1032; citation_lastpage=1037; citation_publication_date=2013; "></meta><meta name="citation_reference" content="citation_title=Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study; citation_author=M. Pfreundschuh; citation_author=A.D. Ho; citation_author=E. Cavallin-Stahl; citation_author=et al.; citation_journal_title=Lancet Oncol; citation_volume=9; citation_firstpage=435; citation_lastpage=444; citation_publication_date=2008; "></meta><meta name="citation_reference" content="citation_title=CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group; citation_author=M. Pfreundschuh; citation_author=E. Kuhnt; citation_author=L. Trumper; citation_author=et al.; citation_journal_title=Lancet Oncol; citation_volume=12; citation_firstpage=1013; citation_lastpage=1022; citation_publication_date=2011; "></meta><meta name="citation_reference" content="citation_title=ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma; citation_author=F. Reyes; citation_author=E. Lepage; citation_author=G. Ganem; citation_author=et al.; citation_journal_title=N Engl J Med; citation_volume=352; citation_firstpage=1197; citation_lastpage=1205; citation_publication_date=2005; "></meta><meta name="citation_reference" content="TLamy, GDamaj, EGyanet al. R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B cell lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02-03 trial from the Lysa/Goelams Group. In: 2014 ASH Annual Meeting, Orlando, Florida. Abstract 393."></meta><meta name="citation_reference" content="citation_title=Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles; citation_author=D. Cunningham; citation_author=E.A. Hawkes; citation_author=A. Jack; citation_author=et al.; citation_journal_title=Lancet; citation_volume=381; citation_firstpage=1817; citation_lastpage=1826; citation_publication_date=2013; "></meta><meta name="citation_reference" content="citation_title=Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002–1); citation_author=N. Schmitz; citation_author=M. Nickelsen; citation_author=M. Ziepert; citation_author=et al.; citation_journal_title=Lancet Oncol; citation_volume=13; citation_firstpage=1250; citation_lastpage=1259; citation_publication_date=2012; "></meta><meta name="citation_reference" content="citation_title=Rituximab dose-dense chemotherapy followed by intensified high-dose chemotherapy and autologous stem cell transplantation (HDC+ASCT) significantly reduces the risk of progression compared to standard rituximab dose-dense chemotherapy as first line treatment in young patients with high-risk (aa-IPI 2-3) diffuse large B-cell lymphoma (DLBCL): final results of phase III randomized trial DLCL04 of the Fondazione Italiana Linfomi (FIL); citation_author=U. Vitolo; citation_author=A. Chiappella; citation_author=E. Brusamolino; citation_author=et al.; citation_journal_title=Blood; citation_volume=120; citation_firstpage=688; citation_publication_date=2012; "></meta><meta name="citation_reference" content="citation_title=Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma; citation_author=P.J. Stiff; citation_author=J.M. Unger; citation_author=J.R. Cook; citation_author=et al.; citation_journal_title=N Engl J Med; citation_volume=369; citation_firstpage=1681; citation_lastpage=1690; citation_publication_date=2013; "></meta><meta name="citation_reference" content="citation_title=First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: preliminary results of the GOELAMS 075 prospective multicenter randomized trial; citation_author=S. Le Gouill; citation_author=N.J. Milpied; citation_author=T. Lamy; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=29; citation_firstpage=8003; citation_publication_date=2011; "></meta><meta name="citation_reference" content="citation_title=Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL); citation_author=R.O. Casasnovas; citation_author=L. Ysebaert; citation_author=C. Thieblemont; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=32; citation_firstpage=8503; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC); citation_author=L.H. Sehn; citation_author=E.L.G. Hardy; citation_author=K.K. Gill; citation_author=et al.; citation_journal_title=Blood; citation_volume=124; citation_firstpage=392; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte; citation_author=B. Coiffier; citation_author=C. Thieblemont; citation_author=E. Van Den Neste; citation_author=et al.; citation_journal_title=Blood; citation_volume=116; citation_firstpage=2040; citation_lastpage=2045; citation_publication_date=2010; "></meta><meta name="citation_reference" content="citation_title=Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial; citation_author=R. Delarue; citation_author=H. Tilly; citation_author=N. Mounier; citation_author=et al.; citation_journal_title=Lancet Oncol; citation_volume=14; citation_firstpage=525; citation_lastpage=533; citation_publication_date=2013; "></meta><meta name="citation_reference" content="citation_title=Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60); citation_author=M. Pfreundschuh; citation_author=J. Schubert; citation_author=M. Ziepert; citation_author=et al.; citation_journal_title=Lancet Oncol; citation_volume=9; citation_firstpage=105; citation_lastpage=116; citation_publication_date=2008; "></meta><meta name="citation_reference" content="citation_title=CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte; citation_author=C. Bonnet; citation_author=G. Fillet; citation_author=N. Mounier; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=25; citation_firstpage=787; citation_lastpage=792; citation_publication_date=2007; "></meta><meta name="citation_reference" content="citation_title=Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma; citation_author=G. Held; citation_author=N. Murawski; citation_author=M. Ziepert; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=32; citation_firstpage=1112; citation_lastpage=1118; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group; citation_author=M. Pfreundschuh; citation_author=V. Poeschel; citation_author=S. Zeynalova; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=32; citation_firstpage=4127; citation_lastpage=4133; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper; citation_author=V.A. Morrison; citation_author=P. Hamlin; citation_author=P. Soubeyran; citation_author=et al.; citation_journal_title=J Geriatr Oncol; citation_volume=6; citation_firstpage=141; citation_lastpage=152; citation_publication_date=2015; "></meta><meta name="citation_reference" content="citation_title=Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL); citation_author=A. Tucci; citation_author=M. Martelli; citation_author=L. Rigacci; citation_author=et al.; citation_journal_title=Leuk Lymphoma; citation_volume=56; citation_firstpage=921; citation_lastpage=926; citation_publication_date=2015; "></meta><meta name="citation_reference" content="citation_title=Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma; citation_author=M. Spina; citation_author=M. Balzarotti; citation_author=L. Uziel; citation_author=et al.; citation_journal_title=Oncologist; citation_volume=17; citation_firstpage=838; citation_lastpage=846; citation_publication_date=2012; "></meta><meta name="citation_reference" content="citation_title=Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial; citation_author=F. Peyrade; citation_author=F. Jardin; citation_author=C. Thieblemont; citation_author=et al.; citation_journal_title=Lancet Oncol; citation_volume=12; citation_firstpage=460; citation_lastpage=468; citation_publication_date=2011; "></meta><meta name="citation_reference" content="citation_title=De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial; citation_author=P.A. Fields; citation_author=W. Townsend; citation_author=A. Webb; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=32; citation_firstpage=282; citation_lastpage=287; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Prevention of CNS relapse in diffuse large B-cell lymphoma; citation_author=R. Kridel; citation_author=P.Y. Dietrich; citation_journal_title=Lancet Oncol; citation_volume=12; citation_firstpage=1258; citation_lastpage=1266; citation_publication_date=2011; "></meta><meta name="citation_reference" content="citation_title=Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma; citation_author=K.J. Savage; citation_author=S. Zeynalova; citation_author=R.R. Kansara; citation_author=et al.; citation_journal_title=Blood; citation_volume=124; citation_firstpage=394; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma; citation_author=H. Tilly; citation_author=E. Lepage; citation_author=B. Coiffier; citation_author=et al.; citation_journal_title=Blood; citation_volume=102; citation_firstpage=4284; citation_lastpage=4289; citation_publication_date=2003; "></meta><meta name="citation_reference" content="citation_title=Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma; citation_author=J.S. Abramson; citation_author=M. Hellmann; citation_author=J.A. Barnes; citation_author=et al.; citation_journal_title=Cancer; citation_volume=116; citation_firstpage=4283; citation_lastpage=4290; citation_publication_date=2010; "></meta><meta name="citation_reference" content="citation_title=A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma; citation_author=C.Y. Cheah; citation_author=K.E. Herbert; citation_author=K. O'Rourke; citation_author=et al.; citation_journal_title=Br J Cancer; citation_volume=111; citation_firstpage=1072; citation_lastpage=1079; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era; citation_author=R. Coutinho; citation_author=A.D. Pria; citation_author=S. Gandhi; citation_author=et al.; citation_journal_title=AIDS; citation_volume=28; citation_firstpage=689; citation_lastpage=697; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study; citation_author=W.K. Seto; citation_author=T.S. Chan; citation_author=Y.Y. Hwang; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=32; citation_firstpage=3736; citation_lastpage=3743; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation—where do we stand?; citation_author=M. Meignan; citation_author=E. Itti; citation_author=A. Gallamini; citation_author=C. Haioun; citation_journal_title=Leuk Lymphoma; citation_volume=50; citation_firstpage=1753; citation_lastpage=1756; citation_publication_date=2009; "></meta><meta name="citation_reference" content="citation_title=Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy; citation_author=M.J. Maurer; citation_author=H. Ghesquieres; citation_author=J.P. Jais; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=32; citation_firstpage=1066; citation_lastpage=1073; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma; citation_author=C.A. Thompson; citation_author=H. Ghesquieres; citation_author=M.J. Maurer; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=32; citation_firstpage=3506; citation_lastpage=3512; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: a nationwide population-based study; citation_author=S.H. Chien; citation_author=C.J. Liu; citation_author=Y.W. Hu; citation_author=et al.; citation_journal_title=Int J Cancer; citation_volume=137; citation_firstpage=658; citation_lastpage=665; citation_publication_date=2015; "></meta><meta name="citation_reference" content="citation_title=Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era; citation_author=C. Gisselbrecht; citation_author=B. Glass; citation_author=N. Mounier; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=28; citation_firstpage=4184; citation_lastpage=4190; citation_publication_date=2010; "></meta><meta name="citation_reference" content="citation_title=Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma; citation_author=S.M. Horwitz; citation_author=R.S. Negrin; citation_author=K.G. Blume; citation_author=et al.; citation_journal_title=Blood; citation_volume=103; citation_firstpage=777; citation_lastpage=783; citation_publication_date=2004; "></meta><meta name="citation_reference" content="citation_title=Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma; citation_author=T. Kewalramani; citation_author=A.D. Zelenetz; citation_author=S.D. Nimer; citation_author=et al.; citation_journal_title=Blood; citation_volume=103; citation_firstpage=3684; citation_lastpage=3688; citation_publication_date=2004; "></meta><meta name="citation_reference" content="citation_title=Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12; citation_author=M. Crump; citation_author=J. Kuruvilla; citation_author=S. Couban; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=32; citation_firstpage=3490; citation_lastpage=3496; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study; citation_author=C. Thieblemont; citation_author=J. Briere; citation_author=N. Mounier; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=29; citation_firstpage=4079; citation_lastpage=4087; citation_publication_date=2011; "></meta><meta name="citation_reference" content="citation_title=Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma; citation_author=C. Gisselbrecht; citation_author=N. Schmitz; citation_author=N. Mounier; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=30; citation_firstpage=4462; citation_lastpage=4469; citation_publication_date=2012; "></meta><meta name="citation_reference" content="citation_title=Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial; citation_author=B. Glass; citation_author=J. Hasenkamp; citation_author=G. Wulf; citation_author=et al.; citation_journal_title=Lancet Oncol; citation_volume=15; citation_firstpage=757; citation_lastpage=766; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial; citation_author=N. Mounier; citation_author=T. El Gnaoui; citation_author=H. Tilly; citation_author=et al.; citation_journal_title=Haematologica; citation_volume=98; citation_firstpage=1726; citation_lastpage=1731; citation_publication_date=2013; "></meta><meta name="citation_reference" content="citation_title=Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial; citation_author=R. Pettengell; citation_author=B. Coiffier; citation_author=G. Narayanan; citation_author=et al.; citation_journal_title=Lancet Oncol; citation_volume=13; citation_firstpage=696; citation_lastpage=706; citation_publication_date=2012; "></meta><meta name="citation_reference" content="citation_title=Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy; citation_author=M. Dickinson; citation_author=R. Hoyt; citation_author=A.W. Roberts; citation_author=et al.; citation_journal_title=Br J Haematol; citation_volume=150; citation_firstpage=39; citation_lastpage=45; citation_publication_date=2010; "></meta><meta name="citation_reference" content="citation_title=Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03–2B; citation_author=T.J. Molina; citation_author=D. Canioni; citation_author=C. Copie-Bergman; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=32; citation_firstpage=3996; citation_lastpage=4003; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma; citation_author=K. Dunleavy; citation_author=S. Pittaluga; citation_author=M.S. Czuczman; citation_author=et al.; citation_journal_title=Blood; citation_volume=113; citation_firstpage=6069; citation_lastpage=6076; citation_publication_date=2009; "></meta><meta name="citation_reference" content="citation_title=Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype; citation_author=F.J. Hernandez-Ilizaliturri; citation_author=G. Deeb; citation_author=P.L. Zinzani; citation_author=et al.; citation_journal_title=Cancer; citation_volume=117; citation_firstpage=5058; citation_lastpage=5066; citation_publication_date=2011; "></meta><meta name="citation_reference" content="citation_title=A phase 2/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator's choice in relapsed/refractory DLBCL; citation_author=M.S. Czuczman; citation_author=A. Davies; citation_author=K.M. Linton; citation_author=et al.; citation_journal_title=Blood; citation_volume=124; citation_firstpage=628; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial; citation_author=U. Vitolo; citation_author=A. Chiappella; citation_author=S. Franceschetti; citation_author=et al.; citation_journal_title=Lancet Oncol; citation_volume=15; citation_firstpage=730; citation_lastpage=737; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study; citation_author=G.S. Nowakowski; citation_author=B. LaPlant; citation_author=W.R. Macon; citation_author=et al.; citation_journal_title=J Clin Oncol; citation_volume=33; citation_firstpage=251; citation_lastpage=257; citation_publication_date=2015; "></meta><meta name="citation_reference" content="citation_title=Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study; citation_author=A. Younes; citation_author=C. Thieblemont; citation_author=F. Morschhauser; citation_author=et al.; citation_journal_title=Lancet Oncol; citation_volume=15; citation_firstpage=1019; citation_lastpage=1026; citation_publication_date=2014; "></meta><meta name="citation_reference" content='citation_title=Diagnosis of &#34;double hit&#34; diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate Burkitt lymphoma: when and how, FISH versus IHC.; citation_author=S.H. Swerdlow; citation_journal_title=Hematology Am Soc Hematol Educ Program; citation_volume=2014; citation_firstpage=90; citation_lastpage=99; citation_publication_date=2014; '></meta><meta name="citation_reference" content="citation_title=Double hit lymphoma: the MD Anderson Cancer Center clinical experience; citation_author=Y. Oki; citation_author=M. Noorani; citation_author=P. Lin; citation_author=et al.; citation_journal_title=Br J Haematol; citation_volume=166; citation_firstpage=891; citation_lastpage=901; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis; citation_author=A.M. Petrich; citation_author=M. Gandhi; citation_author=B. Jovanovic; citation_author=et al.; citation_journal_title=Blood; citation_volume=124; citation_firstpage=2354; citation_lastpage=2361; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Precision therapy for lymphoma—current state and future directions; citation_author=A.M. Intlekofer; citation_author=A. Younes; citation_journal_title=Nat Rev Clin Oncol; citation_volume=11; citation_firstpage=585; citation_lastpage=596; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype; citation_author=K. Dunleavy; citation_author=M. Roschewski; citation_author=W.H. Wilson; citation_journal_title=Clin Cancer Res; citation_volume=20; citation_firstpage=5182; citation_lastpage=5193; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy; citation_author=F. Jardin; citation_journal_title=Discov Med; citation_volume=18; citation_firstpage=51; citation_lastpage=65; citation_publication_date=2014; "></meta><meta name="citation_reference" content="citation_title=Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients; citation_author=C.A. Dykewicz; citation_journal_title=Clin Infect Dis; citation_volume=33; citation_firstpage=139; citation_lastpage=144; citation_publication_date=2001; "></meta><meta charset="UTF-8" /><!--

    Pagebuild admin UI
-->



<script type="text/javascript">
    ;window.NREUM||(NREUM={});NREUM.init={privacy:{cookies_enabled:true}};
    window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o||e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<n.length;o++)r(n[o]);return r}({1:[function(t,e,n){function r(t){try{c.console&&console.log(t)}catch(e){}}var o,i=t("ee"),a=t(26),c={};try{o=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(c.console=!0,o.indexOf("dev")!==-1&&(c.dev=!0),o.indexOf("nr_dev")!==-1&&(c.nrDev=!0))}catch(s){}c.nrDev&&i.on("internal-error",function(t){r(t.stack)}),c.dev&&i.on("fn-err",function(t,e,n){r(n.stack)}),c.dev&&(r("NR AGENT IN DEVELOPMENT MODE"),r("flags: "+a(c,function(t,e){return t}).join(", ")))},{}],2:[function(t,e,n){function r(t,e,n,r,c){try{l?l-=1:o(c||new UncaughtException(t,e,n),!0)}catch(f){try{i("ierr",[f,s.now(),!0])}catch(d){}}return"function"==typeof u&&u.apply(this,a(arguments))}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function o(t,e){var n=e?null:s.now();i("err",[t,n])}var i=t("handle"),a=t(27),c=t("ee"),s=t("loader"),f=t("gos"),u=window.onerror,d=!1,p="nr@seenError",l=0;s.features.err=!0,t(1),window.onerror=r;try{throw new Error}catch(h){"stack"in h&&(t(13),t(12),"addEventListener"in window&&t(6),s.xhrWrappable&&t(14),d=!0)}c.on("fn-start",function(t,e,n){d&&(l+=1)}),c.on("fn-err",function(t,e,n){d&&!n[p]&&(f(n,p,function(){return!0}),this.thrown=!0,o(n))}),c.on("fn-end",function(){d&&!this.thrown&&l>0&&(l-=1)}),c.on("internal-error",function(t){i("ierr",[t,s.now(),!0])})},{}],3:[function(t,e,n){t("loader").features.ins=!0},{}],4:[function(t,e,n){function r(){_++,T=g.hash,this[u]=y.now()}function o(){_--,g.hash!==T&&i(0,!0);var t=y.now();this[h]=~~this[h]+t-this[u],this[d]=t}function i(t,e){E.emit("newURL",[""+g,e])}function a(t,e){t.on(e,function(){this[e]=y.now()})}var c="-start",s="-end",f="-body",u="fn"+c,d="fn"+s,p="cb"+c,l="cb"+s,h="jsTime",m="fetch",v="addEventListener",w=window,g=w.location,y=t("loader");if(w[v]&&y.xhrWrappable){var x=t(10),b=t(11),E=t(8),R=t(6),O=t(13),N=t(7),M=t(14),P=t(9),S=t("ee"),C=S.get("tracer");t(16),y.features.spa=!0;var T,_=0;S.on(u,r),S.on(p,r),S.on(d,o),S.on(l,o),S.buffer([u,d,"xhr-done","xhr-resolved"]),R.buffer([u]),O.buffer(["setTimeout"+s,"clearTimeout"+c,u]),M.buffer([u,"new-xhr","send-xhr"+c]),N.buffer([m+c,m+"-done",m+f+c,m+f+s]),E.buffer(["newURL"]),x.buffer([u]),b.buffer(["propagate",p,l,"executor-err","resolve"+c]),C.buffer([u,"no-"+u]),P.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"]),a(M,"send-xhr"+c),a(S,"xhr-resolved"),a(S,"xhr-done"),a(N,m+c),a(N,m+"-done"),a(P,"new-jsonp"),a(P,"jsonp-end"),a(P,"cb-start"),E.on("pushState-end",i),E.on("replaceState-end",i),w[v]("hashchange",i,!0),w[v]("load",i,!0),w[v]("popstate",function(){i(0,_>1)},!0)}},{}],5:[function(t,e,n){function r(t){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var o=t("ee"),i=t("handle"),a=t(13),c=t(12),s="learResourceTimings",f="addEventListener",u="resourcetimingbufferfull",d="bstResource",p="resource",l="-start",h="-end",m="fn"+l,v="fn"+h,w="bstTimer",g="pushState",y=t("loader");y.features.stn=!0,t(8),"addEventListener"in window&&t(6);var x=NREUM.o.EV;o.on(m,function(t,e){var n=t[0];n instanceof x&&(this.bstStart=y.now())}),o.on(v,function(t,e){var n=t[0];n instanceof x&&i("bst",[n,e,this.bstStart,y.now()])}),a.on(m,function(t,e,n){this.bstStart=y.now(),this.bstType=n}),a.on(v,function(t,e){i(w,[e,this.bstStart,y.now(),this.bstType])}),c.on(m,function(){this.bstStart=y.now()}),c.on(v,function(t,e){i(w,[e,this.bstStart,y.now(),"requestAnimationFrame"])}),o.on(g+l,function(t){this.time=y.now(),this.startPath=location.pathname+location.hash}),o.on(g+h,function(t){i("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),f in window.performance&&(window.performance["c"+s]?window.performance[f](u,function(t){i(d,[window.performance.getEntriesByType(p)]),window.performance["c"+s]()},!1):window.performance[f]("webkit"+u,function(t){i(d,[window.performance.getEntriesByType(p)]),window.performance["webkitC"+s]()},!1)),document[f]("scroll",r,{passive:!0}),document[f]("keypress",r,!1),document[f]("click",r,!1)}},{}],6:[function(t,e,n){function r(t){for(var e=t;e&&!e.hasOwnProperty(u);)e=Object.getPrototypeOf(e);e&&o(e)}function o(t){c.inPlace(t,[u,d],"-",i)}function i(t,e){return t[1]}var a=t("ee").get("events"),c=t("wrap-function")(a,!0),s=t("gos"),f=XMLHttpRequest,u="addEventListener",d="removeEventListener";e.exports=a,"getPrototypeOf"in Object?(r(document),r(window),r(f.prototype)):f.prototype.hasOwnProperty(u)&&(o(window),o(f.prototype)),a.on(u+"-start",function(t,e){var n=t[1],r=s(n,"nr@wrapped",function(){function t(){if("function"==typeof n.handleEvent)return n.handleEvent.apply(n,arguments)}var e={object:t,"function":n}[typeof n];return e?c(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=t[1]=r}),a.on(d+"-start",function(t){t[1]=this.wrapped||t[1]})},{}],7:[function(t,e,n){function r(t,e,n){var r=t[e];"function"==typeof r&&(t[e]=function(){var t=i(arguments),e={};o.emit(n+"before-start",[t],e);var a;e[m]&&e[m].dt&&(a=e[m].dt);var c=r.apply(this,t);return o.emit(n+"start",[t,a],c),c.then(function(t){return o.emit(n+"end",[null,t],c),t},function(t){throw o.emit(n+"end",[t],c),t})})}var o=t("ee").get("fetch"),i=t(27),a=t(26);e.exports=o;var c=window,s="fetch-",f=s+"body-",u=["arrayBuffer","blob","json","text","formData"],d=c.Request,p=c.Response,l=c.fetch,h="prototype",m="nr@context";d&&p&&l&&(a(u,function(t,e){r(d[h],e,f),r(p[h],e,f)}),r(c,"fetch",s),o.on(s+"end",function(t,e){var n=this;if(e){var r=e.headers.get("content-length");null!==r&&(n.rxSize=r),o.emit(s+"done",[null,e],n)}else o.emit(s+"done",[t],n)}))},{}],8:[function(t,e,n){var r=t("ee").get("history"),o=t("wrap-function")(r);e.exports=r;var i=window.history&&window.history.constructor&&window.history.constructor.prototype,a=window.history;i&&i.pushState&&i.replaceState&&(a=i),o.inPlace(a,["pushState","replaceState"],"-")},{}],9:[function(t,e,n){function r(t){function e(){s.emit("jsonp-end",[],p),t.removeEventListener("load",e,!1),t.removeEventListener("error",n,!1)}function n(){s.emit("jsonp-error",[],p),s.emit("jsonp-end",[],p),t.removeEventListener("load",e,!1),t.removeEventListener("error",n,!1)}var r=t&&"string"==typeof t.nodeName&&"script"===t.nodeName.toLowerCase();if(r){var o="function"==typeof t.addEventListener;if(o){var a=i(t.src);if(a){var u=c(a),d="function"==typeof u.parent[u.key];if(d){var p={};f.inPlace(u.parent,[u.key],"cb-",p),t.addEventListener("load",e,!1),t.addEventListener("error",n,!1),s.emit("new-jsonp",[t.src],p)}}}}}function o(){return"addEventListener"in window}function i(t){var e=t.match(u);return e?e[1]:null}function a(t,e){var n=t.match(p),r=n[1],o=n[3];return o?a(o,e[r]):e[r]}function c(t){var e=t.match(d);return e&&e.length>=3?{key:e[2],parent:a(e[1],window)}:{key:t,parent:window}}var s=t("ee").get("jsonp"),f=t("wrap-function")(s);if(e.exports=s,o()){var u=/[?&](?:callback|cb)=([^&#]+)/,d=/(.*)\.([^.]+)/,p=/^(\w+)(\.|$)(.*)$/,l=["appendChild","insertBefore","replaceChild"];Node&&Node.prototype&&Node.prototype.appendChild?f.inPlace(Node.prototype,l,"dom-"):(f.inPlace(HTMLElement.prototype,l,"dom-"),f.inPlace(HTMLHeadElement.prototype,l,"dom-"),f.inPlace(HTMLBodyElement.prototype,l,"dom-")),s.on("dom-start",function(t){r(t[0])})}},{}],10:[function(t,e,n){var r=t("ee").get("mutation"),o=t("wrap-function")(r),i=NREUM.o.MO;e.exports=r,i&&(window.MutationObserver=function(t){return this instanceof i?new i(o(t,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype)},{}],11:[function(t,e,n){function r(t){var e=a.context(),n=c(t,"executor-",e),r=new f(n);return a.context(r).getCtx=function(){return e},a.emit("new-promise",[r,e],e),r}function o(t,e){return e}var i=t("wrap-function"),a=t("ee").get("promise"),c=i(a),s=t(26),f=NREUM.o.PR;e.exports=a,f&&(window.Promise=r,["all","race"].forEach(function(t){var e=f[t];f[t]=function(n){function r(t){return function(){a.emit("propagate",[null,!o],i),o=o||!t}}var o=!1;s(n,function(e,n){Promise.resolve(n).then(r("all"===t),r(!1))});var i=e.apply(f,arguments),c=f.resolve(i);return c}}),["resolve","reject"].forEach(function(t){var e=f[t];f[t]=function(t){var n=e.apply(f,arguments);return t!==n&&a.emit("propagate",[t,!0],n),n}}),f.prototype["catch"]=function(t){return this.then(null,t)},f.prototype=Object.create(f.prototype,{constructor:{value:r}}),s(Object.getOwnPropertyNames(f),function(t,e){try{r[e]=f[e]}catch(n){}}),a.on("executor-start",function(t){t[0]=c(t[0],"resolve-",this),t[1]=c(t[1],"resolve-",this)}),a.on("executor-err",function(t,e,n){t[1](n)}),c.inPlace(f.prototype,["then"],"then-",o),a.on("then-start",function(t,e){this.promise=e,t[0]=c(t[0],"cb-",this),t[1]=c(t[1],"cb-",this)}),a.on("then-end",function(t,e,n){this.nextPromise=n;var r=this.promise;a.emit("propagate",[r,!0],n)}),a.on("cb-end",function(t,e,n){a.emit("propagate",[n,!0],this.nextPromise)}),a.on("propagate",function(t,e,n){this.getCtx&&!e||(this.getCtx=function(){if(t instanceof Promise)var e=a.context(t);return e&&e.getCtx?e.getCtx():this})}),r.toString=function(){return""+f})},{}],12:[function(t,e,n){var r=t("ee").get("raf"),o=t("wrap-function")(r),i="equestAnimationFrame";e.exports=r,o.inPlace(window,["r"+i,"mozR"+i,"webkitR"+i,"msR"+i],"raf-"),r.on("raf-start",function(t){t[0]=o(t[0],"fn-")})},{}],13:[function(t,e,n){function r(t,e,n){t[0]=a(t[0],"fn-",null,n)}function o(t,e,n){this.method=n,this.timerDuration=isNaN(t[1])?0:+t[1],t[0]=a(t[0],"fn-",this,n)}var i=t("ee").get("timer"),a=t("wrap-function")(i),c="setTimeout",s="setInterval",f="clearTimeout",u="-start",d="-";e.exports=i,a.inPlace(window,[c,"setImmediate"],c+d),a.inPlace(window,[s],s+d),a.inPlace(window,[f,"clearImmediate"],f+d),i.on(s+u,r),i.on(c+u,o)},{}],14:[function(t,e,n){function r(t,e){d.inPlace(e,["onreadystatechange"],"fn-",c)}function o(){var t=this,e=u.context(t);t.readyState>3&&!e.resolved&&(e.resolved=!0,u.emit("xhr-resolved",[],t)),d.inPlace(t,g,"fn-",c)}function i(t){y.push(t),h&&(b?b.then(a):v?v(a):(E=-E,R.data=E))}function a(){for(var t=0;t<y.length;t++)r([],y[t]);y.length&&(y=[])}function c(t,e){return e}function s(t,e){for(var n in t)e[n]=t[n];return e}t(6);var f=t("ee"),u=f.get("xhr"),d=t("wrap-function")(u),p=NREUM.o,l=p.XHR,h=p.MO,m=p.PR,v=p.SI,w="readystatechange",g=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],y=[];e.exports=u;var x=window.XMLHttpRequest=function(t){var e=new l(t);try{u.emit("new-xhr",[e],e),e.addEventListener(w,o,!1)}catch(n){try{u.emit("internal-error",[n])}catch(r){}}return e};if(s(l,x),x.prototype=l.prototype,d.inPlace(x.prototype,["open","send"],"-xhr-",c),u.on("send-xhr-start",function(t,e){r(t,e),i(e)}),u.on("open-xhr-start",r),h){var b=m&&m.resolve();if(!v&&!m){var E=1,R=document.createTextNode(E);new h(a).observe(R,{characterData:!0})}}else f.on("fn-end",function(t){t[0]&&t[0].type===w||a()})},{}],15:[function(t,e,n){function r(t){if(!c(t))return null;var e=window.NREUM;if(!e.loader_config)return null;var n=(e.loader_config.accountID||"").toString()||null,r=(e.loader_config.agentID||"").toString()||null,f=(e.loader_config.trustKey||"").toString()||null;if(!n||!r)return null;var h=l.generateSpanId(),m=l.generateTraceId(),v=Date.now(),w={spanId:h,traceId:m,timestamp:v};return(t.sameOrigin||s(t)&&p())&&(w.traceContextParentHeader=o(h,m),w.traceContextStateHeader=i(h,v,n,r,f)),(t.sameOrigin&&!u()||!t.sameOrigin&&s(t)&&d())&&(w.newrelicHeader=a(h,m,v,n,r,f)),w}function o(t,e){return"00-"+e+"-"+t+"-01"}function i(t,e,n,r,o){var i=0,a="",c=1,s="",f="";return o+"@nr="+i+"-"+c+"-"+n+"-"+r+"-"+t+"-"+a+"-"+s+"-"+f+"-"+e}function a(t,e,n,r,o,i){var a="btoa"in window&&"function"==typeof window.btoa;if(!a)return null;var c={v:[0,1],d:{ty:"Browser",ac:r,ap:o,id:t,tr:e,ti:n}};return i&&r!==i&&(c.d.tk=i),btoa(JSON.stringify(c))}function c(t){return f()&&s(t)}function s(t){var e=!1,n={};if("init"in NREUM&&"distributed_tracing"in NREUM.init&&(n=NREUM.init.distributed_tracing),t.sameOrigin)e=!0;else if(n.allowed_origins instanceof Array)for(var r=0;r<n.allowed_origins.length;r++){var o=h(n.allowed_origins[r]);if(t.hostname===o.hostname&&t.protocol===o.protocol&&t.port===o.port){e=!0;break}}return e}function f(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.enabled}function u(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.exclude_newrelic_header}function d(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&NREUM.init.distributed_tracing.cors_use_newrelic_header!==!1}function p(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.cors_use_tracecontext_headers}var l=t(23),h=t(17);e.exports={generateTracePayload:r,shouldGenerateTrace:c}},{}],16:[function(t,e,n){function r(t){var e=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var r=0;r<p;r++)t.removeEventListener(d[r],this.listener,!1);e.aborted||(n.duration=a.now()-this.startTime,this.loadCaptureCalled||4!==t.readyState?null==e.status&&(e.status=0):i(this,t),n.cbTime=this.cbTime,u.emit("xhr-done",[t],t),c("xhr",[e,n,this.startTime]))}}function o(t,e){var n=s(e),r=t.params;r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.parsedOrigin=s(e),t.sameOrigin=t.parsedOrigin.sameOrigin}function i(t,e){t.params.status=e.status;var n=v(e,t.lastSize);if(n&&(t.metrics.rxSize=n),t.sameOrigin){var r=e.getResponseHeader("X-NewRelic-App-Data");r&&(t.params.cat=r.split(", ").pop())}t.loadCaptureCalled=!0}var a=t("loader");if(a.xhrWrappable){var c=t("handle"),s=t(17),f=t(15).generateTracePayload,u=t("ee"),d=["load","error","abort","timeout"],p=d.length,l=t("id"),h=t(21),m=t(20),v=t(18),w=window.XMLHttpRequest;a.features.xhr=!0,t(14),t(7),u.on("new-xhr",function(t){var e=this;e.totalCbs=0,e.called=0,e.cbTime=0,e.end=r,e.ended=!1,e.xhrGuids={},e.lastSize=null,e.loadCaptureCalled=!1,t.addEventListener("load",function(n){i(e,t)},!1),h&&(h>34||h<10)||window.opera||t.addEventListener("progress",function(t){e.lastSize=t.loaded},!1)}),u.on("open-xhr-start",function(t){this.params={method:t[0]},o(this,t[1]),this.metrics={}}),u.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid);var n=f(this.parsedOrigin);if(n){var r=!1;n.newrelicHeader&&(e.setRequestHeader("newrelic",n.newrelicHeader),r=!0),n.traceContextParentHeader&&(e.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&e.setRequestHeader("tracestate",n.traceContextStateHeader),r=!0),r&&(this.dt=n)}}),u.on("send-xhr-start",function(t,e){var n=this.metrics,r=t[0],o=this;if(n&&r){var i=m(r);i&&(n.txSize=i)}this.startTime=a.now(),this.listener=function(t){try{"abort"!==t.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==t.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof e.onload))&&o.end(e)}catch(n){try{u.emit("internal-error",[n])}catch(r){}}};for(var c=0;c<p;c++)e.addEventListener(d[c],this.listener,!1)}),u.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),u.on("xhr-load-added",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),u.on("xhr-load-removed",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),u.on("addEventListener-end",function(t,e){e instanceof w&&"load"===t[0]&&u.emit("xhr-load-added",[t[1],t[2]],e)}),u.on("removeEventListener-end",function(t,e){e instanceof w&&"load"===t[0]&&u.emit("xhr-load-removed",[t[1],t[2]],e)}),u.on("fn-start",function(t,e,n){e instanceof w&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=a.now()))}),u.on("fn-end",function(t,e){this.xhrCbStart&&u.emit("xhr-cb-time",[a.now()-this.xhrCbStart,this.onload,e],e)}),u.on("fetch-before-start",function(t){function e(t,e){var n=!1;return e.newrelicHeader&&(t.set("newrelic",e.newrelicHeader),n=!0),e.traceContextParentHeader&&(t.set("traceparent",e.traceContextParentHeader),e.traceContextStateHeader&&t.set("tracestate",e.traceContextStateHeader),n=!0),n}var n,r=t[1]||{};"string"==typeof t[0]?n=t[0]:t[0]&&t[0].url&&(n=t[0].url),n&&(this.parsedOrigin=s(n),this.sameOrigin=this.parsedOrigin.sameOrigin);var o=f(this.parsedOrigin);if(o&&(o.newrelicHeader||o.traceContextParentHeader))if("string"==typeof t[0]){var i={};for(var a in r)i[a]=r[a];i.headers=new Headers(r.headers||{}),e(i.headers,o)&&(this.dt=o),t.length>1?t[1]=i:t.push(i)}else t[0]&&t[0].headers&&e(t[0].headers,o)&&(this.dt=o)})}},{}],17:[function(t,e,n){var r={};e.exports=function(t){if(t in r)return r[t];var e=document.createElement("a"),n=window.location,o={};e.href=t,o.port=e.port;var i=e.href.split("://");!o.port&&i[1]&&(o.port=i[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===i[0]?"443":"80"),o.hostname=e.hostname||n.hostname,o.pathname=e.pathname,o.protocol=i[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var a=!e.protocol||":"===e.protocol||e.protocol===n.protocol,c=e.hostname===document.domain&&e.port===n.port;return o.sameOrigin=a&&(!e.hostname||c),"/"===o.pathname&&(r[t]=o),o}},{}],18:[function(t,e,n){function r(t,e){var n=t.responseType;return"json"===n&&null!==e?e:"arraybuffer"===n||"blob"===n||"json"===n?o(t.response):"text"===n||""===n||void 0===n?o(t.responseText):void 0}var o=t(20);e.exports=r},{}],19:[function(t,e,n){function r(){}function o(t,e,n){return function(){return i(t,[f.now()].concat(c(arguments)),e?null:this,n),e?void 0:this}}var i=t("handle"),a=t(26),c=t(27),s=t("ee").get("tracer"),f=t("loader"),u=NREUM;"undefined"==typeof window.newrelic&&(newrelic=u);var d=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],p="api-",l=p+"ixn-";a(d,function(t,e){u[e]=o(p+e,!0,"api")}),u.addPageAction=o(p+"addPageAction",!0),u.setCurrentRouteName=o(p+"routeName",!0),e.exports=newrelic,u.interaction=function(){return(new r).get()};var h=r.prototype={createTracer:function(t,e){var n={},r=this,o="function"==typeof e;return i(l+"tracer",[f.now(),t,n],r),function(){if(s.emit((o?"":"no-")+"fn-start",[f.now(),r,o],n),o)try{return e.apply(this,arguments)}catch(t){throw s.emit("fn-err",[arguments,this,t],n),t}finally{s.emit("fn-end",[f.now()],n)}}}};a("actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(t,e){h[e]=o(l+e)}),newrelic.noticeError=function(t,e){"string"==typeof t&&(t=new Error(t)),i("err",[t,f.now(),!1,e])}},{}],20:[function(t,e,n){e.exports=function(t){if("string"==typeof t&&t.length)return t.length;if("object"==typeof t){if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if(!("undefined"!=typeof FormData&&t instanceof FormData))try{return JSON.stringify(t).length}catch(e){return}}}},{}],21:[function(t,e,n){var r=0,o=navigator.userAgent.match(/Firefox[\/\s](\d+\.\d+)/);o&&(r=+o[1]),e.exports=r},{}],22:[function(t,e,n){function r(t,e){var n=t.getEntries();n.forEach(function(t){"first-paint"===t.name?d("timing",["fp",Math.floor(t.startTime)]):"first-contentful-paint"===t.name&&d("timing",["fcp",Math.floor(t.startTime)])})}function o(t,e){var n=t.getEntries();n.length>0&&d("lcp",[n[n.length-1]])}function i(t){t.getEntries().forEach(function(t){t.hadRecentInput||d("cls",[t])})}function a(t){if(t instanceof h&&!v){var e=Math.round(t.timeStamp),n={type:t.type};e<=p.now()?n.fid=p.now()-e:e>p.offset&&e<=Date.now()?(e-=p.offset,n.fid=p.now()-e):e=p.now(),v=!0,d("timing",["fi",e,n])}}function c(t){d("pageHide",[p.now(),t])}if(!("init"in NREUM&&"page_view_timing"in NREUM.init&&"enabled"in NREUM.init.page_view_timing&&NREUM.init.page_view_timing.enabled===!1)){var s,f,u,d=t("handle"),p=t("loader"),l=t(25),h=NREUM.o.EV;if("PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver){s=new PerformanceObserver(r);try{s.observe({entryTypes:["paint"]})}catch(m){}f=new PerformanceObserver(o);try{f.observe({entryTypes:["largest-contentful-paint"]})}catch(m){}u=new PerformanceObserver(i);try{u.observe({type:"layout-shift",buffered:!0})}catch(m){}}if("addEventListener"in document){var v=!1,w=["click","keydown","mousedown","pointerdown","touchstart"];w.forEach(function(t){document.addEventListener(t,a,!1)})}l(c)}},{}],23:[function(t,e,n){function r(){function t(){return e?15&e[n++]:16*Math.random()|0}var e=null,n=0,r=window.crypto||window.msCrypto;r&&r.getRandomValues&&(e=r.getRandomValues(new Uint8Array(31)));for(var o,i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx",a="",c=0;c<i.length;c++)o=i[c],"x"===o?a+=t().toString(16):"y"===o?(o=3&t()|8,a+=o.toString(16)):a+=o;return a}function o(){return a(16)}function i(){return a(32)}function a(t){function e(){return n?15&n[r++]:16*Math.random()|0}var n=null,r=0,o=window.crypto||window.msCrypto;o&&o.getRandomValues&&Uint8Array&&(n=o.getRandomValues(new Uint8Array(31)));for(var i=[],a=0;a<t;a++)i.push(e().toString(16));return i.join("")}e.exports={generateUuid:r,generateSpanId:o,generateTraceId:i}},{}],24:[function(t,e,n){function r(t,e){if(!o)return!1;if(t!==o)return!1;if(!e)return!0;if(!i)return!1;for(var n=i.split("."),r=e.split("."),a=0;a<r.length;a++)if(r[a]!==n[a])return!1;return!0}var o=null,i=null,a=/Version\/(\S+)\s+Safari/;if(navigator.userAgent){var c=navigator.userAgent,s=c.match(a);s&&c.indexOf("Chrome")===-1&&c.indexOf("Chromium")===-1&&(o="Safari",i=s[1])}e.exports={agent:o,version:i,match:r}},{}],25:[function(t,e,n){function r(t){function e(){t(a&&document[a]?document[a]:document[o]?"hidden":"visible")}"addEventListener"in document&&i&&document.addEventListener(i,e,!1)}e.exports=r;var o,i,a;"undefined"!=typeof document.hidden?(o="hidden",i="visibilitychange",a="visibilityState"):"undefined"!=typeof document.msHidden?(o="msHidden",i="msvisibilitychange"):"undefined"!=typeof document.webkitHidden&&(o="webkitHidden",i="webkitvisibilitychange",a="webkitVisibilityState")},{}],26:[function(t,e,n){function r(t,e){var n=[],r="",i=0;for(r in t)o.call(t,r)&&(n[i]=e(r,t[r]),i+=1);return n}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],27:[function(t,e,n){function r(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(o<0?0:o);++r<o;)i[r]=t[e+r];return i}e.exports=r},{}],28:[function(t,e,n){e.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(t,e,n){function r(){}function o(t){function e(t){return t&&t instanceof r?t:t?s(t,c,i):i()}function n(n,r,o,i){if(!p.aborted||i){t&&t(n,r,o);for(var a=e(o),c=m(n),s=c.length,f=0;f<s;f++)c[f].apply(a,r);var d=u[y[n]];return d&&d.push([x,n,r,a]),a}}function l(t,e){g[t]=m(t).concat(e)}function h(t,e){var n=g[t];if(n)for(var r=0;r<n.length;r++)n[r]===e&&n.splice(r,1)}function m(t){return g[t]||[]}function v(t){return d[t]=d[t]||o(n)}function w(t,e){f(t,function(t,n){e=e||"feature",y[n]=e,e in u||(u[e]=[])})}var g={},y={},x={on:l,addEventListener:l,removeEventListener:h,emit:n,get:v,listeners:m,context:e,buffer:w,abort:a,aborted:!1};return x}function i(){return new r}function a(){(u.api||u.feature)&&(p.aborted=!0,u=p.backlog={})}var c="nr@context",s=t("gos"),f=t(26),u={},d={},p=e.exports=o();p.backlog=u},{}],gos:[function(t,e,n){function r(t,e,n){if(o.call(t,e))return t[e];var r=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return t[e]=r,r}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],handle:[function(t,e,n){function r(t,e,n,r){o.buffer([t],r),o.emit(t,e,n)}var o=t("ee").get("handle");e.exports=r,r.ee=o},{}],id:[function(t,e,n){function r(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:a(t,i,function(){return o++})}var o=1,i="nr@id",a=t("gos");e.exports=r},{}],loader:[function(t,e,n){function r(){if(!E++){var t=b.info=NREUM.info,e=l.getElementsByTagName("script")[0];if(setTimeout(u.abort,3e4),!(t&&t.licenseKey&&t.applicationID&&e))return u.abort();f(y,function(e,n){t[e]||(t[e]=n)});var n=a();s("mark",["onload",n+b.offset],null,"api"),s("timing",["load",n]);var r=l.createElement("script");r.src="https://"+t.agent,e.parentNode.insertBefore(r,e)}}function o(){"complete"===l.readyState&&i()}function i(){s("mark",["domContent",a()+b.offset],null,"api")}function a(){return R.exists&&performance.now?Math.round(performance.now()):(c=Math.max((new Date).getTime(),c))-b.offset}var c=(new Date).getTime(),s=t("handle"),f=t(26),u=t("ee"),d=t(24),p=window,l=p.document,h="addEventListener",m="attachEvent",v=p.XMLHttpRequest,w=v&&v.prototype;NREUM.o={ST:setTimeout,SI:p.setImmediate,CT:clearTimeout,XHR:v,REQ:p.Request,EV:p.Event,PR:p.Promise,MO:p.MutationObserver};var g=""+location,y={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-spa-1177.min.js"},x=v&&w&&w[h]&&!/CriOS/.test(navigator.userAgent),b=e.exports={offset:c,now:a,origin:g,features:{},xhrWrappable:x,userAgent:d};t(19),t(22),l[h]?(l[h]("DOMContentLoaded",i,!1),p[h]("load",r,!1)):(l[m]("onreadystatechange",o),p[m]("onload",r)),s("mark",["firstbyte",c],null,"api");var E=0,R=t(28)},{}],"wrap-function":[function(t,e,n){function r(t){return!(t&&t instanceof Function&&t.apply&&!t[a])}var o=t("ee"),i=t(27),a="nr@original",c=Object.prototype.hasOwnProperty,s=!1;e.exports=function(t,e){function n(t,e,n,o){function nrWrapper(){var r,a,c,s;try{a=this,r=i(arguments),c="function"==typeof n?n(r,a):n||{}}catch(f){p([f,"",[r,a,o],c])}u(e+"start",[r,a,o],c);try{return s=t.apply(a,r)}catch(d){throw u(e+"err",[r,a,d],c),d}finally{u(e+"end",[r,a,s],c)}}return r(t)?t:(e||(e=""),nrWrapper[a]=t,d(t,nrWrapper),nrWrapper)}function f(t,e,o,i){o||(o="");var a,c,s,f="-"===o.charAt(0);for(s=0;s<e.length;s++)c=e[s],a=t[c],r(a)||(t[c]=n(a,f?c+o:o,i,c))}function u(n,r,o){if(!s||e){var i=s;s=!0;try{t.emit(n,r,o,e)}catch(a){p([a,n,r,o])}s=i}}function d(t,e){if(Object.defineProperty&&Object.keys)try{var n=Object.keys(t);return n.forEach(function(n){Object.defineProperty(e,n,{get:function(){return t[n]},set:function(e){return t[n]=e,e}})}),e}catch(r){p([r])}for(var o in t)c.call(t,o)&&(e[o]=t[o]);return e}function p(e){try{t.emit("internal-error",e)}catch(n){}}return t||(t=o),n.inPlace=f,n.flag=a,n}},{}]},{},["loader",2,16,5,3,4]);
    ;NREUM.loader_config={accountID:"2095297",trustKey:"2038175",agentID:"916964291",licenseKey:"16e2192192",applicationID:"916964291"}
    ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"16e2192192",applicationID:"916964291",sa:1}
</script>
    <script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" type="text/javascript" charset="UTF-8"
            data-domain-script="2a5758bd-9ad0-4c38-b9e8-601e217fda1b"></script>
    <script type="text/javascript">
        function getCookie(name) {
            var value = "; " + document.cookie;
            var parts = value.split("; " + name + "=");
            if (parts.length == 2) {
                return true;
            }
        }
            function OptanonWrapper() {
                var optCookie = getCookie("OptanonAlertBoxClosed");
                var isActiveCategory = "false";
                var isFoundCookieBox = "false";
                if(isActiveCategory == 'false' && isFoundCookieBox == 'false' && optCookie) {
                    OneTrust.InsertScript('/pb-assets/adobe/prod/adobedtm-1616606406233.js', 'head', null, null, '2');
                }
            }
    </script>


<noscript>
    <style>.requiresJS {
        display: none
    }

    .dartAd {
        display: block !important
    }</style>
</noscript>
        <script type="text/javascript" src="/wro/nnkn~selected-legacy.js"></script>
        <link rel="stylesheet" type="text/css" href="/wro/nnkn~selected-legacy.css"/>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans"/>
        <script>window.MSInputMethodContext && document.documentMode && document.write('<script src="https://cdn.jsdelivr.net/gh/nuxodin/ie11CustomProperties@4.1.0/ie11CustomProperties.min.js"><\x2fscript>');</script><link rel="stylesheet" href="/products/marlin/ha/releasedAssets/css/build-e279c5ca7d640a5bf24d.css"/><link rel="stylesheet" href="/products/marlin/ha/releasedAssets/css/print-e279c5ca7d640a5bf24d.css" media="print"/><link rel="stylesheet" href="/products/marlin/ha/releasedAssets/css/themes/theme-annonc.css"/>







        
        
        <script class="optanon-category-4" type="text/plain" async src="https://www.youtube.com/iframe_api"></script>
        
    





<!---->
<meta http-equiv="X-UA-Compatible" content="IE=edge">












</head>
<body class="pb-ui">
    <div class="skip">
        <a href="#page-body-id" id="skipNavigationLink" title="Skip to Main Content" tabindex="0" class="skipToContent">Skip to Main Content</a>
        <a href="#mega-menu-nav" id="skipToMainMenu" title="Skip to Main Menu" tabindex="0" class="skipToContent">Skip to Main Menu</a>
    </div>



    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="ux3-layout-widget" data-widget-id="54cf691d-1d44-49ee-922c-5ca55dc1d4af" class="ux3">
        
    

        


    

            

            
                <div class="annonc">
            

            <div data-widget-id="54cf691d-1d44-49ee-922c-5ca55dc1d4af" data-widget-name="ux3-layout-widget"><div>
    

        


    

            

            

            <div id="6ee85045-2441-4b5c-8a4b-4c078d548375" class="widget loginPopup none widget-none widget-compact-all"><div class="wrapped"><div class="widget-body body body-none body-compact-all"><div role="dialog" aria-modal="true" aria-label="Login" class="popup login-popup hidden"><div class="content"><a href="#" aria-label="Close login popup" title="Close login popup" role="button" class="close"><i class="icon-close_thin"></i></a><h2 class="login-title">Login to your account</h2><div class="login-form"><p tabindex="-1" class="message error"></p><form action="/action/doLogin?redirectUri=https%3A%2F%2Fwww.annalsofoncology.org%2Farticle%2FS0923-7534%2819%2947184-6%2Ffulltext" method="post"><input type="hidden" name="redirectUri" value="https://www.annalsofoncology.org/article/S0923-7534(19)47184-6/fulltext"/><input type="hidden" name="referer" value="/article/S0923-7534(19)47184-6/fulltext"/><input type="hidden" name="ecommRedirect"/><input type="hidden" name="code" value="annonc-site"/><input type="hidden" name="UX3LoginWidget" value="true"/><input type="hidden" name="isPopup" value="true"/><div class="input-group login-input--wrapper"><div class="label"><label for="login">Email/Username</label></div><input id="login" type="text" name="login" value="" size="15" class="login"/><div role="alert" class="error-hint js--hidden"><div class="error-hint__text"><div class="error-text">Your email address is a required field.</div><div class="email-example">E.g., <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a7cd89d4caced3cfe7cac6cecb89c4c8ca">[email&#160;protected]</a></div></div></div></div><div class="input-group login-input--wrapper"><div class="label"><label for="password">Password</label></div><input id="password" type="password" name="password" value="" autocomplete="off" class="password"/><a href="#" class="login__field__action js-show-password">Show</a><div role="alert" class="error-hint js--hidden"><span class="error-hint__text">Your password is a required field.</span></div><div class="actions"><a href="https://www.annalsofoncology.org/action/requestResetPassword" class="link show-request-reset-password">Forgot password?</a></div></div><div class="remember"><input type="checkbox" name="savePassword" id="6ee85045-2441-4b5c-8a4b-4c078d548375-remember" value="1" checked="checked"/><label for="6ee85045-2441-4b5c-8a4b-4c078d548375-remember">Remember me</label></div><div class="submit"><input type="submit" name="submit" value="Log in" class="button submit primary"/></div></form></div><div class="create-account"><div>Don’t have an account?</div><a href="/action/registration?redirectUri=https%3A%2F%2Fwww.annalsofoncology.org%2Farticle%2FS0923-7534%2819%2947184-6%2Ffulltext" class="show-registration">Create a Free Account</a></div></div></div></div></div></div>

            

        

    

        


    

            

            

            <div role="dialog" aria-modal="true" aria-label="Reset password" class="popup top-drawer request-reset-password-drawer hidden"><div class="content"><a href="#" aria-label="Close reset password popup" title="Close reset password popup" role="button" class="close"><i class="icon-close_thin"></i></a><div class="request-reset"><div class="form"><p class="sub">If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password</p><div tabindex="-1" class="message error"></div><form action="/action/requestResetPassword" method="post" class="request-reset-password-form"><input type="hidden" name="platform"/><input type="hidden" name="requestResetPassword" value="true"/><input type="hidden" name="codeSite" value="annonc-site"/><div class="input-group"><div class="label"><label for="reset-password-email">Email*</label></div><input id="reset-password-email" type="text" name="email" value="" size="15" class="email"/></div><div class="submit"><input type="submit" name="submit" value="Submit" disabled="disabled" class="button primary submit"/></div></form></div><div class="success-template hidden"><p>If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password</p></div></div><div class="request-reset-cancel"><a href="#" aria-label="Close reset password popup" title="Close reset password popup" class="cancel">Cancel</a></div></div></div>

            

        

    

        


    

            

            
                <div class="ux3-ads">
            

            <div class="pb-ad">
            <!-- Do Not Modify without contacting ELS-HSOnlineCampaign@elsevier.com -->
<!-- To be kept in sync with Global Commercial Publishing Operations-->
<!-- Start: GPT Async -->
<div id="gpt-Variables" data-adfile="JBS">
    <input type="hidden" id="gptSite" value="annonc">
    <input type="hidden" id="gptLoggedIn" value="no">
    <input type="hidden" id="gptAccessType" value="ae:ANON_GUEST|ae:ANON_GUEST">
</div>
<div id="gpt-Interscroller" class="gpt-InScrollBox" style="display:none;">
    <div class="gpt-InScrollLabel">ADVERTISEMENT</div>
    <div class="gpt-InScrollContainer">
        <div class="gpt-InScrollWrapper">
            <div class="gpt-InScrollInner">
                <div class="gpt-adinterscroller" data-adsize="interscroller"></div>
            </div>
        </div>
    </div>
    <div class="gpt-InScrollLabel">SCROLL TO CONTINUE WITH CONTENT</div>
</div>
<div id="gpt-DebugDiv" class="gpt-DebugDiv" style="display:none;">
    <div style="width: 100%; display: table;">
        <div style="display: table-row">
            <div style="width: 200px; display: table-cell;">
                <button class="gpt-DebugBtn" onclick="gpt_ShowConsole()">Open GPT Console</button><br />
                <button id="gpt_GrapeShotDebugBtn" class="gpt-DebugBtn" onclick="gpt_GrapeShotDebug();">Open Oracle Keywords</button><br />
                <br />
                <button class="gpt-DebugBtn" onclick="gpt_LoadDebugValues()">Refresh Values</button>
            </div>
            <div style="display: table-cell;">
                <table class="gpt-DebugTable">
                    <thead>
                        <tr>
                            <th>Property</th>
                            <th>Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr><td class="gpt-DebugTitle">Status</td><td><div class="gptStatus_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Version</td><td><div class="gptVersion_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Ad File</td><td><div class="gptAdFile_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Disable Ads Flag</td><td><div class="gptDisableAds_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Environment</td><td><div class="gptTestENV_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Moat Init</td><td><div class="gptMoatInit_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Moat Ready</td><td><div class="gptMoatReady_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Contextual Ready</td><td><div class="gptContextualReady_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Contextual URL</td><td><div class="gptContextualURL_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Contextual Initial Segments</td><td><div class="gptContextualInit_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Contextual Used Segments</td><td><div class="gptContextualResult_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">AdUnit</td><td><div class="gptSite_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">SubAdUnit</td><td><div class="gptPage_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Custom Targeting</td><td><div class="gptCustomTargeting_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Ad Events</td><td><div class="gptEvent_Debug"></div></td></tr>
                        <tr><td class="gpt-DebugTitle">Invalid Ad Sizes</td><td><div class="gptInvalidAdSize_Debug"></div></td></tr>
                    </tbody>
                </table>
            </div>
        </div>
    </div>
</div>
<style type="text/css">
    .gpt-DebugBtn {
        display: inline-block;
        text-align: center;
        text-decoration: none;
        margin: 2px 0;
        border: solid 1px #122b40;
        border-radius: 0.4em;
        padding: 0.5em 1em;
        color: #ffffff;
        background-color: #204d74;
        font-weight: normal;
        font-size: 12px;
    }

    .gpt-DebugDiv {
        margin: 5px;
    }

    .gpt-DebugTitle {
        font-weight: bold;
    }

    .gpt-DebugTable {
        border: 1px solid #dddddd;
        border-collapse: collapse;
        margin: 5px;
        font-size: 0.9em;
        font-family: sans-serif;
        min-width: 400px;
        margin-bottom: 25px;
    }

        .gpt-DebugTable td:first-child {
            padding: 5px;
        }

        .gpt-DebugTable thead tr th {
            background-color: #d9edf7;
            color: #ffffff;
            text-align: left;
            padding: 5px;
            border-bottom: 2px solid #204d74;
        }

        .gpt-DebugTable th,
        .gpt-DebugTable td {
            padding: 5px;
        }

        .gpt-DebugTable tbody tr {
            border-bottom: 1px solid #dddddd;
        }

            .gpt-DebugTable tbody tr:nth-of-type(even) {
                background-color: #f3f3f3;
            }

            .gpt-DebugTable tbody tr:last-of-type {
                border-bottom: 2px solid #204d74;
            }

    .gpt-InScrollLabel {
        background-color: rgb(0, 0, 0);
        color: rgb(255, 255, 255);
        position: relative;
        max-width: 100vw;
        left: 50%;
        right: 50%;
        margin-left: -50vw;
        margin-right: -50vw;
        padding: 0;
        text-align: center;
        width: 100vw !important;
        font-size: 10px;
    }

    .gpt-InScrollBox {
        height: 100vh !important;
        width: 100vw;
        cursor: pointer;
        max-width: 100vw;
        position: relative;
        left: 50%;
        right: 50%;
        margin-left: -50vw;
        margin-right: -50vw;
        margin-bottom: 50px;
        padding-top: 5px;
        padding-bottom: 5px;
        z-index: 10001;
        background-color: white;
    }

        .gpt-InScrollBox .gpt-InScrollContainer {
            height: 95vh !important;
            position: relative;
        }

        .gpt-InScrollBox .gpt-InScrollWrapper {
            position: absolute !important;
            top: 0 !important;
            left: 0;
            width: 100%;
            height: 95vh !important;
            border: 0 !important;
            margin: 0 !important;
            padding: 0 !important;
            clip: rect(0, auto, auto, 0) !important;
            -webkit-clip-path: polygon(0px 0px, 100% 0px, 100% 100%, 0px 100%) !important;
            clip-path: polygon(0px 0px, 100% 0px, 100% 100%, 0px 100%) !important;
        }

        .gpt-InScrollBox .gpt-InScrollInner {
            position: fixed !important;
            top: 0 !important;
            left: 0 !important;
            bottom: 0;
            margin: auto;
            width: 100vw;
            height: 95vh;
            -webkit-transform: translateZ(0) !important;
            display: -webkit-box;
            display: -ms-flexbox;
            display: flex;
            -webkit-box-orient: vertical;
            -webkit-box-direction: normal;
            -ms-flex-direction: column;
            flex-direction: column;
            -webkit-box-align: center;
            -ms-flex-align: center;
            align-items: center;
            -webkit-box-pack: center;
            -ms-flex-pack: center;
            justify-content: center;
            text-align: center;
        }
</style>
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script class="optanon-category-4" type="text/plain">
    //--------------------------------------------------------------------------
    var gpt_Version = '04072023';
    var gpt_AdFile = $('#gpt-Variables').data('adfile');
    var gpt_MaxMOATInitAttempts = 11;
    var gpt_MaxMOATReadyAttempts = 11;
    var gpt_MaxContextualReadyAttempts = 21;
    var gpt_MOATInitAttempts = 0;
    var gpt_MOATReadyAttempts = 0;
    var gpt_ContextualReadyAttempts = 0;
    var gpt_IsProd = true;
    var gpt_StartTime;
    var gs_channels = 'DEFAULT';
    var gpt_ContextualReady = false;
    var gpt_ContextualURL = 'Not enabled outside of Production';
    var gpt_DisableAdsFlagFound = false;

    var gptEvent_Debug = '';
    var gptCustomTargeting_Debug = '';
    var gptSite_Debug = "";
    var gptPage_Debug = "";
    var gptContextualEnabled = false;
    var gptContextualResult_Debug = '';
    var gptContextualInit_Debug = '';
    var gptContextualURL_Debug = '';
    var gptContextualReady_Debug = '';
    var gptMoatReady_Debug = '';
    var gptMoatInit_Debug = '';
    var gptTestENV_Debug = '';
    var gptDisableAds_Debug = '';
    var gptStatus_Debug = 'GPT Still Loading - Refresh Values';
    var gptInvalidAdSize_Debug = '';
    //--------------------------------------------------------------------------
    $(document).ready(function () {
        //Check to see if we are on a development env
        gpt_CheckEnvironment();

        if (!gpt_DisableAdsFlagFound) {
            gpt_StartTime = new Date();
            if (gpt_AdFile !== "PU") {
                //Once the dom has loaded, begin the process to init the ads.
                gpt_InitScripts();
                gpt_CheckForMOATInit();
            }
        }
    });
</script>
<script type="text/javascript">
    function gpt_CheckEnvironment() {
        if ($('#gptDisableAds').length > 0) {
            gptDisableAds_Debug = 'Flag Detected - Ads Disabled';
            gpt_DisableAdsFlagFound = true;
        }
        else {
            gptDisableAds_Debug = 'Ads Enabled';
            gpt_DisableAdsFlagFound = false;
        }
        switch (gpt_AdFile) {
            case 'PU':
                gptContextualEnabled = true;
                if ($("#Environment").val() !== "Prod") {
                    gpt_IsProd = false;
                    gptTestENV_Debug = 'Test Environment Detected';
                }
                else {
                    gptTestENV_Debug = 'Production Environment Detected';
                }
                break;
            case 'JBS':
            case 'LANCET':
                gptContextualEnabled = true;
                if ($(".gpt-ad").length > 0) {
                    //Other ads exist, allow the Prestitial
                    $(document.body).append("<div class='gpt-ad' data-adsize='prestitial'></div>");
                }
                if (window.location.hostname.toLowerCase().indexOf('.literatumonline.') >= 0) {
                    gpt_IsProd = false;
                    gptTestENV_Debug = 'Test Environment Detected';
                }
                else {
                    gptTestENV_Debug = 'Production Environment Detected';
                }
                break;
            default:
                //Cell
                gptContextualEnabled = false;
                if (window.location.hostname.toLowerCase().indexOf('.literatumonline.') >= 0) {
                    gpt_IsProd = false;
                    gptTestENV_Debug = 'Test Environment Detected';
                }
                else {
                    gptTestENV_Debug = 'Production Environment Detected';
                }
                break;
        }
    }
    //--------------------------------------------------------------------------
    function gpt_GetNonCMEArticle() {
        var url;
        $('.articleCitation').each(function (i, obj) {
            if ($(obj).find('.toc__item__detials').length > 0) {
                var itemDetails = $(obj).first().find('.toc__item__detials');
                var cmeFound = 0;
                if (cmeFound == 0) { cmeFound = $(itemDetails).find("img[title~='CME']").length; }
                if (cmeFound == 0) { cmeFound = $(itemDetails).find("img[title~='(CME)']").length; }
                if (cmeFound == 0) { cmeFound = $(itemDetails).find("img[title~='Education']").length; }
                if (cmeFound == 0) { cmeFound = $(itemDetails).find("img[title~='education']").length; }
                if (cmeFound == 0) {
                    var itemLink = $(itemDetails).first().find('.toc__item__title');
                    var linkCount = $(itemLink).first().find("a:contains('CME')").length;
                    if (linkCount == 0) {
                        url = $(itemLink).first().find('a').attr('href');
                        return false;   //Found a URL, break the loop
                    }
                }
            }
        });
        return url;
    }
    //--------------------------------------------------------------------------
    function gpt_GetElapsedTime() {
        var endTime = new Date();
        var timeDiff = endTime - gpt_StartTime; //in ms
        // strip the ms
        timeDiff /= 1000;

        // get seconds
        return seconds = Math.round(timeDiff) + " seconds";
    }
    //--------------------------------------------------------------------------
    function gpt_CheckSSC() {
        //Check for ScreenShot Client
        var gpt_SSC = gpt_GetQuerystring('gpt_ssc', '');
        if (gpt_SSC == '1') {
            //it's the ScreenShotClient, disable MOAT IVT Detection
            $('#gpt-Variables').append('<input type="hidden" id="gptm_data">');
            $('#gptm_data').val(0);
            gpt_Target("m_data");
        }
    }
    //--------------------------------------------------------------------------
    function gpt_LocalSS(adTypeId) {
        window.scrollTo(0, 0);
        gpt_Sleep(1000);
        gpt_ScrollToAd(adTypeId);
        gpt_PreTearsheet(adTypeId);
    }
    //--------------------------------------------------------------------------
    function gpt_InitScripts() {
        if (gpt_AdFile == "PU") {
            if (gpt_IsProd) {
                gpt_ContextualURL = gpt_CheckForNULL($('#canonicalurl').val());
                if (gpt_ContextualURL === null) {
                    gpt_ContextualURL = window.location.href.split('?')[0].split('#')[0];
                }
                else {
                    gpt_ContextualURL = window.location.origin + gpt_ContextualURL;
                }
                var useSSL = 'https:' == document.location.protocol;
                var gs = document.createElement('script');
                gs.async = true;
                gs.type = 'text/javascript';
                gs.src = (useSSL ? 'https:' : 'http:') + '//elsevier.gscontxt.net/multizone/channels.cgi?url=' + encodeURIComponent(gpt_ContextualURL);
                gs.onload = function () {
                    gpt_ContextualReady = true;
                };
                document.head.appendChild(gs);
            }
        }
        else {
            //JBS-Cell-Lancet
            var useSSL = 'https:' == document.location.protocol;

            var gads = document.createElement('script');
            gads.async = true;
            gads.type = 'text/javascript';
            gads.src = (useSSL ? 'https:' : 'http:') + '//securepubads.g.doubleclick.net/tag/js/gpt.js';
            document.head.appendChild(gads);

            if (gpt_IsProd && gptContextualEnabled) {
                gpt_ContextualURL = window.location.href.split('?')[0].split('#')[0];
                var gs = document.createElement('script');
                gs.async = true;
                gs.type = 'text/javascript';
                gs.src = (useSSL ? 'https:' : 'http:') + '//elsevier.gscontxt.net/multizone/channels.cgi?url=' + encodeURIComponent(gpt_ContextualURL);
                gs.onload = function () {
                    gpt_ContextualReady = true;
                };
                document.head.appendChild(gs);
            }

            var elsevierMoatHeader = document.createElement('link');
            elsevierMoatHeader.rel = 'preload';
            elsevierMoatHeader.as = 'script';
            elsevierMoatHeader.src = (useSSL ? 'https:' : 'http:') + '//z.moatads.com/elsevierheader150204004183/moatheader.js';
            document.head.appendChild(elsevierMoatHeader);

            var elsevierMoatAds = document.createElement('link');
            elsevierMoatAds.rel = 'preconnect';
            elsevierMoatAds.src = (useSSL ? 'https:' : 'http:') + '//mb.moatads.com';
            document.head.appendChild(elsevierMoatAds);

            var moatHeader = document.createElement('script');
            moatHeader.async = true; gads.type = 'text/javascript';
            moatHeader.src = (useSSL ? 'https:' : 'http:') + '//z.moatads.com/elsevierheader150204004183/moatheader.js';
            document.head.appendChild(moatHeader);
        }
    }
    //--------------------------------------------------------------------------
    async function gpt_CheckForMOATInit() {
        //Check every 1/10 of a second until MOAT is Loaded or 1 second timeout
        if (gpt_MOATInitAttempts < gpt_MaxMOATInitAttempts) {
            gpt_MOATInitAttempts += 1;
            if (typeof window.moatPrebidApi === "object") {
                //MOAT LOADED
                gptMoatInit_Debug = '0.0' + gpt_MOATInitAttempts + ' seconds';
                gpt_CheckForMOATReady();
            }
            else {
                setTimeout(() => { gpt_CheckForMOATInit(); }, 100);
            }
        }
        else {
            //TIMEOUT: MOAT Not LOADED
            gptMoatInit_Debug = 'Timeout Expired';
            var googletag = googletag || {};
            googletag.cmd = googletag.cmd || [];
            gpt_CheckForContextualReady();
        }
    }
    //--------------------------------------------------------------------------
    function gpt_CheckForMOATReady() {
        //Check every 1/10 of a second until MOAT is Ready or 1 second timeout
        if (gpt_MOATReadyAttempts < gpt_MaxMOATReadyAttempts) {
            gpt_MOATReadyAttempts += 1;
            if (window.moatPrebidApi.safetyDataAvailable()) {
                //MOAT Ready
                gptMoatReady_Debug = '0.0' + gpt_MOATReadyAttempts + " seconds";
                gpt_CheckForContextualReady();
            }
            else {
                setTimeout(() => { gpt_CheckForMOATReady(); }, 100);
            }
        }
        else {
            //TIMEOUT: MOAT Not Ready
            gptMoatReady_Debug = 'Timeout Expired';
            gpt_CheckForContextualReady();
        }
    }
    //--------------------------------------------------------------------------
    function gpt_CheckForContextualReady() {
        //Check every 1/10 of a second until Contextual is Ready or 2 second timeout
        if (gpt_IsProd && gptContextualEnabled) {
            //Enabled
            if (gpt_ContextualReadyAttempts < gpt_MaxContextualReadyAttempts) {
                gpt_ContextualReadyAttempts += 1;
                if (gpt_ContextualReady) {
                    //Contextual Ready
                    gptContextualURL_Debug = gpt_ContextualURL;
                    gptContextualReady_Debug = '0.0' + gpt_ContextualReadyAttempts + " seconds";
                    gptContextualInit_Debug = gs_channels;
                    gpt_InitAds();
                }
                else {
                    setTimeout(() => { gpt_CheckForContextualReady(); }, 100);
                }
            }
            else {
                //LOG TIMEOUT error
                //REMOVE FOR NOW (SHOULD LOG TO A DIFF LOCATION)
                //TIMEOUT: Contextual Not Ready
                $('#gpt_GrapeShotDebugBtn').remove();
                gptContextualURL_Debug = gpt_ContextualURL;
                gptContextualReady_Debug = 'Timeout Expired';
                gptContextualInit_Debug = "";
                gpt_InitAds();
            }
        }
        else {
            //Not Enabled
            $('#gpt_GrapeShotDebugBtn').remove();
            switch (gpt_AdFile) {
                case 'PU':
                case 'LANCET':
                case 'JBS':
                    gptContextualURL_Debug = 'Not enabled outside of Production';
                    gptContextualReady_Debug = 'Not enabled outside of Production';
                    gptContextualInit_Debug = 'Not enabled outside of Production';
                    break;
                case "CELLJOURNAL":
                case "CELLBUCKET":
                    gptContextualReady_Debug = 'Not enabled on Cell';
                    gptContextualInit_Debug = 'Not enabled on Cell';
                    gptContextualURL_Debug = 'Not enabled on Cell';
                    break;
            }
            gpt_InitAds();
        }
    }
    //--------------------------------------------------------------------------
    function GPT_GetPageByURL() {
        var host = window.location.host.toLocaleLowerCase()
        var localpath = window.location.pathname.toLocaleLowerCase();

        ///Check for Cell.com
        if (host.indexOf('cell.com') >= 0) {
            return null;
        }

        ///Check for Cell.com (marlin-stag)
        if (host.indexOf('www-cell-com') >= 0) {
            return null;
        }

        ///Check for Lancet
        if (host.indexOf('thelancet') >= 0) {
            return null;
        }

        if (localpath.indexOf('/article/') >= 0) {
            return 'article.fulltext';
        }

        if (localpath.indexOf('/action/dosearch') >= 0) {
            return 'search.searchResults';
        }

        if (localpath.indexOf('/content/') >= 0) {
            return 'periodical.editorial';
        }

        return 'periodical.home';
    }
    //--------------------------------------------------------------------------
    function gpt_CheckForNULL(x, valueifnull) {
        if (typeof valueifnull == "undefined") {
            valueifnull = null;
        }

        if (typeof x == 'undefined') {
            return valueifnull;
        }
        if (x == null) {
            return valueifnull;
        }
        if (x == "null") {
            return valueifnull;
        }
        if ($.trim(x) == '') {
            return valueifnull;
        }

        return x;
    }
    //--------------------------------------------------------------------------
    function gpt_GetAdditionalTargeting() {
        //adds page level targeting of custom variables
        //the id (minus gpt) and the value will be used as a key-value pair
        //eg: <input type="hidden" id="gptissuepii" value="x" class="gpt-Target">
        //eg: target issuepii=x
        $(".gpt-Target").each(function (index) {
            var gptTargetId = $(this).attr('id');
            gptTargetId = gptTargetId.replace('gpt', '').toLowerCase();
            if (gptTargetId !== '') {
                gpt_Target(gptTargetId);
            }
        })
    }
    //--------------------------------------------------------------------------
    function gpt_GetQuerystring(key, default_) {
        //function to read querystring variables
        if (default_ === null) default_ = '';
        key = key.replace(/[\[]/, "\\\[").replace(/[\]]/, "\\\]");
        var regex = new RegExp("[\\?&]" + key + "=([^&#]*)");
        var qs = regex.exec(window.location.href);
        if (qs === null)
            return default_;
        else
            return qs[1];
    }
    //--------------------------------------------------------------------------
    function gpt_GetDFPTestId() {
        //Get any request for a test id from querystring and set custom targeting parameter
        var gptDFPTestId = gpt_GetQuerystring('dfptestid', '');
        if (gptDFPTestId !== '') {
            $('#gpt-Variables').append('<input type="hidden" id="gptDFPTestId">');
            $('#gptDFPTestId').val(gptDFPTestId);
            gpt_Target("DFPTestId");
        }
    }
    //--------------------------------------------------------------------------
    function gpt_Target(targetName) {
        //Set page level target if value is found
        if ($('#gpt' + targetName).length > 0) {
            var targetValue = $('#gpt' + targetName).val();

            if (targetValue !== '') {
                targetValue = targetValue.replace(/[^-a-z0-9]/ig, '');	//Only Allow a-z, 0-9
                googletag.pubads().setTargeting(targetName.toLowerCase(), targetValue.toLowerCase());
                gptCustomTargeting_Debug = gptCustomTargeting_Debug + targetName.toLowerCase() + ' = ' + targetValue.toLowerCase() + '<br>';
            }
        }
    }
    //--------------------------------------------------------------------------
    function gpt_TargetAccessType() {
        var currentAccessType = $('#gptAccessType').val();
        if (typeof currentAccessType == "undefined") {
            currentAccessType = "";
        }
        if (currentAccessType.indexOf('ANON_IP') >= 0) {
            googletag.pubads().setTargeting("loggedin", "yes");
        }
        else {
            gpt_Target("LoggedIn");
        }
    }
    //--------------------------------------------------------------------------
    async function gpt_PreTearsheet(adTypeId) {
        if (typeof adTypeId === "undefined") {
            adTypeId = 0;
        }
        //Remove Elsevier Cookie Policy Notice
        if ($("#onetrust-consent-sdk").length > 0) {
            $("#onetrust-consent-sdk").remove();
        }

        //Mobile Nav
        $('#skip').remove();
        $('#skipNavigationLink').remove();

        //JBS Modals
        if ($('.leadinModal').length > 0) {
            $('.leadinModal').remove();
        }
        if ($('.leadinModal').length > 0) {
            $('.leadinModal').remove();
        }
        if ($('.usabilla__overlay').length > 0) {
            $('.usabilla__overlay').remove();
        }

        //Pendo
        if ($('._pendo-step-container').length > 0) {
            $('._pendo-step-container').remove();
        }
        if ($('._pendo-guide-tt_').length > 0) {
            $('._pendo-guide-tt_').remove();
        }
        if ($('._pendo-image').length > 0) {
            $('._pendo-image').remove();
        }
        if ($('._pendo-badge-image').length > 0) {
            $('._pendo-badge-image').remove();
        }

        switch (gpt_AdFile) {
            case "CELLJOURNAL":
            case "CELLBUCKET":
                //Mobile Bug Fix on Cell
                if (parseInt(adTypeId) == 5) {
                    $('.widget-horizontalAd').css('position', 'static');
                    $('.body-horizontalAd').css('display', 'block');
                }
                break;
            case "JBS":
            case "LANCET":
                objLeaderboard = ".container-leaderboard";
                offset = 53;
                switch (parseInt(adTypeId)) {
                    case 3: //MPU
                    case 4: //SkyScraper
                        //BUGFIX: Show Sidebar ad for JBS
                        //skyscraper & mpu
                        if ($('.widget-verticalAd').length > 0) {
                            $('.widget-verticalAd').css('display', 'block');
                        }
                        $('#backgroundLayer').css('display', 'none');   //Hide any Prestitial
                        break;
                    case 6:     //Prestitial
                        $('#backgroundLayer').css('display', 'block');
                        break;
                    default:
                        $('#backgroundLayer').css('display', 'none');   //Hide any Prestitial
                        break;
                }
                break;
        }
    }
    //--------------------------------------------------------------------------
    function gpt_Sleep(ms) {
        return new Promise(resolve => setTimeout(resolve, ms));
    }
    //--------------------------------------------------------------------------
    async function gpt_ScrollToAd(adTypeId) {
        if (typeof adTypeId === "undefined") {
            adTypeId = 0;
        }
        var adId = "";
        var offset = 0;
        var objLeaderboard = "";
        var gpt_ScrollToAd = true;

        switch (gpt_AdFile) {
            case "PU": //PracticeUpdate
                var hideOtherAds = true;
                $('#modalPrestitial').modal('hide');
                $('.jumbotron-welcome').hide();
                objLeaderboard = ".container-leaderboard";
                offset = 53;
                switch (parseInt(adTypeId)) {
                    case 2:
                        //LeaderBoard, no Scroll Needed
                        gpt_ScrollToAd = false;
                        adId = "adSlot1";
                        break;
                    case 3:
                        //MPU
                        adId = "adSlot2";
                        break;
                    case 4:
                        //SkyScraper
                        adId = "adSlot3";
                        $('.most-read').hide();
                        break;
                    case 5:
                        //Mobile, no Scroll Needed
                        gpt_ScrollToAd = false;
                        adId = "adSlot1";
                        break;
                    case 6:
                        //Interstitial
                        gpt_ScrollToAd = false;
                        adId = "adSlot15";
                        await gpt_Sleep(1000);
                        $(objLeaderboard).hide();
                        $('#modalPrestitial').unbind();
                        $('#modalPrestitial').modal();
                        break;
                    case 7:
                        //Native Ad
                        break;
                    case 10:
                        //Master Companion
                        hideOtherAds = false;
                        gpt_ScrollToAd = false;
                        break;
                    default:
                        //Unknown Ad Type
                        gpt_ScrollToAd = false;
                        adId = "adSlot1";
                        break;
                }
                if (hideOtherAds) {
                    //Hide all other ads
                    $('.ad-container').each(function (i, obj) {
                        if (this.id !== adId) {
                            var tempParent = this.id;
                            tempParent = tempParent.replace("adSlot", "adParent");
                            $("#" + tempParent).addClass('hide');
                        }
                    });
                }
                break;
            case "JBS":
                objLeaderboard = ".js__adToHide";
                offset = 80;
                switch (parseInt(adTypeId)) {
                    case 2:
                        //Leaderboard
                        gpt_ScrollToAd = false;
                        $(".widget-verticalAd").hide();
                        break;
                    case 5:
                        //Mobile
                        //Scroll to Top
                        gpt_ScrollToAd = false;
                        break;
                    case 3: //MPU
                    case 4: //SkyScraper
                        $(objLeaderboard).hide();
                        adId = $('.gpt-ad-defined[data-adsize="sidebar"').attr('id');
                        break;
                    case 10:
                        //MasterCompanion
                        gpt_ScrollToAd = false;
                        break;
                    case 13:	    //Phone - Portrait
                    case 14:        //Phone - Landscape
                        $(objLeaderboard).hide();
                        offset = 60;
                        adId = 'gpt-Interscroller';
                        gpt_ScrollToAd = true;
                        break;
                    default:
                        //Unknown Ad Type
                        gpt_ScrollToAd = false;
                        break;
                }
                break;
            case "CELLJOURNAL":
            case "CELLBUCKET":
                objLeaderboard = ".js__adToHide";
                offset = 260;
                switch (parseInt(adTypeId)) {
                    case 2:
                        //Leaderboard
                        gpt_ScrollToAd = false;
                        $('.body-verticalAd').hide();
                        break;
                    case 5:
                        //Mobile
                        //Scroll to Top
                        gpt_ScrollToAd = false;
                        break;
                    case 3: //MPU
                    case 4: //SkyScraper
                        $(objLeaderboard).hide();
                        adId = $('.gpt-ad-defined[data-adsize="boombox"').attr('id');
                        break;
                    case 10:
                        //MasterCompanion
                        gpt_ScrollToAd = false;
                        break;
                    default:
                        //Unknown Ad Type
                        gpt_ScrollToAd = false;
                        break;
                }
                //Hide the second ad if found
                var tCount = 0;
                $(".widget.literatumAd.none.GPT-ad-placeholder.widget-horizontalAd.widget-compact-all").each(function (index) {
                    tCount += 1;
                    if (tCount !== 1) {
                        $(this).hide();
                    }
                });
                break;
            case "LANCET":
                objLeaderboard = ".js__adToHide";
                offset = 80;
                switch (parseInt(adTypeId)) {
                    case 2:
                        //Leaderboard
                        gpt_ScrollToAd = false;
                        $('.body-verticalAd').hide();
                        break;
                    case 5:
                        //Mobile
                        //Scroll to Top
                        gpt_ScrollToAd = false;
                        break;
                    case 3: //MPU
                    case 4: //SkyScraper
                        $(objLeaderboard).hide();
                        adId = $('.gpt-ad-defined[data-adsize="skyscraper"').attr('id');
                        break;
                    case 10:
                        //MasterCompanion
                        gpt_ScrollToAd = false;
                        break;
                    default:
                        //Unknown Ad Type
                        gpt_ScrollToAd = false;
                        break;
                }
                break;
        }

        //Scroll to Top
        var gpt_container = $("html,body");
        gpt_container.animate({ scrollTop: 0, scrollLeft: 0 });

        if (gpt_ScrollToAd) {
            //If Adexists, scroll to it
            var gpt_scrollTo = $('#' + adId);
            if (gpt_scrollTo.length > 0) {
                //Scroll to the Ad
                var gpt_topPosition = gpt_scrollTo.offset().top - gpt_container.offset().top + gpt_container.scrollTop();
                if (gpt_topPosition > 0) {
                    gpt_container.animate({ scrollTop: gpt_topPosition, scrollLeft: 0 });
                    if (gpt_topPosition - offset > 0 && offset > 0) {
                        gpt_container.animate({ scrollTop: gpt_topPosition - offset, scrollLeft: 0 });
                    }
                }
            }
        }
    }
    //--------------------------------------------------------------------------
    async function gpt_CheckForCookiePolicy() {
        var returnVal = false;
        if ($('#onetrust-accept-btn-handler').length > 0) {
            $('#onetrust-accept-btn-handler').click();
            returnVal = true;
        }
        return returnVal;
    }
    //--------------------------------------------------------------------------
    function gpt_InitAds() {
        var gpt_ResponsiveHomepage = false;

        switch (gpt_AdFile) {
            case "JBS":
            case "CELLJOURNAL":
            case "CELLBUCKET":
                //Responsive Check
                if ($('#hdrHomeBrand').length > 0) {
                    gpt_ResponsiveHomepage = true;
                }
                break;
        }

        //InterScroller Check
        if (gpt_AdFile === "JBS") {
            var gpt_InterScrollerEnabled = false;
            var gpt_InterScrollerInsertObj;

            if ($("#articleHeader").length > 0) {
                //It's an article Page
                if ($('.article__sections > section').length > 0) {
                    gpt_InterScrollerEnabled = true;
                    gpt_InterScrollerInsertObj = $(".article__sections > section");
                }
            }
            else {
                if ($('.toc__section').length > 0) {
                    //It's a TOC Page
                    gpt_InterScrollerEnabled = true;
                    gpt_InterScrollerInsertObj = $(".toc__section").first();
                }
            }

            //Add the Interscroller
            if (gpt_InterScrollerEnabled) {
                gpt_InterScrollerInsertObj.first().append($("#gpt-Interscroller").clone());
                $("#gpt-Interscroller").remove();
                $(".gpt-adinterscroller").addClass("gpt-ad");
            }
        }

        googletag.cmd.push(function () {
            var gptBoomBoxSizeMapping;
            var gptFluidMapping;
            var gptHomePageSidebarMapping;
            var gptCellHomePageSidebarMapping;
            var gptInterscrollerMapping;
            var gptLeaderboardSizeMapping;
            var gptMobileSizeMapping;
            var gptPrestitialMapping;
            var gptRectangleShortSizeMapping;
            var gptRectangleSizeMapping;
            var gptSideBarSizeMapping;
            var gptTallSizeMapping;
            var gptWideSizeMapping;
            var gptWideRectangleSizeMapping;

            //***********************************************
            //Start Define Size mapping based on client Viewport
            //***********************************************
            if (gpt_AdFile === 'PU') {
                gptTallSizeMapping = googletag.sizeMapping().
                    addSize([992, 0], [[300, 600], [160, 600], [120, 600]]).
                    addSize([0, 0], []).
                    build();

                gptRectangleSizeMapping = googletag.sizeMapping().
                    addSize([992, 0], [[300, 250]]).
                    addSize([0, 0], []).
                    build();

                gptRectangleShortSizeMapping = googletag.sizeMapping().
                    addSize([992, 0], [[300, 250], [320, 50], [300, 50]]).
                    addSize([0, 0], [[300, 250], [320, 50], [300, 50]]).
                    build();

                gptWideSizeMapping = googletag.sizeMapping().
                    addSize([992, 0], [[728, 90]]).
                    addSize([760, 0], [[728, 90], [320, 50], [300, 50]]).
                    addSize([0, 0], [[320, 50], [300, 50]]).
                    build();

                gptWideRectangleSizeMapping = googletag.sizeMapping().
                    addSize([992, 0], []).
                    addSize([760, 0], [[320, 50], [300, 50], [300, 250]]).
                    addSize([0, 0], [[320, 50], [300, 50], [300, 250]]).
                    build();

                gptMobileSizeMapping = googletag.sizeMapping().
                    addSize([0, 0], [[320, 50], [300, 50]]).
                    build();

                gptFluidMapping = googletag.sizeMapping().
                    addSize([0, 0], ['fluid']).
                    build();

                gptPrestitialMapping = googletag.sizeMapping().
                    addSize([760, 0], [[1, 1]]).
                    build();
            }
            else {
                //JBS-CELL-LANCET
                gptLeaderboardSizeMapping = googletag.sizeMapping().
                    addSize([992, 0], [[728, 90]]). 						// Desktop
                    addSize([768, 0], [[728, 90]]). 								// Tablet Landscape
                    addSize([0, 0], [[320, 50], [300, 50]]). 						// Phone & Tablet Portrait
                    build();

                gptHomePageSidebarMapping = googletag.sizeMapping().
                    addSize([2090, 795], [[300, 600], [300, 250], [160, 600], [120, 600]]).
                    addSize([1910, 795], [[160, 600], [120, 600]]).
                    addSize([0, 0], []).
                    build();

                gptCellHomePageSidebarMapping = googletag.sizeMapping().
                    addSize([2090, 795], [[300, 600], [300, 250], [336, 280], [160, 600], [120, 600]]).
                    addSize([1910, 795], [[160, 600], [120, 600]]).
                    addSize([0, 0], []).
                    build();

                gptSideBarSizeMapping = googletag.sizeMapping().
                    addSize([1140, 795], [[300, 600], [160, 600], [120, 600], [300, 250]]). 	// SkyScraper - Desktop (Require min 630 vertical)
                    addSize([1140, 445], [[300, 250]]).			 				// BoomBox Fall Back - Desktop (Require min 280 vertical)
                    addSize([0, 0], []). 										// Phone
                    build();

                gptBoomBoxSizeMapping = googletag.sizeMapping().
                    addSize([768, 0], [[300, 250], [336, 280]]). 					// Desktop & Tablet Landscape
                    addSize([0, 0], []). 											// Phone
                    build();

                gptFluidMapping = googletag.sizeMapping().
                    addSize([0, 0], ['fluid']).
                    build();

                gptPrestitialMapping = googletag.sizeMapping().
                    addSize([600, 700], [[1, 1]]). 					// Desktop & Tablet Landscape
                    addSize([0, 0], []). 							// Phone
                    build();

                gptInterscrollerMapping = googletag.sizeMapping().
                    addSize([1140, 445], []).
                    addSize([1024, 768], [[1024, 768]]).
                    addSize([768, 1024], [[768, 1024]]).
                    addSize([480, 320], [[480, 320]]).
                    addSize([320, 480], [[320, 480]]).
                    build();
            }
            //***********************************************
            //End Define Size mapping based on client Viewport
            //***********************************************

            //***********************************************
            //Start detection for ad slots on page
            //***********************************************
            var gptMasterPage = gpt_CheckForNULL($('#gptPage').val());
            var gptMasterSite;

            if (gpt_AdFile === 'PU') {
                gptMasterSite = $('#gptSite').val();
            }
            else {
                //JBS-CELL-LANCET
                gptMasterSite = "dev";

                if (gpt_IsProd) {
                    gptMasterSite = gpt_CheckForNULL($('#gptSite').val());

                    //If there is no master site, check for a defaultsite
                    if (gptMasterSite == null) {
                        gptMasterSite = gpt_CheckForNULL($('#gptDefaultSite').val());
                    }
                }
                else {
                    //Dev ENV
                    //If the page has no gptSite Value, assume no value which will disable ads
                    if (gpt_CheckForNULL($('#gptSite').val()) === null) {
                        gptMasterSite = null;
                    }
                }

                //If there is no master Page, check for a Page using the URL
                if (gptMasterPage === null) {
                    gptMasterPage = GPT_GetPageByURL();
                }
            }

            $(".gpt-ad").each(function (index) {
                var gptPage = '';
                var adSizeMapping = '';
                var gptPOS;
                var gptTC;
                var gptNative;
                var adId;
                var gptSite;
                var tempSlot = null;

                if (gpt_IsProd) {
                    //Check if the ad slot has it's own site defined
                    if (typeof $(this).data('site') === 'undefined') {
                        gptSite = gptMasterSite;
                    }
                    else {
                        gptSite = gpt_CheckForNULL($(this).data('site'));
                    }
                }
                else {
                    gptSite = gptMasterSite;
                }

                if (gpt_AdFile === 'PU') {
                    adId = $(this).attr('id');
                }
                else {
                    //JBS-CELL-LANCET
                    adId = 'gpt-ad-' + index + 1;
                }

                if (gpt_CheckForNULL(gptSite) !== null) {
                    gptSite_Debug = gptSite;

                    gptPOS = parseInt($(this).data('pos')) || -1;
                    if (gptPOS === -1) {
                        gptPOS = index + 1;
                    }

                    //Check if the ad slot has it's own page defined
                    gptPage = $(this).data('page');
                    if (gpt_CheckForNULL(gptPage) == null) {
                        //Use the Master Page
                        gptPage = gptMasterPage;
                    }


                    //If the page is not null, preceed it with a slash
                    if (gptPage !== null) {
                        gptPage = '/' + gptPage;
                    }
                    else {
                        gptPage = '';
                    }
                    gptPage_Debug = gptPage;


                    gptTC = $(this).data('tc');
                    if (typeof gptTC === "undefined") {
                        gptTC = '';
                    }

                    gptNative = $(this).data('native');
                    if (typeof gptNative === "undefined") {
                        gptNative = '';
                    }

                    //Determine sizemapping based on data-adsize
                    if (gpt_AdFile === 'PU') {
                        switch ($(this).data('adsize')) {
                            case 'tall':
                                adSizeMapping = gptTallSizeMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[120, 600], [160, 600], [300, 600]], adId);
                                break;
                            case 'rectangle':
                                adSizeMapping = gptRectangleSizeMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[300, 250]], adId);
                                break;
                            case 'rectangleshort':
                                adSizeMapping = gptRectangleShortSizeMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[300, 250], [320, 50], [300, 50]], adId);
                                break;
                            case 'wide':
                                adSizeMapping = gptWideSizeMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[728, 90], [320, 50], [300, 50]], adId);
                                break;
                            case 'widerectangle':
                                adSizeMapping = gptWideRectangleSizeMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[320, 50], [300, 50], [300, 250]], adId);
                                break;
                            case 'mobile':
                                adSizeMapping = gptMobileSizeMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[320, 50], [300, 50]], adId);
                                break;
                            case 'fluid':
                                adSizeMapping = gptFluidMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, 'fluid', adId);
                                break;
                            case 'prestitial':
                                adSizeMapping = gptPrestitialMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[1, 1]], adId);
                                break;
                        }
                    }
                    else {
                        //JBS-CELL-LANCET
                        switch ($(this).data('adsize')) {
                            case 'cell-leaderboard':
                            case 'leaderboard':
                                adSizeMapping = gptLeaderboardSizeMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[728, 90], [320, 50], [300, 50]], adId);
                                break;
                            case 'bottom':
                                if (gpt_ResponsiveHomepage) {
                                    adSizeMapping = gptHomePageSidebarMapping;
                                    tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[120, 600], [160, 600], [300, 600], [300, 250]], adId);
                                }
                                else {
                                    adSizeMapping = gptBoomBoxSizeMapping;
                                    tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[300, 250]], adId);
                                }
                                break;
                            case 'boombox':
                                if (gpt_AdFile === "CELLJOURNAL" || gpt_AdFile == "CELLBUCKET") {
                                    if (gpt_ResponsiveHomepage) {
                                        adSizeMapping = gptCellHomePageSidebarMapping;
                                        tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[120, 600], [160, 600], [300, 600], [300, 250], [336, 280]], adId);
                                    }
                                    else {
                                        adSizeMapping = gptBoomBoxSizeMapping;
                                        tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[300, 250], [336, 280]], adId);
                                    }
                                }
                                else {
                                    adSizeMapping = gptBoomBoxSizeMapping;
                                    tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[300, 250]], adId);
                                }
                                break;
                            case 'interscroller':
                                adSizeMapping = gptInterscrollerMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[320, 480], [480, 320], [768, 1024], [1024, 768]], adId);
                                break;
                            case 'sidebar':
                            case 'skyscraper':
                                adSizeMapping = gptSideBarSizeMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[120, 600], [160, 600], [300, 600], [300, 250]], adId);
                                break;
                            case 'native':
                            case 'fluid':
                                adSizeMapping = gptFluidMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, 'fluid', adId);
                                break;
                            case 'prestitial':
                                adSizeMapping = gptPrestitialMapping;
                                tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, 'fluid', adId);
                                break;
                        }
                    }
                }

                //Ignore any invalid adsizes that could be on the page
                if (adSizeMapping !== '') {
                    $(this).addClass('gpt-ad-defined');
                    if (gpt_AdFile !== 'PU') {
                        $(this).attr('id', adId);
                    }
                    tempSlot.defineSizeMapping(adSizeMapping).addService(googletag.pubads()).setTargeting("pos", gptPOS);

                    if (gptTC !== '') {
                        tempSlot.setTargeting("tc", gptTC);
                    }
                    if (gptNative !== '') {
                        tempSlot.setTargeting("native", gptNative);
                    }
                    gptEvent_Debug = gptEvent_Debug + $(this).data('adsize') + ' Requested<br>';
                }
                else {
                    gptInvalidAdSize_Debug = gptInvalidAdSize_Debug + "Invalid Size Found, Id: " + $(this).prop('id') + ', adSize: ' + $(this).data('adsize') + '<br>';
                    $(this).remove();
                }
            });
            if (gpt_CheckForNULL(gptInvalidAdSize_Debug) === null) {
                gptInvalidAdSize_Debug = "None Detected";
            }
            //***********************************************
            //End detection for ad slots on page
            //***********************************************

            //***********************************************
            //Start page level targeting
            //***********************************************
            if (gpt_AdFile !== 'PU') {
                //Logged in or IP Access
                gpt_TargetAccessType();

                //Check for Screenshot Client
                gpt_CheckSSC();
            }

            //Check for DFP Test
            gpt_GetDFPTestId();

            //Check for Additional Targeting
            gpt_GetAdditionalTargeting();

            if (gpt_IsProd && gptContextualEnabled) {
                var gpt_ContextualRetry = false;
                //Check for Contextual Targeting
                if (gs_channels !== "DEFAULT") {
                    var gpt_ContextualCategories = Array.from(gs_channels);
                    for (var i = 0; i < gpt_ContextualCategories.length; i++) {
                        if (gpt_ContextualCategories[i] == 'gx_retry') {
                            gpt_ContextualRetry = true;
                        }
                        if (!gpt_ContextualCategories[i].startsWith("custom_")) {
                            //Remove any tag that is not custom
                            gpt_ContextualCategories.splice(i, 1);
                            i--;
                        }
                        else {
                            //Strip the 'custom_' from the tag
                            gpt_ContextualCategories[i] = gpt_ContextualCategories[i].replace("custom_", "")
                        }
                    }
                    if (gpt_ContextualCategories.length > 0) {
                        googletag.pubads().setTargeting("gs_cat", gpt_ContextualCategories);
                    }
                    else {
                        gpt_ContextualCategories = 'none';
                    }
                    if (gpt_ContextualRetry) {
                        gpt_ContextualCategories = "*Indexing*";
                    }
                    gptContextualResult_Debug = gpt_ContextualCategories;
                }
                else {
                    gptContextualResult_Debug = 'No segments found';
                }
            }
            else {
                //Not Prod
                gptContextualResult_Debug = 'Not enabled';
                var gpt_DevSite = gpt_CheckForNULL($('#gptSite').val(), "dev");
                $('#gpt-Variables').append('<input type="hidden" id="gptEnvironment" value="' + gpt_DevSite + '">');
                gpt_Target("Environment");
            }
            //***********************************************
            //End page level targeting
            //***********************************************

            //Enable google dfp services
            if (parseInt($('#gptLazyLoading').val()) === 1) {
                googletag.pubads().enableLazyLoad({
                    fetchMarginPercent: 200,
                    renderMarginPercent: 0,
                    mobileScaling: 2.0
                });
            }
            else {
                googletag.pubads().enableSingleRequest();
            }

            //Add Listener for RenderEnded
            googletag.pubads().addEventListener('slotRenderEnded', function (event) {
                if (!event.isEmpty) {
                    if (typeof LocalAdLoaded === "function") {
                        LocalAdLoaded(event);
                    }
                    if (gpt_ResponsiveHomepage) {
                        if (typeof positionAd === "function") {
                            positionAd();
                        }
                    }
                    if (event.size[0] == "480" || event.size[1] == "480") {
                        $('.gpt-InScrollBox').css('display', 'block');
                        gptEvent_Debug = gptEvent_Debug + 'Interscroller ' + event.size + ' rendered: ' + gpt_GetElapsedTime() + '<br>';
                    }
                    else {
                        gptEvent_Debug = gptEvent_Debug + event.size + ' rendered: ' + gpt_GetElapsedTime() + '<br>';
                    }

                }
            });

            if (gpt_AdFile !== 'PU') {
                googletag.pubads().collapseEmptyDivs();
            }
            googletag.enableServices();

            //Populate Defined Ad Slots
            $(".gpt-ad-defined").each(function (index) {
                var adId = $(this).attr('id');
                googletag.cmd.push(function () { googletag.display(adId); });
            });

            gptStatus_Debug = 'GPT Complete';
        });
    }
    //--------------------------------------------------------------------------
    function gpt_DisplayDebug() {
        //Clone the template and append to Body
        $(document.body).append($('#gpt-DebugDiv').clone());
        $('#gpt-DebugDiv').remove();

        //Populate the Values
        gpt_LoadDebugValues();

        //Display and scroll to debug section
        $('.gpt-DebugDiv').css('display', 'block');
        window.scrollTo(0, document.body.scrollHeight);
    }
    //--------------------------------------------------------------------------
    function gpt_LoadDebugValues() {
        $('.gpt-DebugBtn').blur();
        $('.gptVersion_Debug').text(gpt_Version);
        $('.gptAdFile_Debug').html(gpt_AdFile);
        $('.gptEvent_Debug').html(gptEvent_Debug);
        $('.gptCustomTargeting_Debug').html(gptCustomTargeting_Debug);
        $('.gptSite_Debug').text(gptSite_Debug);
        $('.gptContextualResult_Debug').text(gptContextualResult_Debug);
        $('.gptContextualInit_Debug').text(gptContextualInit_Debug);
        $('.gptContextualURL_Debug').text(gptContextualURL_Debug);
        $('.gptContextualReady_Debug').text(gptContextualReady_Debug);
        $('.gptMoatReady_Debug').text(gptMoatReady_Debug);
        $('.gptMoatInit_Debug').text(gptMoatInit_Debug);
        $('.gptTestENV_Debug').text(gptTestENV_Debug);
        $('.gptDisableAds_Debug').text(gptDisableAds_Debug);
        $('.gptStatus_Debug').text(gptStatus_Debug);
        $('.gptPage_Debug').text(gptPage_Debug);
        $('.gptInvalidAdSize_Debug').html(gptInvalidAdSize_Debug);
    }
    //--------------------------------------------------------------------------
    function gpt_GrapeShotDebug() {
        $('.gpt-DebugBtn').blur();
        window.open("http://admin-elsevier.grapeshot.co.uk/custom/bookmarklet.cgi?blocking=1&vn=2&url=" + encodeURIComponent(document.location), "GRAPESHOT_POPUP", "width=650,height=600,scrollbars=yes,screenX=40,screenY=50,menubar=no,toolbar=no,resizable=yes", "Custom").focus();
    }
    //--------------------------------------------------------------------------
    function gpt_ShowConsole() {
        $('.gpt-DebugBtn').blur();
        googletag.openConsole();
    }
    //--------------------------------------------------------------------------
</script>
        </div>

            
                </div>
            

        

    

        


    

            

            

            <div data-widget-id="53023812-5eb3-476f-8922-6f6f95be0a5c" data-widget-name="ux3-layout-widget"><header class="header base fixed">
    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget literatumAd none adplaceholder adplaceholder--header js__adToHide widget-horizontalAd" id="ad532c9c-4e0f-4b0d-8b27-9bd0ddbdb190">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-horizontalAd "><div class="horizontalAdContainer">
    <div class="horizontalAdLabelContainer">
        <div class="horizontalAdLabel">
                <img src="/templates/jsp/_style2/_marlin/images/bg_adHoriz.gif" alt="Advertisement"/>
        </div>
    </div>
    <div class="horizontalAd">
        





        <div class="pb-ad">
            <div class="gpt-ad" data-adsize="leaderboard"></div>
        </div>
    

    </div>
</div></div>
                </div>
                </div>

        










        <div data-widget-def="ux3-layout-widget" data-widget-id="3bd430f7-bd17-4546-89a2-5b0ca3b18cdf" class="header__wrapper clearfix" data-db-parent-of="quickSearch">
        
    

        


    

            

            

            <div data-widget-id="3bd430f7-bd17-4546-89a2-5b0ca3b18cdf" data-widget-name="ux3-layout-widget"><div class="col-xs-6 col-lg-6 journal-logos-wrapper header__left-side">
    

        


    

            

            
                <div class="journal-logos">
            

            <span data-widget-id="ecdbcba0-b4aa-4389-a4c7-33705333b11e" data-widget-name="ux3-general-image"><a href="/home" title="Annals of Oncology"><img alt="Annals of Oncology" src="/pb-assets/ux3/logos/ha/annonc-masthead2-1724936535753.svg"/></a></span>

            
                </div>
            

        
</div><div class="col-xs-6 col-lg-6">
    

        


    

            

            

            <div data-widget-id="27014d70-9f94-467d-857b-805d256132d2" data-widget-name="ux3-layout-widget"><div class="header__nav row">
    

        


    

            

            

            <ul data-widget-id="337ee8a8-34c0-420d-84ae-7906e01fd189" data-widget-name="UX3ProfileLinksWidget" class="rlist rlist--inline profile-links"><li class="profile-links__user-list"><div class="dropBlock profile-links__user-list__wrapper"><a href="#" data-db-target-for="loginmenu" aria-expanded="false" aria-controls="login-links" title="LogIn" aria-label="Log in" class="profile-links__username">Log in</a><div data-db-target-of="loginmenu" id="login-links" class="dropBlock__holder profile-links__user-list__holder"><ul class="rlist article-tools__sub-list"><li class="article-tools__sub-item"><a href="https://www.annalsofoncology.org/action/marlinSso?redirectUri=https%3A%2F%2Fwww.annalsofoncology.org%2Farticle%2FS0923-7534%2819%2947184-6%2Ffulltext" title="ESMO Login">ESMO Login</a></li><li class="article-tools__sub-item"><a href="/action/showLogin?redirectUri=https%3A%2F%2Fwww.annalsofoncology.org%2Farticle%2FS0923-7534%2819%2947184-6%2Ffulltext&amp;pii=S0923-7534%2819%2947184-6" title="Non-Member login" class="show-login">Non-Member login</a></li></ul></div></div></li><li class="profile-links__register"><a href="/action/registration?redirectUri=https%3A%2F%2Fwww.annalsofoncology.org%2Farticle%2FS0923-7534%2819%2947184-6%2Ffulltext&amp;directReg=true" title="Register a username and password for free">Register</a></li><li class="profile-links__subscribe"><a href="/action/ecommerce" title="Subscribe">Subscribe</a></li><li class="profile-links__claim"><a href="/action/activateClaim" title="Claim your online subscription">Claim</a></li></ul>

            

        
</div></div>

            

        
</div></div>

            

        

        </div>
    

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget csasInstitutionBanner none  widget-none" id="ee8e0108-277d-418e-a042-5980d028efd5">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-none "><div class="ui-state-highlight ui-corner-all csas-institution-banner hidden" data-doi="10.1093/annonc/mdv304">
    <span class="ui-icon ui-icon-close banner-close"></span>
    <p>
        Access provided by <span class="accountName"></span>
    </p>
</div>

<style>
    .csas-institution-banner {
        padding: 10px 0 0 10px;
        margin: 5px;
    }

    .csas-institution-banner.ui-state-highlight .ui-icon {
        background-image: url("/templates/jsp/css/jquery-ui-1.10.2/base/images/ui-icons_454545_256x240.png");
        margin-right: 5px;
        margin-top: -4px;
    }

    .csas-institution-banner .banner-close {
        float: right;
    }
</style>

<script>

    function resetBanner(doi) {
        $.get('/action/getAccount?doi=' + doi, function(data) {
            if (data) {
                $(".csas-institution-banner p .accountName").html(data);
                $(".csasInstitutionBanner").fadeIn();
                $(".csas-institution-banner").fadeIn();
            }
        });
    }

    var flag = 0;
    $(document).ready(function() {
        if(!$(".csas-institution-banner").is(":visible")){
            $(".csasInstitutionBanner").hide();
        }

        $(".banner-close").click(function() {
            $.get("/action/dismissBanner", function(data) {
                $(".csasInstitutionBanner").fadeOut(function () {
                    if(typeof UX !== 'undefined') {
                        UX.pageBody.init();
                    }
                });
            });
        });

        $(".articleContent .tabs li[role='tab'].showFullText").click(function() {
           flag = 1;
        });

        $(document).on("reloadTabsContent", function() {
            var isSelected = $(".articleContent .tabs li[role='tab'].showFullText").hasClass("active");
            if (isSelected) {
                var isHidden =  $(".csas-institution-banner").is(".hidden");
                if (!isHidden) {
                    resetBanner($(".csas-institution-banner").data("doi"));
                    console.log("fadeIn");
                }
            } else {
                $(".csas-institution-banner").fadeOut();
                console.log("fadeOut");
            }
            flag = 0;
        });

        $(document).on("click", ".articleContent .tabs li[role='tab']", function() {

        });
    });
</script></div>
                </div>
                </div>

        
</header></div>

            

        










        <div data-widget-def="graphQueryWidget" data-widget-id="fad9a144-1a93-40be-baba-cf44f74c2b48" class="ux3">
        
    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                            
                        
                        
                            
                            
                            
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget graphQueryWidget none top-padding-handler noMargin axel-mega-menu widget-none  widget-compact-all" id="fad9a144-1a93-40be-baba-cf44f74c2b48">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-none  body-compact-all"><nav id="mega-menu-nav" role="navigation" class="mega-menu-nav">
  <!--.skip//a(href='#searchText' aria-label='Skip menu') Skip menu
  -->
  <div class="mega-menu-nav__wrapper">
    <button class="mega-menu__toggle"><span class="sr-only">Main menu</span><i aria-hidden="true" class="icon-gizmo-hamburger"></i></button>
    <ul role="menubar" class="mega-menu rlist">
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-1" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-1" data-item-link="main-menu-link-1" data-index="0" class="mega-menu__item-link menu-link"><span>ESMO Journals</span></a>
        <div id="main-menu-panel-1" aria-labelledby="main-menu-link-1" data-item-wrapper="main-menu-link-1" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/3" class="double-width sub-menu__item">
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-2">
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.esmojournals.org" data-index="0" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>ESMOjournals.org
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.annalsofoncology.org" data-index="1" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Annals of Oncology
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.esmogastro.org" data-index="2" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>ESMO Gastrointestinal Oncology
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.esmoopen.com" data-index="3" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>ESMO Open
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.esmorwd.org" data-index="4" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>ESMO Real World Data and Digital Oncology
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.esmoiotech.org" data-index="5" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Immuno-Oncology and Technology
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.thebreastonline.com" data-index="6" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>The Breast
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.lungcancerjournal.info" data-index="7" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Lung Cancer
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.cancertreatmentreviews.com" data-index="8" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Cancer Treatment Reviews
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.clinical-lymphoma-myeloma-leukemia.com" data-index="9" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Clinical Lymphoma Myeloma & Leukaemia
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
              </ul>
            </li>
          </ul>
        </div>
      </li>
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-2" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-2" data-item-link="main-menu-link-2" data-index="1" class="mega-menu__item-link menu-link"><span>Articles</span></a>
        <div id="main-menu-panel-2" aria-labelledby="main-menu-link-2" data-item-wrapper="main-menu-link-2" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/2" class="double-width sub-menu__item">
              <div aria-label="Menu dropzone section" tabindex="-1" class="listDropZone">
    

        


    

            

            
                <div class="hidden-xs hidden-sm">
            

            <div class="cover-image"><div class="cover-image__thumb"><a href="/issue/S0923-7534(24)X0011-3"><img src="/cms/asset/atypon:cms:attachment:img:d97e6:rev:1726103890783-6669:pii:S0923753424X00113/cover.tif.jpg" alt="Cover Image - Annals of Oncology, Volume 35, Issue 10"/></a></div><div class="cover-image__meta"></div></div>

            
                </div>
            

        
</div>
            </li>
            <li style="grid-column: 2/3" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-2-2" class="sub-menu__heading">Latest
              </h4>
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/inpress" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Articles in Press</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/current" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Current Issue</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/issues" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>Past Issues</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/content/supplements" data-index="3" role="menuitem" class="sub-menu__item-link menu-link"><span>Supplements</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/content/editors_choices" data-index="4" role="menuitem" class="sub-menu__item-link menu-link"><span>Editor's Choice</span></a></li>
              </ul>
            </li>
            <li style="grid-column: 3/5" class="double-width sub-menu__item">
              <div aria-label="Menu dropzone section" tabindex="-1" class="listDropZone">









        <div data-widget-def="UX3MultiSearchWidget" data-widget-id="0e3a8eee-9121-417e-b2cd-9dfad40852d6" class="hidden-xs hidden-sm">
        
    

        


    

            
                <h2>Popular Articles</h2>
            

            
                <div class="navarticlecss">
            

            <ul class="publication-list rlist publication-list--list"><li class="search__item clearfix separator"><div class="search__item__body"><!--S0923-7534(23)05104-9--><div class="meta__header"><div class="meta__type-access"><div class="meta__type">Special article</div></div></div><span class="hlFld-Title"><h4 class="meta__title"><a href="/article/S0923-7534(23)05104-9/fulltext" class="full-title-multi-search">Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up</a></h4></span><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Loibl et al.</li></ul><div class="action-links"></div><div class="alt-multi-search__article__preview"></div></div></li><li class="search__item clearfix separator"><div class="search__item__body"><!--S0923-7534(24)03762-1--><div class="meta__header"><div class="meta__type-access"><div class="meta__type">Original article</div></div></div><span class="hlFld-Title"><h4 class="meta__title"><a href="/article/S0923-7534(24)03762-1/fulltext" class="full-title-multi-search">Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial</a></h4></span><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Monk et al.</li></ul><div class="action-links"></div><div class="alt-multi-search__article__preview"></div></div></li><li class="search__item clearfix separator"><div class="search__item__body"><!--S0923-7534(22)04187-4--><div class="meta__header"><div class="meta__type-access"><div class="meta__type">Special article</div></div></div><span class="hlFld-Title"><h4 class="meta__title"><a href="/article/S0923-7534(22)04187-4/fulltext" class="full-title-multi-search">Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up</a></h4></span><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Haanen et al.</li></ul><div class="action-links"></div><div class="alt-multi-search__article__preview"></div></div></li></ul>

            
                </div>
            

        

        </div>
    
</div>
            </li>
            <li style="grid-column: 5/7" class="double-width sub-menu__item">
              <div aria-label="Menu dropzone section" tabindex="-1" class="listDropZone">
    

        


    

            
                <h2>Latest Articles</h2>
            

            
                <div class="navarticlecss">
            

            <ul class="publication-list rlist publication-list--list"><li class="search__item clearfix separator"><div class="search__item__body"><!--S0923-7534(24)03926-7--><div class="meta__header"><div class="meta__type-access"><div class="meta__type">Letter to the editor</div></div></div><span class="hlFld-Title"><h4 class="meta__title"><a href="/article/S0923-7534(24)03926-7/fulltext" class="full-title-multi-search">Response to letters to the Editor on ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’</a></h4></span><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Goetz et al.</li></ul><div class="action-links"></div><div class="alt-multi-search__article__preview"></div></div></li><li class="search__item clearfix separator"><div class="search__item__body"><!--S0923-7534(24)04055-9--><div class="meta__header"><div class="meta__type-access"><div class="meta__type">Review</div></div></div><span class="hlFld-Title"><h4 class="meta__title"><a href="/article/S0923-7534(24)04055-9/fulltext" class="full-title-multi-search">Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action</a></h4></span><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Meyer et al.</li></ul><div class="action-links"></div><div class="alt-multi-search__article__preview"></div></div></li><li class="search__item clearfix separator"><div class="search__item__body"><!--S0923-7534(24)04062-6--><div class="meta__header"><div class="meta__type-access"><div class="meta__type">Letter to the Editor</div></div></div><span class="hlFld-Title"><h4 class="meta__title"><a href="/article/S0923-7534(24)04062-6/fulltext" class="full-title-multi-search">Chi-Squared and P-Values vs. Machine Learning Feature Selection</a></h4></span><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Y. Takefuji</li></ul><div class="action-links"></div><div class="alt-multi-search__article__preview"></div></div></li></ul>

            
                </div>
            

        
</div>
            </li>
          </ul>
        </div>
      </li>
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-3" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-3" data-item-link="main-menu-link-3" data-index="2" class="mega-menu__item-link menu-link"><span>Publish</span></a>
        <div id="main-menu-panel-3" aria-labelledby="main-menu-link-3" data-item-wrapper="main-menu-link-3" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/2" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-3-1" class="sub-menu__heading">For Authors
              </h4>
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.editorialmanager.com/annonc/default2.aspx" data-index="0" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Submit Article
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.elsevier.com/journals/annals-of-oncology/0923-7534/guide-for-authors" data-index="1" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Guide for Authors
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/aims" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>Aims & Scope</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.elsevier.com/journals/annals-of-oncology/0923-7534/open-access-options" data-index="3" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Open Access Information
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://researcheracademy.elsevier.com/" data-index="4" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Researcher Academy
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/pb/assets/raw/Health%20Advance/journals/annonc/Editable_figures_Guide_For_Authors_final-version_V2-1611939338513.pdf" data-index="5" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Editable Figure Guidance
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.sciencedirect.com/journal/annals-of-oncology/about/insights" data-index="6" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Journal Insights
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
              </ul>
            </li>
          </ul>
        </div>
      </li>
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-4" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-4" data-item-link="main-menu-link-4" data-index="3" class="mega-menu__item-link menu-link"><span>Topics</span></a>
        <div id="main-menu-panel-4" aria-labelledby="main-menu-link-4" data-item-wrapper="main-menu-link-4" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/2" class="double-width sub-menu__item">
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/content/ESMO_clinical_practice_guidelines" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>ESMO Guidelines</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/content/review" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Reviews</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/content/COVID-19" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>COVID-19</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/content/plain_language_summaries" data-index="3" role="menuitem" class="sub-menu__item-link menu-link"><span>Plain language summaries</span></a></li>
              </ul>
            </li>
          </ul>
        </div>
      </li>
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-5" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-5" data-item-link="main-menu-link-5" data-index="4" class="mega-menu__item-link menu-link"><span>Multimedia</span></a>
        <div id="main-menu-panel-5" aria-labelledby="main-menu-link-5" data-item-wrapper="main-menu-link-5" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/2" class="double-width sub-menu__item">
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="https://soundcloud.com/esmo-podcasts" data-index="0" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Podcasts
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
              </ul>
            </li>
          </ul>
        </div>
      </li>
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-6" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-6" data-item-link="main-menu-link-6" data-index="5" class="mega-menu__item-link menu-link"><span>About</span></a>
        <div id="main-menu-panel-6" aria-labelledby="main-menu-link-6" data-item-wrapper="main-menu-link-6" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/2" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-6-1" class="sub-menu__heading">Society
              </h4>
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.esmo.org/" data-index="0" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>ESMO
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.sciencedirect.com/journal/annals-of-oncology/about/editorial-board" data-index="1" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Editorial Board
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.esmo.org/membership/join-esmo" data-index="2" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Join our Society
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
              </ul>
            </li>
            <li style="grid-column: 2/3" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-6-2" class="sub-menu__heading">Journal Information
              </h4>
              <ul role="menubar" data-index="1" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/aims" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Aims & Scope</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.sciencedirect.com/journal/annals-of-oncology/about/insights" data-index="1" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Journal Insights
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/content/permission" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>Permissions</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.medreprints.com" data-index="3" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Reprints
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
              </ul>
            </li>
            <li style="grid-column: 3/4" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-6-3" class="sub-menu__heading">Access
              </h4>
              <ul role="menubar" data-index="2" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/action/ecommerce" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Subscribe</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/action/activateClaim" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Activate Online Access</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://esmo.my.site.com/myesmo/s/login" data-index="2" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Society Member Log In
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
              </ul>
            </li>
          </ul>
        </div>
      </li>
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-7" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-7" data-item-link="main-menu-link-7" data-index="6" class="mega-menu__item-link menu-link"><span>Contact</span></a>
        <div id="main-menu-panel-7" aria-labelledby="main-menu-link-7" data-item-wrapper="main-menu-link-7" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/2" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-7-1" class="sub-menu__heading">Contact
              </h4>
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/contact-us" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Contact Us</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.elsmediakits.com/specialty-audiences/oncologyhematology/annals-oncology/annonc/2023" data-index="1" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Advertise with Us
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="http://www.elsevierhealth.com/index.jsp" data-index="2" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Go to Product Catalog
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
              </ul>
            </li>
            <li style="grid-column: 2/3" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-7-2" class="sub-menu__heading">Follow Us
              </h4>
              <ul role="menubar" data-index="1" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=annonc&amp;referrer=/" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>New Content Alerts</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://twitter.com/Annals_Oncology" data-index="1" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Twitter
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.facebook.com/esmo.org/" data-index="2" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Facebook
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.linkedin.com/company/european-society-for-medical-oncology" data-index="3" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>LinkedIn
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
              </ul>
            </li>
          </ul>
        </div>
      </li>
    </ul>
    <div class="mega-menu-nav__quick-search">
    

        


    

            

            

            <div data-widget-id="4b13527a-8285-4636-ac31-0e0ddddf175f" data-widget-name="UX3QuickSearchWidget" class="quick-search"><div class="dropBlock"><form action="https://www.annalsofoncology.org/action/doSearch?journalCode=annonc" name="quickSearchBar" method="get" title="Quick Search"><input id="type" type="hidden" value="quicksearch" name="type"/><div class="quick-search__toggle"><input id="searchText" type="text" name="text1" placeholder="Search for..." enterkeyhint="search" autocomplete="off" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" data-group-titles-conf="3" data-publication-items-conf="3" aria-label="Enter a search term" class="searchText searchText-autocomplete"/><button type="submit" title="Search" aria-label="Submit the search form" class="btn quick-search__button icon-search"><span>Go search</span></button><a href="https://www.annalsofoncology.org/search/advanced?SeriesKey=annonc&amp;ISSN=0923-7534&amp;journalCode=annonc" title="Advanced search" class="quick-search__advanced-link">Advanced search</a></div><div class="quick-search__box"><div class="quick-search__box-inner"><div class="quick-search__box-wrapper"><select name="field1" aria-label="Select a search area"><option value="AllField">All content</option><option value="Title">Article title</option><option value="Contrib">Authors</option><option value="Keyword">Keywords</option><option value="Abstract">Abstract</option><option value="AbstractTitleKeywordFilterField">Article title, abstract, keywords</option></select><a href="https://www.annalsofoncology.org/search/advanced?SeriesKey=annonc&amp;ISSN=0923-7534&amp;journalCode=annonc" title="Advanced search" class="quick-search__advanced-link">Advanced search</a></div><a href="javascript:void(0)" aria-label="Close search options" title="Close search options" class="quick-search__box-close"><i aria-hidden="true" class="icon-tools_close"></i></a></div></div><div class="quick-search__alert hidden"><p>Please enter a term before submitting your search.</p><a href="#" class="quick-search__alert--close"> Ok</a></div></form></div></div>

            

        
</div>
  </div>
</nav>
<div id="page-body-id" class="page-body-flag"></div></div>
                </div>
                </div>

        

        </div>
    

    

        


    

            

            

            <div data-widget-id="cce513c3-ede2-454b-83a2-b235c17a37ed" data-widget-name="UX3HTMLWidget"></div>

            

        

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget axelPublicationContent none  widget-none" id="922bea2a-77ad-4d06-a464-4510160d2279">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-none "><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/marlin/ha/releasedAssets/css/build-article-e279c5ca7d640a5bf24d.css"/><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail long-title" vocab="http://schema.org/" typeof="ScholarlyArticle" data-pii="S0923-7534(19)47184-6" lang="en" dir="ltr"><div data-core-wrapper="header"><header data-extent="frontmatter"><div class="core-container"><div data-article-access="free" data-article-access-type="open" class="meta-panel"><span class="meta-panel__left"><span class="meta-panel__type"><span>haematological malignancies</span></span></span><span class="meta-panel__middle"><span class="meta-panel__volumeIssue"><a href="/issue/S0923-7534(15)X6800-1"><span>Volume 26</span>, <span>Supplement 5</span></a></span><span class="meta-panel__pages"><span>v116-v125</span></span><span class="meta-panel__onlineDate">September 2015</span></span><span class="meta-panel__right"><span class="meta-panel__access meta-panel__access--archive"><span>Open Archive</span></span></span></div><h1 property="name">Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<a id="cf0015" href="#fn0010" role="doc-noteref"><sup>†</sup></a></h1><div class="contributors"><span class="authors"><span role="list"><span property="author" typeof="Person" role="listitem"><a href="#au0010"><span property="givenName">H.</span> <span property="familyName">Tilly</span></a><sup class="xref"><a href="#af0010" property="affiliation" typeof="Organization" role="doc-noteref">1</a></sup></span> ∙ <span property="author" typeof="Person" role="listitem"><a href="#au0015"><span property="givenName">M.</span> <span property="familyName">Gomes da Silva</span></a><sup class="xref"><a href="#af0015" property="affiliation" typeof="Organization" role="doc-noteref">2</a></sup></span> ∙ <span property="author" typeof="Person" role="listitem"><a href="#au0020"><span property="givenName">U.</span> <span property="familyName">Vitolo</span></a><sup class="xref"><a href="#af0020" property="affiliation" typeof="Organization" role="doc-noteref">3</a></sup></span><span data-displayed-on="all"> ∙ … </span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><a href="#au0025"><span property="givenName">A.</span> <span property="familyName">Jack</span></a><sup class="xref"><a href="#af0025" property="affiliation" typeof="Organization" role="doc-noteref">4</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><a href="#au0030"><span property="givenName">M.</span> <span property="familyName">Meignan</span></a><sup class="xref"><a href="#af0030" property="affiliation" typeof="Organization" role="doc-noteref">5</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><a href="#au0035"><span property="givenName">A.</span> <span property="familyName">Lopez-Guillermo</span></a><sup class="xref"><a href="#af0035" property="affiliation" typeof="Organization" role="doc-noteref">6</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><a href="#au0040"><span property="givenName">J.</span> <span property="familyName">Walewski</span></a><sup class="xref"><a href="#af0040" property="affiliation" typeof="Organization" role="doc-noteref">7</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><a href="#au0045"><span property="givenName">M.</span> <span property="familyName">André</span></a><sup class="xref"><a href="#af0045" property="affiliation" typeof="Organization" role="doc-noteref">8</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><a href="#au0050"><span property="givenName">P.W.</span> <span property="familyName">Johnson</span></a><sup class="xref"><a href="#af0050" property="affiliation" typeof="Organization" role="doc-noteref">9</a></sup></span></span> ∙ <span property="author" typeof="Person" role="listitem"><a href="#au0055"><span property="givenName">M.</span> <span property="familyName">Pfreundschuh</span></a><sup class="xref"><a href="#af0055" property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span> ∙ <span property="author" typeof="Person" role="listitem"><a href="#au0060"><span property="givenName">M.</span> <span property="familyName">Ladetto</span></a><sup class="xref"><a href="#af0060" property="affiliation" typeof="Organization" role="doc-noteref">11</a></sup></span> ∙ <span property="author" typeof="Person" role="listitem"><a href="#co9000"><span property="name">on behalf of the ESMO Guidelines Committee</span></a></span><span data-displayed-on="all"> … <span><span data-action="reveal">Show more</span></span> </span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide">Show less</span></span></span></span></div><div class="core-self-citation"><div id="core-affiliations-notes"><div class="affiliations"><div property="affiliation" typeof="Organization"><span class="label">1</span><span id="af0010" property="name">Centre Henri-Becquerel, Université de Rouen, Rouen, France</span></div><div property="affiliation" typeof="Organization"><span class="label">2</span><span id="af0015" property="name">Portuguese Institute of Oncology, Lisbon, Portugal</span></div><div property="affiliation" typeof="Organization"><span class="label">3</span><span id="af0020" property="name">A.O. Città della Salute e della Scienza di Torino, Turin, Italy</span></div><div property="affiliation" typeof="Organization"><span class="label">4</span><span id="af0025" property="name">St James's University Hospital, Leeds, UK</span></div><div property="affiliation" typeof="Organization"><span class="label">5</span><span id="af0030" property="name">Henri Mondor University Hospital, Créteil, France</span></div><div property="affiliation" typeof="Organization"><span class="label">6</span><span id="af0035" property="name">Hospital Clinic, Barcelona, Spain</span></div><div property="affiliation" typeof="Organization"><span class="label">7</span><span id="af0040" property="name">Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland</span></div><div property="affiliation" typeof="Organization"><span class="label">8</span><span id="af0045" property="name">CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium</span></div><div property="affiliation" typeof="Organization"><span class="label">9</span><span id="af0050" property="name">Cancer Research UK, University of Southampton, Southampton, UK</span></div><div property="affiliation" typeof="Organization"><span class="label">10</span><span id="af0055" property="name">Innere Medizin I, Universität des Saarlandes, Hamburg, Germany</span></div><div property="affiliation" typeof="Organization"><span class="label">11</span><span id="af0060" property="name">Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy</span></div></div><div class="core-authors-notes"><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="fn0010"><div id="np0010" role="paragraph">Approved by the ESMO Guidelines Committee: February 2002, last update August 2015.</div><div id="np0015" role="paragraph">This publication supersedes the previously published version—Ann Oncol 2012; 23 (Suppl. 7): vii78–vii82.</div></div></div></div></div><div id="core-content-info"><div class="core-links"><span class="doi">DOI: <a href="https://doi.org/10.1093/annonc/mdv304" property="sameAs" target="_blank">10.1093/annonc/mdv304</a></span><span class="science-direct">Also available on <a href="https://www.sciencedirect.com/science/article/pii/S0923753419471846" target="_blank">ScienceDirect</a></span></div><div role="paragraph">Copyright: © 2015 European Society for Medical Oncology. Published by Elsevier Inc.</div><div class="core-links"><span>User License: <a href="http://www.elsevier.com/open-access/userlicense/1.0/" target="_blank">Elsevier user license</a> | <a href="https://www.elsevier.com/open-access" target="_blank">Elsevier&apos;s open access license policy</a></span></div><div class="core-content-info"></div></div><div id="core-linked-content">
    

        

</div></div></div></header><div class="core-header-aside"><div class="article-header__download-full-issue"><button title="Download full issue" type="submit" formaction="/action/downloadMultiplePdf?action=downloadIssuePdf&amp;journal=annonc&amp;volume=26&amp;pii=S0923-7534%2815%29X6800-1" class="btn--download-issue btn--cancel table-of-content__links--item download-full-issue"><i class="icon-download-new"></i><span>Download Full Issue</span></button><div class="table-of-content__alert table-of-content__alert--download"><p>Download started</p><a href="#" class="table-of-content__alert--close">Ok</a></div></div>
    

        


    

            

            

            <div class="cover-image cover-image--axel"><div class="cover-image__thumb"><a href="https://www.annalsofoncology.org/issue/S0923-7534(15)X6800-1"><img src="/cms/asset/497eaff7-67c1-4516-96f6-147c034e1f61/cov200h.gif" alt="Cover Image - Annals of Oncology, Volume 26, Issue undefined"/></a></div></div>

            

        
</div></div><div data-core-wrapper="content"><div data-core-nav="header" data-extent="frontmatter"><ul class="core-nav-wrapper core-container" role="menubar" aria-label="Article navigation"><li role="none" class="navigation-menu-pdf">
    

        


    

            

            

            <div data-widget-id="b88e1592-f246-4733-9913-d71c9f598189" data-widget-name="UX3ArticleToolsWidget" class="article-tools"><a href="/action/showPdf?pii=S0923-7534%2819%2947184-6" title="Standard PDF (opens in a new tab)" target="_blank" aria-hidden="false" role="menuitem" class="article-tools__item__pdf"><svg focusable="false" viewBox="0 0 32 32" width="20" height="20" title="PDF" class="pdf-icon"><path id="pdfwhite" d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path id="pdfda0000" d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path id="pdffff9f9" fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492 1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0 .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0 1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0 2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534 2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path id="pdff91d0a" d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317 2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32 24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153 1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306 2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047 1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="basic">Download PDF</span><span class="alternative">Download PDF</span></a></div>

            

        
</li><li role="none"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-haspopup="true" aria-label="Toggle section navigation menu" role="menuitem"><i class="icon-list" aria-hidden="true"></i><span>Outline</span></button><nav id="article_sections_menu" role="menu" aria-label="Contents" data-core-nav="article"><ul role="group"><li role="none"><a role="menuitem" href="#sec-1">incidence and epidemiology</a></li><li role="none"><a role="menuitem" href="#sec-2">diagnosis and pathology/molecular biology</a></li><li role="none"><a role="menuitem" href="#sec-3">staging and risk assessment</a></li><li role="none"><a role="menuitem" href="#sec-4">treatment</a></li><li role="none"><a role="menuitem" href="#sec-5">response evaluation</a></li><li role="none"><a role="menuitem" href="#sec-6">follow-up</a></li><li role="none"><a role="menuitem" href="#sec-7">personalised medicine</a></li><li role="none"><a role="menuitem" href="#sec-8">methodology</a></li><li role="none"><a role="menuitem" href="#sec-9">conflict of interest</a></li><li role="none"><a role="menuitem" href="#references">references</a></li></ul></nav></li><li role="none" class="navigation-menu-share">
    

        


    

            

            

            <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js"></script><script>var a2a_config = a2a_config || {};
let res = window.location.href.replace(/\(/g, "%28").replace(/\)/g, "%29");
a2a_config.templates = a2a_config.templates || {};

a2a_config.templates.email = {
    body: res
};
</script><div data-widget-id="9a0a26e7-03bd-4d47-8984-9e7fa650db97" data-widget-name="UX3share" aria-hidden="false" role="group" class="article-tools__dropblock article-tools__share"><button aria-label="Toggle share menu" aria-expanded="false" aria-haspopup="true" role="menuitem" aria-controls="navigation_menu_share_block" aria-labelledby="share-label" class="article-tools__item__share"><i aria-hidden="true" class="icon-article-share"></i><span id="share-label">Share</span></button><div id="navigation_menu_share_block" role="menu" class="share__block axel-share article-tools__dropblock__holder"><h4 class="axel-share__title heading">Share<button title="Close share menu" aria-expanded="false" aria-haspopup="true" aria-controls="navigation_menu_share_block"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></h4><div class="axel-share__inner"><span class="sr-only">Share on</span><ul class="a2a__share-list rlist w-slide--list a2a a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-url="https://www.annalsofoncology.org/article/S0923-7534%2819%2947184-6/fulltext"><li class="a2a_listitem_custom"><a role="link" title="Email" class="a2a_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-gizmo-email-plus"></i><span>Email</span></a></li><li class="a2a_listitem_custom"><a role="link" title="formerly known as Twitter" class="a2a_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-x-default"></i><span>X</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Facebook" class="a2a_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook-square-2"></i><span>Facebook</span></a></li><li class="a2a_listitem_custom"><a role="link" title="LinkedIn" class="a2a_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin-square"></i><span>LinkedIn</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Sina Weibo" class="a2a_button_sina_weibo"><i aria-hidden="true" class="at-icon-wrapper icon-weibo"></i><span>Sina Weibo</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Add to Mendeley" class="a2a_button_mendeley"><i aria-hidden="true" class="at-icon-wrapper icon-mendeley-2"></i><span>Add to Mendeley</span></a></li></ul><div class="extra-links-drop-zone">
    

        


    

            

            

            <div data-widget-id="8290640f-f974-44c3-b07b-10ae0de3a777" data-widget-name="UX3HTMLWidget"><a class="axel-share__extra" target="_blank" href="/personalize/addFavoritePublication?doi=10.1093/annonc/mdv304">
	<i class="icon-reading-list" aria-hidden="true"></i>
	<span>Add to my reading list</span>
</a></div>

            

        
</div></div></div></div>

            

        
</li><li role="none"><button data-id="article-nav-menubar-more" aria-controls="article_more_menu" aria-expanded="false" aria-haspopup="true" aria-label="Toggle more menu" role="menuitem"><i aria-hidden="true" class="icon-more-mobile"></i><span>More</span></button><div class="info-panel"><div role="menuitem" class="info-panel__left-content"><div class="info-panel__article_tools info-panel__item"><div id="article_more_menu" aria-label="More menu" data-core-nav="more"><div class="heading">More<button title="Close more menu" aria-controls="article_more_menu" aria-haspopup="true"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div>
    

        


    

            

            

            <ul data-widget-id="456b8a45-7ff3-433c-b2f1-84eabc846406" data-widget-name="UX3ArticleToolsWidget" class="article-tools"><li class="article-tools__item article-tools__pdf"><a href="/action/showPdf?pii=S0923-7534%2819%2947184-6" title="Standard PDF (opens in a new tab)" target="_blank" aria-hidden="false" class="article-tools__ctrl article-tools__item__pdf"><svg focusable="false" viewBox="0 0 32 32" width="20" height="20" title="PDF" class="pdf-icon"><path id="pdfwhite" d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path id="pdfda0000" d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path id="pdffff9f9" fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492 1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0 .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0 1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0 2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534 2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path id="pdff91d0a" d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317 2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32 24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153 1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306 2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047 1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="basic">Download PDF</span><span class="alternative">Download PDF</span></a></li><li><a href="https://www.annalsofoncology.org/action/showCitFormats?doi=10.1093%2Fannonc%2Fmdv304&amp;pii=S0923-7534%2819%2947184-6" title="Cite" target="_blank" aria-label="Open Cite in new tab" class="article-tools__item__displayExportCitation"><i aria-hidden="true" class="icon-export-Citation"></i><span>Cite</span></a></li><li id="article_tools_share">
    

        


    

            

            

            <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js"></script><script>var a2a_config = a2a_config || {};
let res = window.location.href.replace(/\(/g, "%28").replace(/\)/g, "%29");
a2a_config.templates = a2a_config.templates || {};

a2a_config.templates.email = {
    body: res
};
</script><div data-widget-id="eb69bac3-4f48-4142-a6e4-3ba1b70e518e" data-widget-name="UX3share" class="dropBlock article-tools__dropblock article-tools__share"><a href="#" data-db-target-for="eb69bac3-4f48-4142-a6e4-3ba1b70e518e" aria-expanded="false" title="open Share menu" aria-labelledby="share-label-517" class="article-tools__ctrl share__ctrl"><i aria-hidden="true" class="icon-article-share"></i><span id="share-label-517">Share</span></a><div data-db-target-of="eb69bac3-4f48-4142-a6e4-3ba1b70e518e" id="eb69bac3-4f48-4142-a6e4-3ba1b70e518e_Pop" class="share__block axel-share dropBlock__holder article-tools__dropblock__holder"><h4 class="axel-share__title">Share</h4><div class="axel-share__inner"><span class="sr-only">Share on</span><ul class="a2a__share-list rlist w-slide--list a2a a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-url="https://www.annalsofoncology.org/article/S0923-7534%2819%2947184-6/fulltext"><li class="a2a_listitem_custom"><a role="link" title="Email" class="a2a_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-gizmo-email-plus"></i><span>Email</span></a></li><li class="a2a_listitem_custom"><a role="link" title="formerly known as Twitter" class="a2a_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-x-default"></i><span>X</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Facebook" class="a2a_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook-square-2"></i><span>Facebook</span></a></li><li class="a2a_listitem_custom"><a role="link" title="LinkedIn" class="a2a_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin-square"></i><span>LinkedIn</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Sina Weibo" class="a2a_button_sina_weibo"><i aria-hidden="true" class="at-icon-wrapper icon-weibo"></i><span>Sina Weibo</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Add to Mendeley" class="a2a_button_mendeley"><i aria-hidden="true" class="at-icon-wrapper icon-mendeley-2"></i><span>Add to Mendeley</span></a></li></ul><div class="extra-links-drop-zone">
    

        


    

            

            

            <div data-widget-id="602ee1d1-9bea-40c0-9a1e-af73ceca37a1" data-widget-name="UX3HTMLWidget"><a class="axel-share__extra" target="_blank" href="/personalize/addFavoritePublication?doi=10.1093/annonc/mdv304">
	<i class="icon-reading-list" aria-hidden="true"></i>
	<span>Add to my reading list</span>
</a></div>

            

        
</div></div></div></div>

            

        
</li><li><a href="https://www.annalsofoncology.org/action/addCitationAlert?doi=10.1093%2Fannonc%2Fmdv304" title="Set Alert" target="_blank" aria-label="Open Set Alert in new tab" class="article-tools__item__displayCreateCitationAlert"><i aria-hidden="true" class="icon-set-alert"></i><span>Set Alert</span></a></li><li><a href="https://s100.copyright.com/AppDispatchServlet?publisherName=ELS&amp;contentID=S0923753419471846&amp;orderBeanReset=true&amp;orderSource=Phoenix" title="Get Rights" target="_blank" aria-label="Open Get Rights in new tab" class="article-tools__item__request"><i aria-hidden="true" class="icon-get-rights"></i><span>Get Rights</span></a></li><li><a href="http://www.medreprints.com/?pii=S0923753419471846&amp;issn=09237534&amp;source=jbs" title="Reprints" target="_blank" aria-label="Open Reprints in new tab" class="article-tools__item__reprints"><i aria-hidden="true" class="icon-article-reprints"></i><span>Reprints</span></a></li></ul>

            

        
</div></div><div class="info-panel__download-issue info-panel__item"><div class="article-header__download-full-issue"><button title="Download full issue" type="submit" formaction="/action/downloadMultiplePdf?action=downloadIssuePdf&amp;journal=annonc&amp;volume=26&amp;pii=S0923-7534%2815%29X6800-1" class="btn--download-issue btn--cancel table-of-content__links--item download-full-issue"><i class="icon-download-new"></i><span>Download Full Issue</span></button><div class="table-of-content__alert table-of-content__alert--download"><p>Download started</p><a href="#" class="table-of-content__alert--close">Ok</a></div></div></div></div><div class="info-panel__right-content"><div class="info-panel__navigation info-panel__item"><div role="none" class="content-navigation"><a href="/article/S0923-7534(19)47172-X/fulltext" role="menuitem" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><i aria-hidden="true" class="icon-arrow_l"></i><span>Previous article</span></a><a href="/article/S0923-7534(19)47180-9/fulltext" role="menuitem" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><span>Next article</span><i aria-hidden="true" class="icon-arrow_r"></i></a></div></div></div></div></li></ul></div><div><div class="core-content-inner"><div class="core-linked-content"></div><div class="core-linked-content">
    

        

</div><div class="core-linked-content"></div><div class="core-linked-content"></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text"><div class="core-container"><section id="sec-1"><h2>incidence and epidemiology</h2><div id="p0315" role="paragraph">Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma series. The crude incidence in Europe is 3.8/100 000/year [<a id="cf0080" href="#bb0010" role="doc-biblioref" data-xml-rid="bb0010">1</a>]. The incidence increases with age and varies considerably across Europe. A family history of lymphoma, autoimmune disease, human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) seropositivity, a high body mass as a young adult and some occupational exposures have been identified as risk factors of DLBCL [<a id="cf0085" href="#bb0015" role="doc-biblioref" data-xml-rid="bb0015">2</a>]. In recent years, there have been important survival improvements for DLBCL in all European regions [<a id="cf0090" href="#bb0020" role="doc-biblioref" data-xml-rid="bb0020">3</a>].</div></section><section id="sec-2"><h2>diagnosis and pathology/molecular biology</h2><div id="p0320" role="paragraph">The diagnosis of DLBCL should be carried out in a reference haematopathology laboratory with expertise in morphological interpretation and the facilities to carry out the full range of phenotypic and molecular investigations [V, A].</div><div id="p0325" role="paragraph">A surgical excision biopsy remains the optimal method of diagnosis [V, A]. This allows assessment of nodal architecture and provides adequate material for phenotypic and molecular studies. Ideally, the biopsy should be sent unfixed to the laboratory to allow flow cytometric studies to be carried out and high-quality DNA and RNA to be extracted. Needle-core and endoscopic biopsies should be reserved for patients for whom a surgical approach is impractical or would entail excessive risk [IV, B]. A fine-needle aspirate should not be used as the sole basis for a diagnosis of DLBCL [V, E].</div><div id="p0330" role="paragraph">A morphological diagnosis of DLBCL should be confirmed in all cases by immunophenotypic investigations, either immunohistochemistry (IHC) or flow cytometry or a combination of both techniques [V, A]. Panels used must be designed to confirm B-cell lineage, and must be comprehensive enough to highlight possible variant forms such as immunoblastic lymphoma [<a id="cf10085" href="#bb0025" role="doc-biblioref" data-xml-rid="bb0025">4</a>], primary mediastinal B cell lymphoma (PMBCL), T-cell/histiocyte rich large B-cell lymphoma, primary cutaneous DLBCL leg-type or EBV-positive DLBCL of the elderly. They must also distinguish alternative diagnoses that may be difficult to make on the basis of morphology alone, and which have important clinical consequences as plasmablastic lymphoma or soft tissue involvement by myeloma, Burkitt lymphoma, unclassifiable B-cell lymphoma with features intermediate between diffuse large cell lymphoma and Burkitt lymphoma, blastic mantle cell lymphoma and some cases of Hodgkin's lymphoma. A suggested immunohistochemical panel would include CD20, CD79a, BCL6, CD10, MYC, BCL2, Ki67, IRF4, CyclinD1, CD5 and CD23. EBER-1 staining may be used to identify the Epstein–Barr virus-positive DLBCL subtype of the elderly population. The histological report should give the diagnosis according to the current World Health Organization classification [<a id="cf0095" href="#bb0030" role="doc-biblioref" data-xml-rid="bb0030">5</a>].</div><div id="p0335" role="paragraph">Where the level of confidence in the diagnosis is reduced, for example, because only a small biopsy specimen is available or where the putatively neoplastic population has a normal phenotype by IHC, demonstration of B-cell monoclonality by a polymerase chain reaction-based method should be considered [IV, C] [<a id="cf0100" href="#bb0035" role="doc-biblioref" data-xml-rid="bb0035">6</a>].</div><div id="p0340" role="paragraph">The cell of origin phenotype determined by gene expression profiling is also a major prognostic factor in DLBCL [<a id="crs0015" href="#bb0040" role="doc-biblioref" data-xml-rid="bb0040 bb0045 bb0050">7–9</a>]. Tumours with a germinal centre phenotype have a significantly better clinical outcome that those with an activated B-cell phenotype. The nature of type 3 or unclassified subgroups requires further clarification. Newer methods, based on evaluation of a limited set of genes, have been validated in comparison with standard gene expression, and are now used in the setting of clinical trials [<a id="cf0105" href="#bb0050" role="doc-biblioref" data-xml-rid="bb0050">9</a>, <a id="cf0110" href="#bb0055" role="doc-biblioref" data-xml-rid="bb0055">10</a>]. Cell of origin can also be determined by IHC but published data on the prognostic effect of immunohistochemical techniques are contradictory, and it is not recommended to routinely base clinical decisions on these results [<a id="cf0115" href="#bb0060" role="doc-biblioref" data-xml-rid="bb0060">11</a>, <a id="cf0120" href="#bb0065" role="doc-biblioref" data-xml-rid="bb0065">12</a>]. General issues of reproducibility may also limit the value of IHC as a prognostic biomarker [<a id="cf0125" href="#bb0070" role="doc-biblioref" data-xml-rid="bb0070">13</a>].</div><div id="p0345" role="paragraph">The presence of an MYC rearrangement in combination with BCL2 rearrangement, and possibly other genetic abnormalities, has been described as a special entity (‘double-hit’ or ‘triple-hit’ lymphoma). However, the prognostic significance of these rearrangements remains controversial and optimal clinical management is not established [<a id="crs0020" href="#bb0075" role="doc-biblioref" data-xml-rid="bb0075 bb0080 bb0085">14–16</a>]. This assessment is recommended, wherever technically possible, in newly diagnosed and relapsed patients being treated with curative intent, using interphase fluorescence <i>in situ</i> hybridisation [IV, B]. The immunohistochemical expression of MYC and/or BCL2 or both (double expressors) is only partly correlated with genetic abnormalities, but the concurrent expression of MYC and BCL2 is usually associated with a poor outcome [<a id="crs0025" href="#bb0090" role="doc-biblioref" data-xml-rid="bb0090 bb0095 bb0100">17–19</a>].</div></section><section id="sec-3"><h2>staging and risk assessment</h2><div id="p0350" role="paragraph">Physical examination, performance status (PS) and assessment of B symptoms are necessary [V, A]. A complete blood count, routine blood chemistry including lactate dehydrogenase (LDH) and uric acid, as well as screening tests for HIV, hepatitis B virus (HBV) (HBs antigen, anti-HBs and anti-HBc antibodies) and HCV are required [V, A]. Protein electrophoresis is recommended [IV, B].</div><div id="p0355" role="paragraph">Based on recent consensus recommendations for staging and restaging of lymphoma developed by the clinical and imaging working groups of the international conference of malignant lymphomas (Lugano classification), fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT) scan is now recommended as the gold standard for staging DLBCL patients [V, A] [<a id="cf0130" href="#bb0105" role="doc-biblioref" data-xml-rid="bb0105">20</a>, <a id="cf0135" href="#bb0110" role="doc-biblioref" data-xml-rid="bb0110">21</a>]. PET/CT is more accurate than contrast-enhanced CT (CeCT), with increased sensitivity for nodal and extranodal sites; in practice, CeCT is often carried out before PET/CT. Should this not be the case, a full diagnostic high-dose CeCT should be carried out when necessary, in combination with PET/CT and after the PET scan [V, B]. Indeed, CeCT may be necessary for a better delineation of lymphadenopathy from the bowel; the detection of compression/thrombosis of central/mediastinal vessels, radiation planning or a more accurate measurement of nodal sites in the context of a trial. The findings of CeCT when carried out at baseline determine whether the low-dose non-enhanced CT part of the PET/CT scan will be sufficient for restaging.</div><div id="p0360" role="paragraph">Focal bone marrow FDG uptake with or without increased diffuse uptake is more sensitive than bone marrow biopsy (BMB) for infiltration in DLBCL and is highly specific [<a id="cf0140" href="#bb0115" role="doc-biblioref" data-xml-rid="bb0115">22</a>]. Low-volume involvement (&lt;10%–20%) and discordant lymphoma may be missed by PET/CT imaging but these positive BMB/negative PET/CT findings are &lt;10% [<a id="cf0145" href="#bb0120" role="doc-biblioref" data-xml-rid="bb0120">23</a>]. Thus, biopsy is no longer required when a PET/CT scan demonstrates bone or marrow involvement indicating advanced-stage disease but is appropriate in case of negative PET, when its results would change prognosis and treatment, especially when a shortened number of immunochemotherapy cycles is proposed [V, C].</div><div id="p0365" role="paragraph">For suspected central nervous system (CNS) lymphoma, magnetic resonance imaging is the modality of choice [III, A].</div><div id="p0370" role="paragraph">A diagnostic lumbar puncture should be considered in high-risk patients as described above [V, A]. Flow cytometry, when available, enhances the detection of lymphoma cells in the cerebrospinal fluid [<a id="cf0150" href="#bb0125" role="doc-biblioref" data-xml-rid="bb0125">24</a>].</div><div id="p0375" role="paragraph">Cardiac function (left ventricular ejection fraction) should be assessed before treatment [V, A]. The risks of infertility and possibilities of fertility preservation should be discussed, depending on the type of treatment being proposed.</div><div id="p0380" role="paragraph">The staging is established according to the Ann Arbor classification system [I, A] (<a id="cf0155" href="#t0010">Table 1</a>). A new staging system that has not been prospectively validated has been recently proposed [<a id="cf0160" href="#bb0105" role="doc-biblioref" data-xml-rid="bb0105">20</a>]. For prognostic purposes, the International Prognostic Index (IPI) and age-adjusted IPI (aaIPI) should be calculated [I, A] [<a id="cf0165" href="#bb0130" role="doc-biblioref" data-xml-rid="bb0130">25</a>] (<a id="cf0170" href="#t0015">Table 2</a>). Other factors that may affect prognosis and treatment strategies, including the maximum bulk of the disease, should be assessed [<a id="cf0175" href="#bb0155" role="doc-biblioref" data-xml-rid="bb0155">30</a>].</div><div class="figure-wrap"><figure id="t0010" class="table" data-figureviewer-ignore="true"><div class="table-wrap"><table data-figureviewer-ignore="true"><tbody><tr><td colspan="2">Stage</td></tr><tr><td>I</td><td>Involvement of a single lymphatic region (I) or localized involvement of single extralymphatic organ or site (IE)</td></tr><tr><td>II</td><td>Involvement of two or more lymphatic regions on the same side of the diaphragm (II) or localized involvement of a single extralymphatic organ or site and of one or more lymphatic regions on the same side of the diaphragm (IIE)</td></tr><tr><td>III</td><td>Involvement of lymphatic regions on both sides of the diaphragm</td></tr><tr><td>IV</td><td>Diffuse or disseminated involvement of one or more extralymphatic organs with or without lymphatic involvement</td></tr></tbody></table></div><figcaption><span class="heading">Table 1</span><div id="sp0010" role="paragraph">Ann Arbor staging classification</div><div class="core-table-tools"><ul><li><a class="core-table-show-action" href="/action/showFullTableHTML?isHtml=true&amp;tableId=t0010&amp;pii=S0923-7534%2819%2947184-6" target="_blank">Open table in a new tab</a></li></ul></div></figcaption></figure></div><div class="figure-wrap"><figure id="t0015" class="table" data-figureviewer-ignore="true"><div class="table-wrap"><table data-figureviewer-ignore="true"><thead><tr class="rowsep" data-xml-align="left" data-xml-valign="top"><th colspan="2"><span>International prognostic index (IPI)</span></th><td> </td><th>Estimated 3-year overall survival [<a id="crs0010" href="#bb0135" role="doc-biblioref" data-xml-rid="bb0135 bb0140 bb0145 bb0150">26–29</a>] (95% CI)</th></tr></thead><tbody><tr><td rowspan="5">Risk factors</td><td colspan="2">Age &gt;60 years</td><td> </td></tr><tr><td colspan="2">Serum LDH &gt; normal</td><td> </td></tr><tr><td colspan="2">Stage III–IV</td><td> </td></tr><tr><td colspan="2">Performance status 2–4</td><td> </td></tr><tr><td colspan="2">Extranodal sites &gt;1</td><td> </td></tr><tr><td rowspan="4">Risk categories</td><td>Low</td><td>0–1</td><td>91 (89–94)</td></tr><tr><td>Low intermediate</td><td>2</td><td>81 (73–86)</td></tr><tr><td>High intermediate</td><td>3</td><td>65 (58–73)</td></tr><tr><td>High</td><td>4–5</td><td>59 (49–69)</td></tr><tr><td colspan="3">Age-adjusted international prognostic index (aaIPI) in patients ≤60 years</td><td> </td></tr><tr><td rowspan="3">Risk factors</td><td colspan="2">Serum LDH &gt; normal</td><td> </td></tr><tr><td colspan="2">Stage III–IV</td><td> </td></tr><tr><td colspan="2">Performance status 2–4</td><td> </td></tr><tr><td rowspan="4">Risk categories</td><td>Low</td><td>0</td><td>98 (96–100)</td></tr><tr><td>Low intermediate</td><td>1</td><td>92 (87–95)</td></tr><tr><td>High intermediate</td><td>2</td><td rowspan="2"><br />}75 (66–82)</td></tr><tr><td>High</td><td>3</td></tr></tbody></table></div><figcaption><div class="caption"><span class="heading">Table 2</span><div id="sp0015" role="paragraph">International prognostic index (IPI)</div></div><div class="notes"><div id="sp0020" role="paragraph">LDH, lactate dehydrogenase; CI, confidence interval.</div></div><div class="core-table-tools"><ul><li><a class="core-table-show-action" href="/action/showFullTableHTML?isHtml=true&amp;tableId=t0015&amp;pii=S0923-7534%2819%2947184-6" target="_blank">Open table in a new tab</a></li></ul></div></figcaption></figure></div></section><section id="sec-4"><h2>treatment</h2><div id="p0385" role="paragraph">Treatment strategies should be stratified according to age, IPI and feasibility of dose-intensified approaches (<a id="cf0180" href="#t0020">Table 3</a>). Whenever available, the inclusion in a clinical trial is recommended.</div><div class="figure-wrap"><figure id="t0020" class="table" data-figureviewer-ignore="true"><div class="table-wrap"><table data-figureviewer-ignore="true"><thead><tr class="rowsep" data-xml-align="left" data-xml-valign="top"><th colspan="3"><span><b>Patients ≤60 years</b></span></th></tr><tr class="rowsep" data-xml-align="left"><th>IPI low risk (aaIPI = 0) and no bulk</th><th>IPI low risk (aaIPI = 0) with bulk or IPI low-intermediate risk (aaIPI = 1)</th><th>IPI intermediate-high risk or IPI high risk (aaIPI = 2, 3)</th></tr></thead><tbody><tr><td>R-CHOP21 × 6</td><td>R-ACVBP and sequential consolidation<br />or<br />R-CHOP21 × 6 + IF-RT on bulk</td><td>R-CHOP21 × 6–8<br />or<br />R-CHOP14 × 6 with 8 R<br />Consider more intensive regimens in selected patients:<br />R-CHOEP14 × 6<br />or<br />R-CHOP or R-ACVBP plus HDCT with ASCT</td></tr><tr><td colspan="3">Consider CNS prophylaxis in patients at risk for CNS progression</td></tr><tr><td colspan="3"><b>Elderly &gt;60 years</b></td></tr><tr><td>Fit, 60–80 years</td><td>&gt;80 years without cardiac dysfunction</td><td>Unfit or frail or &gt;60 years with cardiac dysfunction</td></tr><tr><td>R-CHOP21 × 6–8<br />(R-CHOP21 × 6 for IPI low risk)<br />or<br />R-CHOP14 × 6 with 8 R</td><td>Attenuated regimens:<br />R-miniCHOP21 × 6</td><td>Doxorubicin substitution with gemcitabine, etoposide or liposomal doxorubicin or others:<br />R-C(X)OP21 × 6<br />or<br />palliative care</td></tr><tr><td colspan="3">Consider CNS prophylaxis in patients at risk</td></tr><tr><td colspan="3"><b>First relapse/progress</b></td></tr><tr><td>Eligible for transplant</td><td>Not eligible for transplant</td><td> </td></tr><tr><td>Platinum-based chemotherapy regimens (i.e. R-DHAP, R-ICE, R-GDP) as salvage treatment<br />For chemosensitive patients: R-HDCT with ASCT as remission consolidation<br />Consider allogeneic transplantation in patients relapsed after R-HDCT with ASCT or in patients with poor-risk factors at relapse</td><td>Platinum- and/or gemcitabine-based regimens<br />Clinical trials with novel drugs</td><td> </td></tr><tr><td colspan="2"><b>&gt;2 relapse/progress</b></td><td> </td></tr><tr><td>Eligible for transplant</td><td>Not eligible for transplant</td><td> </td></tr><tr><td>Allogeneic transplantation<br />Clinical trials with novel drugs</td><td>Clinical trials with novel drugs<br />Palliative care</td><td> </td></tr></tbody></table></div><figcaption><div class="caption"><span class="heading">Table 3</span><div id="sp0025" role="paragraph">Recommended treatment strategies in diffuse large B-cell lymphoma</div></div><div class="notes"><div id="sp0030" role="paragraph">IPI, International Prognostic Index; aaIPI, age-adjusted IPI; R, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; ACVBP, doxorubicin, vindesine, cyclophosphamide, bleomycin and prednisolone; IF-RT, involved-field radiotherapy; HDCT, high-dose chemotherapy; ASCT, autologous stem-cell transplantation; DHAP, cisplatin, cytarabine, dexamethasone; ICE, ifosfamide, carboplatin, etoposide; GDP, cisplatin, gemcitabine, dexamethasone; CNS, central nervous system; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone; R-C(X)OP, R-CHOP with substitution of doxorubicin.</div></div><div class="core-table-tools"><ul><li><a class="core-table-show-action" href="/action/showFullTableHTML?isHtml=true&amp;tableId=t0020&amp;pii=S0923-7534%2819%2947184-6" target="_blank">Open table in a new tab</a></li></ul></div></figcaption></figure></div><div id="p0390" role="paragraph">In cases with high tumour load, precautions such as the administration of prednisone (p.o.) several days as ‘prephase’ treatment are advised to avoid tumour lysis syndrome [I, A]. Dose reductions due to haematological toxicity should be avoided [I, A]. Febrile neutropaenia justifies prophylactic use of haematopoietic growth factors in patients treated with curative intent and in patients older than 60 years of age [I, A].</div><section id="sec-4-1"><h3>young low-risk patients (aa-IPI = 0) without bulky disease</h3><div id="p0395" role="paragraph">Six cycles of combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) treatment combined with six doses of rituximab given every 21 days is the current standard [I, A] [<a id="cf0185" href="#bb0160" role="doc-biblioref" data-xml-rid="bb0160">31</a>]. Consolidation by radiotherapy to initial non-bulky sites has no proven benefit in patients treated with rituximab or not [I, A] [<a id="cf0190" href="#bb0165" role="doc-biblioref" data-xml-rid="bb0165">32</a>, <a id="cf0195" href="#bb0170" role="doc-biblioref" data-xml-rid="bb0170">33</a>].</div></section><section id="sec-4-2"><h3>young low-intermediate-risk patients (aa-IPI = 1) or IPI low risk (aa-IPI = 0) with bulky disease</h3><div id="p0400" role="paragraph">Rituximab (R)-CHOP 21 × 6 with radiotherapy to the sites of previous bulky disease was shown to be effective in this group of patients, based on the results of the MINT study [II, B] [<a id="cf0200" href="#bb0160" role="doc-biblioref" data-xml-rid="bb0160">31</a>]. Alternatively, an intensification of chemotherapy with R-ACVBP (rituximab, doxorubicin, vindesine, cyclophosphamide, bleomycin and prednisolone), given every 2 weeks followed by sequential consolidation, has been shown to improve survival compared with eight cycles of R-CHOP in this category, but radiotherapy was omitted in both arms of this trial [I, A] [<a id="cf0205" href="#bb0135" role="doc-biblioref" data-xml-rid="bb0135">26</a>]. In this group of patients, either R-CHOP21 × 6 with radiotherapy to the sites of previous bulky disease or the intensified regimen R-ACVBP is recommended [II, B].</div></section><section id="sec-4-3"><h3>young high- and high-intermediate-risk patients (aa-IPI ≥ 2)</h3><div id="p0405" role="paragraph">There is no current standard in this subgroup, and in this group especially, enrolment in clinical trials should be a priority. Six to eight cycles of chemotherapy with CHOP combined with eight doses of rituximab given every 21 days are most frequently applied [III, B]. Dose dense treatment with R-CHOP given every 14 days has not demonstrated a survival advantage over standard R-CHOP given every 21 days [I, C] [<a id="cf0210" href="#bb0175" role="doc-biblioref" data-xml-rid="bb0175">34</a>]. In this trial, R-CHOP 14 failed to show a better outcome in any DLBCL subset, including young poor-risk patients, although the trial was not powered to compare multiple clinical subgroups. Intensive treatment with R-ACVBP or R-CHOEP (rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisolone) is frequently used but these regimens have not been directly compared with R-CHOP in this category [II, B] [<a id="cf0215" href="#bb0140" role="doc-biblioref" data-xml-rid="bb0140">27</a>, <a id="cf0220" href="#bb0180" role="doc-biblioref" data-xml-rid="bb0180">35</a>].</div><div id="p0410" role="paragraph">Four randomised trials comparing rituximab chemotherapy (R-chemotherapy) followed by high-dose chemotherapy (HDC) and autologous stem-cell transplantation (ASCT) versus R-chemotherapy alone have been presented. Two trials showed a progression-free survival (PFS) benefit for HDC with ASCT but no impact, at present, on overall survival (OS) [<a id="cf0225" href="#bb0185" role="doc-biblioref" data-xml-rid="bb0185">36</a>, <a id="cf0230" href="#bb0190" role="doc-biblioref" data-xml-rid="bb0190">37</a>], while two trials failed to demonstrate an improvement for the HDC arm [<a id="cf0235" href="#bb0180" role="doc-biblioref" data-xml-rid="bb0180">35</a>, <a id="cf0240" href="#bb0195" role="doc-biblioref" data-xml-rid="bb0195">38</a>]. Therefore, HDC with ASCT in first line remains experimental or may be proposed for selected high-risk patients [II, C]. The role of consolidation by radiotherapy to initial sites of bulky disease is unknown. The role of interim PET to select patients who could benefit from consolidative ASCT [<a id="cf0245" href="#bb0200" role="doc-biblioref" data-xml-rid="bb0200">39</a>] or from radiotherapy [<a id="cf0250" href="#bb0205" role="doc-biblioref" data-xml-rid="bb0205">40</a>] is under evaluation [I, C].</div></section><section id="sec-4-4"><h3>patients aged 60–80 years</h3><div id="p0415" role="paragraph">Six to eight cycles of combination chemotherapy with CHOP plus eight doses of rituximab given every 21 days is the current standard [I, A] [<a id="cf0255" href="#bb0210" role="doc-biblioref" data-xml-rid="bb0210">41</a>]. R-CHOP given every 14 days did not demonstrate a survival advantage over R-CHOP 21 [I, C] [<a id="cf0260" href="#bb0175" role="doc-biblioref" data-xml-rid="bb0175">34</a>, <a id="cf0265" href="#bb0215" role="doc-biblioref" data-xml-rid="bb0215">42</a>]. If R-CHOP is given every 14 days, six cycles of CHOP with eight cycles of rituximab are sufficient [I, A] [<a id="cf0270" href="#bb0220" role="doc-biblioref" data-xml-rid="bb0220">43</a>]. In patients with localised disease (IPI = 0), no benefit of consolidation by radiotherapy was shown in patients treated before the introduction of rituximab [I, A] [<a id="cf0275" href="#bb0225" role="doc-biblioref" data-xml-rid="bb0225">44</a>], but a recent study indicated that irradiation could improve the outcome of elderly patients with bulky disease [II, C] [<a id="cf0280" href="#bb0230" role="doc-biblioref" data-xml-rid="bb0230">45</a>]. In a phase II study, extended rituximab exposure has been shown to improve outcome of elderly poor-prognosis patients without increasing toxicity [III, C] [<a id="cf0285" href="#bb0235" role="doc-biblioref" data-xml-rid="bb0235">46</a>]. A comprehensive geriatric assessment in order to ascertain comorbidities and functional decline is recommended to guide the choice of treatment in these patients [III, A] [<a id="cf0290" href="#bb0240" role="doc-biblioref" data-xml-rid="bb0240">47</a>, <a id="cf0295" href="#bb0245" role="doc-biblioref" data-xml-rid="bb0245">48</a>]. R-CHOP treatment can usually be used up to 80 years of age in fit patients [I, A] but modulation of treatment according to geriatric assessment is recommended [III, C] [<a id="cf0300" href="#bb0250" role="doc-biblioref" data-xml-rid="bb0250">49</a>].</div></section><section id="sec-4-5"><h3>patients aged &gt;80 years</h3><div id="p0420" role="paragraph">The combination of rituximab with attenuated chemotherapy, such as R-miniCHOP, can induce complete remission and long survival in fit patients older than 80 years [III, B] [<a id="cf0305" href="#bb0255" role="doc-biblioref" data-xml-rid="bb0255">50</a>]. Substitution of doxorubicin by gemcitabine, etoposide or liposomal doxorubicin, or even its omission, can be considered from the beginning or after a few cycles in patients with cardiac dysfunction or who are frail or unfit [III, C] [<a id="cf0310" href="#bb0260" role="doc-biblioref" data-xml-rid="bb0260">51</a>].</div></section><section id="sec-4-6"><h3>central nervous system (CNS) prophylaxis</h3><div id="p0425" role="paragraph">Patients with high-intermediate and high-risk IPI, especially those with more than one extranodal site or elevated LDH, are at higher risk of CNS relapse [<a id="cf0315" href="#bb0265" role="doc-biblioref" data-xml-rid="bb0265">52</a>]. Testicular, renal and adrenal involvements have been validated as additional risk factors [<a id="cf0320" href="#bb0270" role="doc-biblioref" data-xml-rid="bb0270">53</a>]. CNS prophylaxis should be recommended in these populations [II, A]. MYC gene rearrangement is associated with a high risk of CNS relapse [<a id="cf0325" href="#bb0220" role="doc-biblioref" data-xml-rid="bb0220">43</a>]. Although widely used, intrathecal injections of methotrexate may not be an optimal method. Intravenous high-dose methotrexate has been shown to be associated with efficient disease control [IV, C] [<a id="crs0030" href="#bb0275" role="doc-biblioref" data-xml-rid="bb0275 bb0280 bb0285">54–56</a>]. Prospective trials are ongoing to evaluate this alternative approach.</div></section><section id="sec-4-7"><h3>some DLBCLs require special consideration</h3><div id="p0430" role="paragraph"><div id="l0070" role="list"><div id="u0290" role="listitem"><div class="label">•</div><div class="content"><div id="p0440" role="paragraph">Extranodal DLBCLs and PMBCLs are considered in other guidelines.</div></div></div><div id="u0295" role="listitem"><div class="label">•</div><div class="content"><div id="p0445" role="paragraph">Patients with HIV infection should usually receive the same treatment as HIV-negative patients in association with antiviral therapy [II, A] [<a id="cf0330" href="#bb0290" role="doc-biblioref" data-xml-rid="bb0290">57</a>].</div></div></div><div id="u0300" role="listitem"><div class="label">•</div><div class="content"><div id="p0450" role="paragraph">Patients previously exposed to HBV (HBs antigen-negative, anti-HBc-positive) are at risk of reactivation during treatment with R-CHOP. Antiviral prophylaxis or periodic HBV DNA monitoring and antiviral treatment in the case of reactivation are recommended [III, A] [<a id="cf0335" href="#bb0295" role="doc-biblioref" data-xml-rid="bb0295">58</a>].</div></div></div></div></div></section></section><section id="sec-5"><h2>response evaluation</h2><section id="sec-5-1"><h3>post-treatment evaluation</h3><div id="p0455" role="paragraph">FDG-PET/CT is now the recommended standard for post-treatment assessment in DLBCL [I, A] [<a id="cf0340" href="#bb0300" role="doc-biblioref" data-xml-rid="bb0300">59</a>]. The recent Lugano classification based on the visual Deauville criteria (5-point scale, <a id="cf0345" href="#t0025">Table 4</a>) has proposed different response categories, termed ‘metabolic response categories’ [<a id="cf0350" href="#bb0105" role="doc-biblioref" data-xml-rid="bb0105">20</a>, <a id="cf0355" href="#bb0110" role="doc-biblioref" data-xml-rid="bb0110">21</a>]:<div id="l0075" role="list"><div id="u0305" role="listitem"><div class="label">•</div><div class="content"><div id="p0465" role="paragraph">Complete metabolic response (CMR) is defined when no residual uptake exists or if the residual uptake is lower to or equal to the liver activity (Deauville score 1–3), with or without evidence of residual mass on the CT part of the examination, and without FDG-avid lesions in the bone marrow. Since most patients with score 3 (uptake greater than mediastinal activity) have a good prognosis with standard treatment, score 3 has been included in the CMR category but a careful evaluation of these patients is recommended.</div></div></div><div id="u0310" role="listitem"><div class="label">•</div><div class="content"><div id="p0470" role="paragraph">Deauville scores 4 and 5 indicate residual disease in most cases. Three categories of response are defined by comparing the residual uptake with the tumour uptake in baseline scan: partial metabolic response when the uptake has decreased, no metabolic response when it has not changed or progressive metabolic disease (PMD) when it has increased. A new site of FDG uptake consistent with lymphoma is graded score 5 and indicates a PMD but should be biopsied or followed by interval scans in case of aetiological uncertainties. In the presence of residual metabolically active tissue, where salvage treatment is being considered, a biopsy is recommended [III, A].</div></div></div></div></div><div class="figure-wrap"><figure id="t0025" class="table" data-figureviewer-ignore="true"><div class="table-wrap"><table data-figureviewer-ignore="true"><tbody><tr><td>1</td><td>No uptake</td></tr><tr><td>2</td><td>Uptake ≤mediastinum</td></tr><tr><td>3</td><td>Uptake &gt;mediastinum but ≤liver</td></tr><tr><td>4</td><td>Moderately increased uptake compared with liver</td></tr><tr><td>5</td><td>Markedly increased uptake to liver and/or new lesions</td></tr></tbody></table></div><figcaption><span class="heading">Table 4</span><div id="sp0035" role="paragraph">PET 5-point scale (Deauville criteria)</div><div class="core-table-tools"><ul><li><a class="core-table-show-action" href="/action/showFullTableHTML?isHtml=true&amp;tableId=t0025&amp;pii=S0923-7534%2819%2947184-6" target="_blank">Open table in a new tab</a></li></ul></div></figcaption></figure></div></section><section id="sec-5-2"><h3>interim evaluation</h3><div id="p0475" role="paragraph">Mid-treatment imaging after three to four cycles may be used to rule out progression in clinical practice [V, B]. It is usually carried out with CT but PET/CT can also be used when available [<a id="cf0360" href="#bb0105" role="doc-biblioref" data-xml-rid="bb0105">20</a>]. Changing treatment solely on the basis of interim PET/CT is discouraged [II, E], unless there is clear evidence of progression.</div><div id="p0480" role="paragraph">Early PET evaluation carried out after one to two cycles of treatment has been shown to be predictive of outcome, but should be reserved for clinical trials at the present time [II, D].</div></section></section><section id="sec-6"><h2>follow-up</h2><div id="p0485" role="paragraph">Patients with DLBCL who are event-free at 2 years have an identical OS to that of the general population, emphasising the need to only specifically monitor the disease in this early period [<a id="cf0365" href="#bb0305" role="doc-biblioref" data-xml-rid="bb0305">60</a>].</div><div id="p0490" role="paragraph">Careful history and physical examination every 3 months for 1 year, every 6 months for 2 more years and then once a year with attention to development of secondary tumours or other long-term side-effects of chemotherapy is recommended [V, D]. Blood count should be carried out at 3, 6, 12 and 24 months, then only as needed for evaluation of suspicious symptoms or clinical findings in those patients suitable for further therapy [V, C].</div><div id="p0495" role="paragraph">Minimal radiological examinations at 6, 12 and 24 months after end of treatment by CT scan are common practice, but there is no definitive evidence that routine imaging in patients in complete remission provides any outcome advantage, and it may increase the incidence of secondary malignancies [V, D] [<a id="cf0370" href="#bb0310" role="doc-biblioref" data-xml-rid="bb0310">61</a>, <a id="cf0375" href="#bb0315" role="doc-biblioref" data-xml-rid="bb0315">62</a>]. Routine surveillance with PET scan is not recommended [V, E]. High-risk patients with curative options may potentially mandate more frequent evaluation.</div><section id="sec-6-1"><h3>relapsed and refractory DLBCL</h3><section id="sec-6-1-1"><h4>incidence</h4><div id="p0500" role="paragraph">Overall, more than 30% of DLBCL will ultimately relapse. The incidence in the European Union is therefore estimated to be around 1/100 000/year. In addition to initial prognostic factors, the nature of previous treatments and time from initial treatment are of utmost importance [<a id="cf0380" href="#bb0320" role="doc-biblioref" data-xml-rid="bb0320">63</a>].</div></section><section id="sec-6-1-2"><h4>diagnosis</h4><div id="p0505" role="paragraph">In patients who are suspected of having relapsed on the basis of imaging studies, the diagnosis should be confirmed by biopsy before proceeding to second-line therapy. In these circumstances, a needle-core biopsy is acceptable as primary investigation.</div></section><section id="sec-6-1-3"><h4>staging and risk assessment</h4><div id="p0510" role="paragraph">Patients still amenable to curative therapy should have the same examinations as at first diagnosis.</div></section><section id="sec-6-1-4"><h4>treatment</h4><div id="p0515" role="paragraph">The following recommendations apply to patients who received adequate rituximab and anthracycline-containing first-line therapy.</div><div id="p0520" role="paragraph">In patients aged &lt;65–70 years with good PS and no major organ dysfunction, salvage regimens with rituximab and chemotherapy followed, in responsive patients, by HDC and ASCT, are recommended [II, A] [<a id="crs0035" href="#bb0320" role="doc-biblioref" data-xml-rid="bb0320 bb0325 bb0330">63–65</a>] Salvage regimens such as R-DHAP (rituximab, cisplatin, cytarabine, dexamethasone) or R-ICE (rituximab, ifosfamide, carboplatin, etoposide) appear to have similar outcomes [I, A] [<a id="cf0385" href="#bb0320" role="doc-biblioref" data-xml-rid="bb0320">63</a>]. However, R-GDP (rituximab, cisplatin, gemcitabine, dexamethasone) has been shown to have similar efficacy but less toxicity than R-DHAP [I, A] [<a id="cf0390" href="#bb0335" role="doc-biblioref" data-xml-rid="bb0335">66</a>]. One study suggested a possible advantage of R-DHAP in the germinal centre B-cell subtype, but this needs confirmation [IV, C] [<a id="cf0395" href="#bb0340" role="doc-biblioref" data-xml-rid="bb0340">67</a>]. BEAM (carmustine, etoposide, cytarabine and melphalan) is the most commonly used high-dose regimen [III, B]. Additional involved-field radiation or iceberg radiation may be used, especially in the few cases with limited stage disease, but this has never been evaluated in controlled trials [IV, C]. Maintenance with rituximab is not recommended [I, E] [<a id="cf0400" href="#bb0345" role="doc-biblioref" data-xml-rid="bb0345">68</a>]. Allogeneic transplantation with a sibling or matched unrelated donor may be considered in patients with refractory disease, early relapse or relapse after ASCT [III, B] [<a id="cf0405" href="#bb0350" role="doc-biblioref" data-xml-rid="bb0350">69</a>].</div><div id="p0525" role="paragraph">Patients not suitable for high-dose therapy may be treated with the same or other salvage regimens as R-GEMOX (rituximab, gemcitabine, oxaliplatin) [III, B] [<a id="cf0410" href="#bb0355" role="doc-biblioref" data-xml-rid="bb0355">70</a>]. Pixantrone, a new anthracycline-like drug with reduced cardiotoxicity, demonstrated some efficacy in heavily treated patients [II, C] [<a id="cf0415" href="#bb0360" role="doc-biblioref" data-xml-rid="bb0360">71</a>]. However, these patients should be preferably enrolled in clinical trials testing the activity of other novel drugs.</div></section><section id="sec-6-1-5"><h4>response evaluation</h4><div id="p0530" role="paragraph">Response criteria are identical to those of first-line treatment evaluation. An evaluation should be carried out after three to four cycles of the salvage regimen (before high-dose treatment) and after the end of all therapy. Results of PET before high-dose treatment are correlated to clinical outcome [<a id="cf0420" href="#bb0365" role="doc-biblioref" data-xml-rid="bb0365">72</a>].</div></section><section id="sec-6-1-6"><h4>follow-up</h4><div id="p0535" role="paragraph">Follow-up of patients in second response is the same as for first response.</div></section></section></section><section id="sec-7"><h2>personalised medicine</h2><div id="p0540" role="paragraph">Progress in the knowledge of pathological and molecular heterogeneity of DLBCL has led to the study of new agents that have distinct activity in molecular subtypes, or have specific efficacy on molecular targets involved in disease pathogenesis. At the present time, pending results of large comparative studies, none of these agents is appropriate for routine therapy in practice.</div><div id="p0545" role="paragraph">The activated B-cell (ABC) subtype has been shown to have a worse prognosis when compared with germinal centre B-cell (GCB) in patients treated by R-CHOP [<a id="cf0425" href="#bb0045" role="doc-biblioref" data-xml-rid="bb0045">8</a>]. A subgroup analysis suggested that R-ACVBP could have a survival benefit over R-CHOP in the non-GCB population [III, C] [<a id="cf0430" href="#bb0370" role="doc-biblioref" data-xml-rid="bb0370">73</a>]. The ABC subtype is characterised by a constitutive activation of the NF-&amp;kgr;B pathway, which could be targeted by different agents as bortezomib and lenalidomide. Bortezomib combined with dose-adjusted-EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone) (DA-EPOCH) has shown selective activity in a small study of relapsed/refractory ABC-DLBCL [<a id="cf0435" href="#bb0375" role="doc-biblioref" data-xml-rid="bb0375">74</a>]. A UK/Swiss phase III trial (REMoDL-B) comparing R-CHOP with R-CHOP-bortezomib in gene expression prolife defined cell of origin subgroups of DLBCL is nearly completed. Lenalidomide, as a single agent, demonstrated selective efficacy in the non-GCB subtype [<a id="cf0440" href="#bb0380" role="doc-biblioref" data-xml-rid="bb0380">75</a>, <a id="cf0445" href="#bb0385" role="doc-biblioref" data-xml-rid="bb0385">76</a>]. In two phase II studies, the combination of lenalidomide and R-CHOP showed acceptable toxicity [<a id="cf0450" href="#bb0390" role="doc-biblioref" data-xml-rid="bb0390">77</a>, <a id="cf0455" href="#bb0395" role="doc-biblioref" data-xml-rid="bb0395">78</a>]. In one of these studies, the PFS and OS of the patients treated with the combination were identical in non-GCB and GCB subtypes [<a id="cf0460" href="#bb0395" role="doc-biblioref" data-xml-rid="bb0395">78</a>], leading to the initiation of a randomised study in the ABC subtype.</div><div id="p0550" role="paragraph">Ibrutinib, a novel oral Bruton's tyrosine kinase inhibitor, has shown selective activity in ABC-DLBCL. The combination of ibrutinib with R-CHOP has demonstrated promising responses, leading to the initiation of a phase III trial in the non-GCB population [<a id="cf0465" href="#bb0400" role="doc-biblioref" data-xml-rid="bb0400">79</a>].</div><div id="p0555" role="paragraph">DLBCL with MYC rearrangement and/or MYC overexpression is usually considered a subgroup with aggressive behaviour. However, many uncertainties remain about the extent of this subgroup concerning translocation partners, additional defects (double or triple hit), combination of genetic abnormalities and MYC protein overexpression and dual overexpression with MYC and BCL2 [<a id="cf0470" href="#bb0405" role="doc-biblioref" data-xml-rid="bb0405">80</a>]. Although R-CHOP gives poor outcomes for double-hit lymphomas, only preliminary results have suggested better results with more intensive regimens, and clinical trials are required in this subtype [<a id="cf0475" href="#bb0410" role="doc-biblioref" data-xml-rid="bb0410">81</a>, <a id="cf0480" href="#bb0415" role="doc-biblioref" data-xml-rid="bb0415">82</a>].</div><div id="p0560" role="paragraph">Whole-genome next-generation sequencing studies have identified frequent and recurrent mutations which may play a crucial role in lymphoma development [<a id="crs0040" href="#bb0420" role="doc-biblioref" data-xml-rid="bb0420 bb0425 bb0430">83–85</a>]. These molecular defects may prove useful targets in the future treatment and management of DLBCL.</div></section><section id="sec-8"><h2>methodology</h2><div id="p0565" role="paragraph">These clinical practice guidelines were developed in accordance with the ESMO standard operating procedures for clinical practice guidelines development. The relevant literature has been selected by the expert authors. A summary of recommendations is shown in <a id="cf0485" href="#t0030">Table 5</a>. Levels of evidence and grades of recommendation have been applied using the system shown in <a id="cf0490" href="#t0035">Table 6</a>. Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty. This manuscript has been subjected to an anonymous peer review process.</div><div class="figure-wrap"><figure id="t0030" class="table" data-figureviewer-ignore="true"><div class="table-wrap"><table data-figureviewer-ignore="true"><tbody><tr><td>Diagnosis and pathology/molecular biology</td></tr><tr><td> </td></tr><tr><td><div id="l0010" role="list"><div id="u0010" role="listitem"><div class="label">•</div><div class="content"><div id="p0015" role="paragraph">Diagnosis should be carried out in a reference haematopathology laboratory with expertise in morphological interpretation and the facilities to carry out the full range of phenotypic and molecular investigations [V, A].</div></div></div><div id="u0015" role="listitem"><div class="label">•</div><div class="content"><div id="p0020" role="paragraph">Surgical biopsy is the optimal method of diagnosis. [V, A].</div></div></div><div id="u0020" role="listitem"><div class="label">•</div><div class="content"><div id="p0025" role="paragraph">Needle-core and endoscopic biopsies should be reserved for patients for whom a surgical approach is impractical or would entail excessive risk [IV, B].</div></div></div><div id="u0025" role="listitem"><div class="label">•</div><div class="content"><div id="p0030" role="paragraph">A fine-needle aspirate should not be used as the sole basis for a diagnosis of DLBCL [V, E].</div></div></div><div id="u0030" role="listitem"><div class="label">•</div><div class="content"><div id="p0035" role="paragraph">A morphological diagnosis of DLBCL should be confirmed in all cases by immunophenotypic investigations [V, A].</div></div></div><div id="u0035" role="listitem"><div class="label">•</div><div class="content"><div id="p0040" role="paragraph">If there is doubt in the diagnosis, demonstration of B-cell monoclonality by a PCR-based method should be considered [IV, C].</div></div></div><div id="u0040" role="listitem"><div class="label">•</div><div class="content"><div id="p0045" role="paragraph">Assessment of MYC and BCL2 rearrangement is recommended (whenever technically possible) in newly diagnosed and relapsed patients treated with curative intent, using interphase FISH [IV, B].</div></div></div></div></td></tr><tr><td>Staging and risk assessment</td></tr><tr><td> </td></tr><tr><td><div id="l0015" role="list"><div id="u0045" role="listitem"><div class="label">•</div><div class="content"><div id="p0055" role="paragraph">Physical exam, performance status and assessment of B symptoms are necessary [V, A].</div></div></div><div id="u0050" role="listitem"><div class="label">•</div><div class="content"><div id="p0060" role="paragraph">A complete blood count, routine blood chemistry including LDH and uric acid, as well as screening tests for HIV, HBV and HCV are required [V, A].</div></div></div><div id="u0055" role="listitem"><div class="label">•</div><div class="content"><div id="p0065" role="paragraph">Protein electrophoresis is recommended [IV, B].</div></div></div><div id="u0060" role="listitem"><div class="label">•</div><div class="content"><div id="p0070" role="paragraph">FDG-PET/CT scan is recommended as the gold standard for staging DLBCL patients [V, A].</div></div></div><div id="u0065" role="listitem"><div class="label">•</div><div class="content"><div id="p0075" role="paragraph">If CeCT is not carried out before PET/CT, a full diagnostic high-dose CeCT should be carried out when necessary, in combination with PET/CT [V, B]. Biopsy may be avoided when PET/CT scans demonstrate bone or marrow involvement indicating advanced-stage disease but is appropriate in the case of negative PET, when its results would change prognosis and treatment, especially when a shortened number of immunochemotherapy cycles is proposed [V, C].</div></div></div><div id="u0070" role="listitem"><div class="label">•</div><div class="content"><div id="p0080" role="paragraph">For suspected CNS lymphoma, MRI is the modality of choice [III, A].</div></div></div><div id="u0075" role="listitem"><div class="label">•</div><div class="content"><div id="p0085" role="paragraph">A diagnostic lumbar puncture should be considered in high-risk patients [V, A].</div></div></div><div id="u0080" role="listitem"><div class="label">•</div><div class="content"><div id="p0090" role="paragraph">Cardiac function (LVEF) should be assessed before treatment [V, A].</div></div></div><div id="u0085" role="listitem"><div class="label">•</div><div class="content"><div id="p0095" role="paragraph">The staging is established according to the Ann Arbor classification system [I, A].</div></div></div><div id="u0090" role="listitem"><div class="label">•</div><div class="content"><div id="p0100" role="paragraph">For prognostic purposes, the IPI and aa-IPI should be calculated [I, A].</div></div></div></div></td></tr><tr><td>Treatment</td></tr><tr><td> </td></tr><tr><td><div id="l0020" role="list"><div id="u0095" role="listitem"><div class="label">•</div><div class="content"><div id="p0110" role="paragraph">Treatment strategies should be stratified according to age, IPI and feasibility of dose-intensified approaches.</div></div></div><div id="u0100" role="listitem"><div class="label">•</div><div class="content"><div id="p0115" role="paragraph">Whenever available, inclusion in a clinical trial is recommended.</div></div></div><div id="u0105" role="listitem"><div class="label">•</div><div class="content"><div id="p0120" role="paragraph">In cases with high tumour load, precautions are advised to avoid tumour lysis syndrome [I, A].</div></div></div><div id="u0110" role="listitem"><div class="label">•</div><div class="content"><div id="p0125" role="paragraph">Dose reductions due to haematological toxicity should be avoided whenever possible [I, A].</div></div></div><div id="u0115" role="listitem"><div class="label">•</div><div class="content"><div id="p0130" role="paragraph">The risk of febrile neutropenia justifies prophylactic use of haematopoietic growth factors in patients treatment with curative intent and in patients &gt;60 years of age [I, A].</div></div></div><div id="u0120" role="listitem"><div class="label">•</div><div class="content"><div id="p0135" role="paragraph">For young, low-risk patients (aa-IPI = 0) without bulky disease:<div id="l0025" role="list"><div id="u0125" role="listitem"><div class="label">○</div><div class="content"><div id="p0140" role="paragraph">six cycles of combination chemotherapy with CHOP treatment combined with six doses of rituximab given every 21 days is the current standard [I, A];</div></div></div><div id="u0130" role="listitem"><div class="label">○</div><div class="content"><div id="p0145" role="paragraph">consolidation by radiotherapy to initial non-bulky sites has no proven benefit in patients treated with rituximab or not [I, A].</div></div></div></div></div></div></div><div id="u0135" role="listitem"><div class="label">•</div><div class="content"><div id="p0150" role="paragraph">For young low-intermediate-risk patients (aa-IPI = 1) or IPI low risk (aa-IPI = 0) with bulky disease:<div id="l0030" role="list"><div id="u0140" role="listitem"><div class="label">○</div><div class="content"><div id="p0155" role="paragraph">either R-CHOP21 × 6 with radiotherapy to the sites of previous bulky disease or the intensified regimen R-ACVBP is recommended [II, B].</div></div></div></div></div></div></div><div id="u0145" role="listitem"><div class="label">•</div><div class="content"><div id="p0160" role="paragraph">For young high- and high-intermediate-risk patients (aa-IPI ≥ 2):<div id="l0035" role="list"><div id="u0150" role="listitem"><div class="label">○</div><div class="content"><div id="p0165" role="paragraph">enrolment in clinical trials should be a priority;</div></div></div><div id="u0155" role="listitem"><div class="label">○</div><div class="content"><div id="p0170" role="paragraph">six to eight cycles of chemotherapy with CHOP combined with eight doses of rituximab given every 21 days are most frequently applied [III, B];</div></div></div><div id="u0160" role="listitem"><div class="label">○</div><div class="content"><div id="p0175" role="paragraph">dose dense treatment with R-CHOP given every 14 days has not demonstrated a survival advantage over standard R-CHOP given every 21 days [I, C];</div></div></div><div id="u0165" role="listitem"><div class="label">○</div><div class="content"><div id="p0180" role="paragraph">intensive treatment with R-ACVBP or R-CHOEP is frequently used but these regimens have not been directly compared with R-CHOP in this category [II, B];</div></div></div><div id="u0170" role="listitem"><div class="label">○</div><div class="content"><div id="p0185" role="paragraph">HDC with ASCT in first line remains experimental or may be proposed for selected high-risk patients [II, C];</div></div></div><div id="u0175" role="listitem"><div class="label">○</div><div class="content"><div id="p0190" role="paragraph">the role of interim PET to select patients who could benefit from consolidative ASCT or from radiotherapy is under evaluation [I, C].</div></div></div></div></div></div></div><div id="u0180" role="listitem"><div class="label">•</div><div class="content"><div id="p0195" role="paragraph">For patients aged 60–80 years:<div id="l0040" role="list"><div id="u0185" role="listitem"><div class="label">○</div><div class="content"><div id="p0200" role="paragraph">six to eight cycles of combination chemotherapy with CHOP plus eight doses of rituximab given every 21 days is the current standard [I, A];</div></div></div><div id="u0190" role="listitem"><div class="label">○</div><div class="content"><div id="p0205" role="paragraph">if R-CHOP is given every 14 days, six cycles of CHOP with eight cycles of rituximab are sufficient [I, A];</div></div></div><div id="u0195" role="listitem"><div class="label">○</div><div class="content"><div id="p0210" role="paragraph">a comprehensive geriatric assessment in order to ascertain comorbidities and functional decline is recommended to guide the choice of treatment in elderly poor-prognosis patients [III, A];</div></div></div><div id="u0200" role="listitem"><div class="label">○</div><div class="content"><div id="p0215" role="paragraph">○ R-CHOP treatment can usually be used up to 80 years of age in fit patients [I, A], but modulation of treatment according to geriatric assessment is recommended [III, C].</div></div></div></div></div></div></div><div id="u0205" role="listitem"><div class="label">•</div><div class="content"><div id="p0220" role="paragraph">For patients aged &gt;80 years:<div id="l0045" role="list"><div id="u0210" role="listitem"><div class="label">○</div><div class="content"><div id="p0225" role="paragraph">the combination of rituximab with attenuated chemotherapy, such as R-miniCHOP, can induce complete remission and long survival in fit patients older than 80 years [III, B];</div></div></div><div id="u0215" role="listitem"><div class="label">○</div><div class="content"><div id="p0230" role="paragraph">substitution of doxorubicin by gemcitabine, etoposide or liposomal doxorubicin, or even its omission, can be considered from the beginning or after a few cycles in patients with cardiac dysfunction or who are frail or unfit [III, C].</div></div></div></div></div></div></div><div id="u0220" role="listitem"><div class="label">•</div><div class="content"><div id="p0235" role="paragraph">CNS prophylaxis:<div id="l0050" role="list"><div id="u0225" role="listitem"><div class="label">○</div><div class="content"><div id="p0240" role="paragraph">should be recommended for patients with high-intermediate-risk and high-risk IPI, especially those with more than one extranodal site or elevated LDH or for patients with testicular, renal or adrenal involvement [II, A];</div></div></div><div id="u0230" role="listitem"><div class="label">○</div><div class="content"><div id="p0245" role="paragraph">intravenous high-dose methotrexate has been shown to be associated with efficient disease control [IV, C].</div></div></div></div></div></div></div><div id="u0235" role="listitem"><div class="label">•</div><div class="content"><div id="p0250" role="paragraph">Patients with human immunodeficiency virus (HIV) infection should usually receive the same treatment as HIV-negative patients in association with antiviral therapy [II, A].</div></div></div><div id="u0240" role="listitem"><div class="label">•</div><div class="content"><div id="p0255" role="paragraph">Antiviral prophylaxis or periodic HBV DNA monitoring and antiviral treatment are recommended for patients previously exposed to HBV who experience reactivation of the virus during treatment [III, A].</div></div></div></div></td></tr><tr><td>Response evaluation</td></tr><tr><td> </td></tr><tr><td><div id="l0055" role="list"><div id="u0245" role="listitem"><div class="label">•</div><div class="content"><div id="p0265" role="paragraph">FDG-PET/CT is the recommended standard for post-treatment assessment in DLBCL [I, A].</div></div></div><div id="u0250" role="listitem"><div class="label">•</div><div class="content"><div id="p0270" role="paragraph">In the presence of residual metabolically active tissue, where salvage treatment is being considered, a biopsy is recommended [III, A].</div></div></div><div id="u0255" role="listitem"><div class="label">•</div><div class="content"><div id="p0275" role="paragraph">Interim evaluation:<div id="l0060" role="list"><div id="u0260" role="listitem"><div class="label">○</div><div class="content"><div id="p0280" role="paragraph">mid-treatment imaging after three to four cycles may be used to rule out progression in clinical practice [V, B];</div></div></div><div id="u0265" role="listitem"><div class="label">○</div><div class="content"><div id="p0285" role="paragraph">changing treatment solely on the basis of interim PET/CT is discouraged [II, E], unless there is clear evidence of progression;</div></div></div><div id="u0270" role="listitem"><div class="label">○</div><div class="content"><div id="p0290" role="paragraph">early PET evaluation carried out after one to two cycles of treatment has been shown to be predictive of outcome, but should be reserved for clinical trials at the present time [II, D].</div></div></div></div></div></div></div></div></td></tr><tr><td>Follow-up</td></tr><tr><td> </td></tr><tr><td><div id="l0065" role="list"><div id="u0275" role="listitem"><div class="label">•</div><div class="content"><div id="p0300" role="paragraph">Careful history and physical examination every 3 months for 1 year, every 6 months for 2 further years and then once a year with attention to development of secondary tumours or other long-term side-effects of chemotherapy is recommended [V, D].</div></div></div><div id="u0280" role="listitem"><div class="label">•</div><div class="content"><div id="p0305" role="paragraph">Blood count should be carried out at 3, 6, 12 and 24 months, then only as needed for evaluation of suspicious symptoms or clinical findings in those patients suitable for further therapy [V, C].</div></div></div><div id="u0285" role="listitem"><div class="label">•</div><div class="content"><div id="p0310" role="paragraph">Minimal radiological examinations at 6, 12 and 24 months after end of treatment, by CT scan, is common practice, but there is no definitive evidence that routine imaging in patients in complete remission provides any outcome advantage and it may increase the incidence of secondary malignancies [V, D]. Routine surveillance with PET scan is not recommended [V, E].</div></div></div></div></td></tr></tbody></table></div><figcaption><div class="caption"><span class="heading">Table 5</span><div id="sp0040" role="paragraph">Summary of recommendations</div></div><div class="notes"><div id="sp0045" role="paragraph">DLBCL, diffuse large B-cell lymphoma; PCR, polymerase chain reaction; FISH, fluorescence <i>in situ</i> hybridisation; LDH, lactate dehydrogenase; HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus; FDG, fluorodeoxyglucose; PET, positron emission tomography; CT, computed tomography; CeCT, contrast-enhanced CT; CNS, central nervous system; MRI, magnetic resonance imaging; LVEF, left ventricular ejection fraction; IPI, International Prognostic Index; aa-IPI, age-adjusted IPI; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; R, rituximab; R-AVCBP, rituximab, doxorubicin, vindesine, cyclophosphamide, bleomycin and prednisolone; R-CHOEP, rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisolone; HDC, high-dose chemotherapy; ASCT, autologous stem-cell transplantation.</div></div><div class="core-table-tools"><ul><li><a class="core-table-show-action" href="/action/showFullTableHTML?isHtml=true&amp;tableId=t0030&amp;pii=S0923-7534%2819%2947184-6" target="_blank">Open table in a new tab</a></li></ul></div></figcaption></figure></div><div class="figure-wrap"><figure id="t0035" class="table" data-figureviewer-ignore="true"><div class="table-wrap"><table data-figureviewer-ignore="true"><tbody><tr><td colspan="2">Levels of evidence</td></tr><tr><td>I</td><td>Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomised trials without heterogeneity</td></tr><tr><td>II</td><td>Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity</td></tr><tr><td>III</td><td>Prospective cohort studies</td></tr><tr><td>IV</td><td>Retrospective cohort studies or case–control studies</td></tr><tr><td>V</td><td>Studies without control group, case reports, experts opinions</td></tr><tr><td colspan="2">Grades of recommendation</td></tr><tr><td>A</td><td>Strong evidence for efficacy with a substantial clinical benefit, strongly recommended</td></tr><tr><td>B</td><td>Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended</td></tr><tr><td>C</td><td>Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, … ), optional</td></tr><tr><td>D</td><td>Moderate evidence against efficacy or for adverse outcome, generally not recommended</td></tr><tr><td>E</td><td>Strong evidence against efficacy or for adverse outcome, never recommended</td></tr></tbody></table></div><figcaption><div class="caption"><span class="heading">Table 6</span><div id="sp0050" role="paragraph">Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System<sup>a</sup>)</div></div><div class="notes"><div id="sp0055" role="paragraph"><sup>a</sup>By permission of the Infectious Diseases Society of America [<a id="cf0010" href="#bb0435" role="doc-biblioref" data-xml-rid="bb0435">86</a>].</div></div><div class="core-table-tools"><ul><li><a class="core-table-show-action" href="/action/showFullTableHTML?isHtml=true&amp;tableId=t0035&amp;pii=S0923-7534%2819%2947184-6" target="_blank">Open table in a new tab</a></li></ul></div></figcaption></figure></div></section><section id="sec-9"><h2>conflict of interest</h2><div id="p0570" role="paragraph">HT has received honoraria from Celgene, Roche, Janssen-Cilag and Takeda; research contracts from Celgene, Roche/Genentech and Janssen-Cilag. MG has reported advisory boards for Roche, Celgene, Janssen-Cilag, Pfizer and Ferrer. UV has reported advisory boards for Roche; lectures sponsored by Roche, Janssen, Celgene and Mundipharma. AL-G has reported advisory boards for Roche, Celgene, Novartis, Mundipharma, Infinity, Bayer and Gilead. JW has declared advisory boards for Roche, Celgene, Janssen-Cilag and Takeda; research support from Roche, Celgene, Janssen-Cilag, Takeda, GlaxoSmithKline, Gilead and Seattle Genetics. PJ has reported research grants partially funded by Janssen-Cilag and Epizyme; member of data monitoring and safety committee for Boehringer Ingelheim; advisory board member for Roche, Bristol-Myers Squibb, Janssen-Cilag and Takeda. MP has declared advisory boards for Boehringer-Ingelheim, Celgene and Roche; research support from Roche, Amgen and Spectrum. ML has reported honoraria from Celgene, Janssen-Cilag, Roche, Amgen Mundipharma and Teva; research contracts from Celgene, Pfizer, Mundipharma and Roche; funds received from Amgen, Roche and Takeda. MM and MA have reported no potential conflicts of interest. UV has not reported any potential conflicts of interest.</div></section></div></section><div class="core-linked-content"></div><section id="backmatter" data-extent="backmatter"><div class="core-container"><section id="references"><h2>references</h2><div id="bibliography" role="doc-bibliography"><div role="list"><div role="listitem" data-has="label"><div id="bb0010" class="citations"><div id="rf0010" class="citation"><div class="citation-content"><div class="label">1.</div><div>Sant, M. ∙ Allemani, C. ∙ Tereanu, C. ...</div><div><strong>Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project</strong></div><em>Blood.</em> 2010; <strong>116</strong>:3724-3734</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2010-05-282632" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-78149436559" target="_blank" aria-label="Open Scopus in new tab">Scopus (714)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20664057/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2010-05-282632&amp;pmid=20664057" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0015" class="citations"><div id="rf0015" class="citation"><div class="citation-content"><div class="label">2.</div><div>Morton, L.M. ∙ Slager, S.L. ∙ Cerhan, J.R. ...</div><div><strong>Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project</strong></div><em>J Natl Cancer Inst Monogr.</em> 2014; 130-144</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/jncimonographs/lgu013" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_2_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84906833192" target="_blank" aria-label="Open Scopus in new tab">Scopus (267)</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fjncimonographs%2Flgu013" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0020" class="citations"><div id="rf0020" class="citation"><div class="citation-content"><div class="label">3.</div><div>Sant, M. ∙ Minicozzi, P. ∙ Mounier, M. ...</div><div><strong>Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study</strong></div><em>Lancet Oncol.</em> 2014; <strong>15</strong>:931-942</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_3_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2814%2970282-7&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_3_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2814%2970282-7&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_3_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84905005458" target="_blank" aria-label="Open Scopus in new tab">Scopus (232)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25030467/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2814%2970282-7&amp;pmid=25030467" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0025" class="citations"><div id="rf0025" class="citation"><div class="citation-content"><div class="label">4.</div><div>Ott, G. ∙ Ziepert, M. ∙ Klapper, W. ...</div><div><strong>Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL</strong></div><em>Blood.</em> 2010; <strong>116</strong>:4916-4925</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2010-03-276766" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_4_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-78649742465" target="_blank" aria-label="Open Scopus in new tab">Scopus (171)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20736456/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2010-03-276766&amp;pmid=20736456" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0030" class="citations"><div id="rf0030" class="citation"><div class="citation-content"><div class="label">5.</div><div>Swerdlow, S.H. ∙ Campo, E. ∙ Harris, N.L. ...</div><div><strong>World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues</strong></div>IARC, Lyon, France, 2008</div><div class="external-links"><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=S.H.SwerdlowE.CampoN.L.HarrisWorld+Health+Organization+Classification+of+Tumours+of+Haematopoietic+and+Lymphoid+Tissues4th+edition2008IARCLyon%2C+France" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0035" class="citations"><div id="rf0035" class="citation"><div class="citation-content"><div class="label">6.</div><div>Langerak, A.W. ∙ Groenen, P.J. ∙ Brüggemann, M. ...</div><div><strong>EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations</strong></div><em>Leukemia.</em> 2012; <strong>26</strong>:2159-2171</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/leu.2012.246" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84867405564" target="_blank" aria-label="Open Scopus in new tab">Scopus (385)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22918122/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fleu.2012.246&amp;pmid=22918122" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0040" class="citations"><div id="rf0040" class="citation"><div class="citation-content"><div class="label">7.</div><div>Wright, G. ∙ Tan, B. ∙ Rosenwald, A. ...</div><div><strong>A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma</strong></div><em>Proc Natl Acad Sci USA.</em> 2003; <strong>100</strong>:9991-9996</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.1732008100" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-0043192901" target="_blank" aria-label="Open Scopus in new tab">Scopus (875)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12900505/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1073%2Fpnas.1732008100&amp;pmid=12900505" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0045" class="citations"><div id="rf0045" class="citation"><div class="citation-content"><div class="label">8.</div><div>Lenz, G. ∙ Wright, G.W. ∙ Emre, N.C. ...</div><div><strong>Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways</strong></div><em>Proc Natl Acad Sci USA.</em> 2008; <strong>105</strong>:13520-13525</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.0804295105" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-51649111684" target="_blank" aria-label="Open Scopus in new tab">Scopus (827)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18765795/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1073%2Fpnas.0804295105&amp;pmid=18765795" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0050" class="citations"><div id="rf0050" class="citation"><div class="citation-content"><div class="label">9.</div><div>Scott, D.W. ∙ Wright, G.W. ∙ Williams, P.M. ...</div><div><strong>Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue</strong></div><em>Blood.</em> 2014; <strong>123</strong>:1214-1217</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2013-11-536433" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84899136028" target="_blank" aria-label="Open Scopus in new tab">Scopus (495)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24398326/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2013-11-536433&amp;pmid=24398326" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0055" class="citations"><div id="rf0055" class="citation"><div class="citation-content"><div class="label">10.</div><div>Mareschal, S. ∙ Ruminy, P. ∙ Bagacean, C. ...</div><div><strong>Accurate classification of germinal center b-cell-like/activated b-cell-like diffuse large b-cell lymphoma using a simple and rapid reverse transcriptase-multiplex ligation-dependent probe amplification assay: a CALYM study</strong></div><em>Mol Diagn.</em> 2015; [Epub ahead of print]</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_10_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2Fj.jmoldx.2015.01.007&amp;cf=fulltext&amp;site=jmdi-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_10_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2Fj.jmoldx.2015.01.007&amp;cf=pdf&amp;site=jmdi-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_10_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84928207042" target="_blank" aria-label="Open Scopus in new tab">Scopus (47)</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.jmoldx.2015.01.007" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0060" class="citations"><div id="rf0060" class="citation"><div class="citation-content"><div class="label">11.</div><div>Hans, C.P. ∙ Weisenburger, D.D. ∙ Greiner, T.C. ...</div><div><strong>Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray</strong></div><em>Blood.</em> 2004; <strong>103</strong>:275-282</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2003-05-1545" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_11_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-9144237554" target="_blank" aria-label="Open Scopus in new tab">Scopus (3535)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14504078/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2003-05-1545&amp;pmid=14504078" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0065" class="citations"><div id="rf0065" class="citation"><div class="citation-content"><div class="label">12.</div><div>Choi, W.W. ∙ Weisenburger, D.D. ∙ Greiner, T.C. ...</div><div><strong>A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy</strong></div><em>Clin Cancer Res.</em> 2009; <strong>15</strong>:5494-5502</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-09-0113" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_12_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-68549124173" target="_blank" aria-label="Open Scopus in new tab">Scopus (571)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19706817/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1158%2F1078-0432.CCR-09-0113&amp;pmid=19706817" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0070" class="citations"><div id="rf0070" class="citation"><div class="citation-content"><div class="label">13.</div><div>de Jong, D. ∙ Rosenwald, A. ∙ Chhanabhai, M. ...</div><div><strong>Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg Lymphoma Biomarker Consortium</strong></div><em>J Clin Oncol.</em> 2007; <strong>25</strong>:805-812</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2006.09.4490" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_13_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-33947538494" target="_blank" aria-label="Open Scopus in new tab">Scopus (266)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17327602/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2006.09.4490&amp;pmid=17327602" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0075" class="citations"><div id="rf0075" class="citation"><div class="citation-content"><div class="label">14.</div><div>Savage, K.J. ∙ Johnson, N.A. ∙ Ben-Neriah, S. ...</div><div><strong>MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy</strong></div><em>Blood.</em> 2009; <strong>114</strong>:3533-3537</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2009-05-220095" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_14_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-70449589073" target="_blank" aria-label="Open Scopus in new tab">Scopus (543)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19704118/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2009-05-220095&amp;pmid=19704118" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0080" class="citations"><div id="rf0080" class="citation"><div class="citation-content"><div class="label">15.</div><div>Barrans, S. ∙ Crouch, S. ∙ Smith, A. ...</div><div><strong>Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab</strong></div><em>J Clin Oncol.</em> 2010; <strong>28</strong>:3360-3365</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2009.26.3947" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_15_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-77954752069" target="_blank" aria-label="Open Scopus in new tab">Scopus (505)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20498406/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2009.26.3947&amp;pmid=20498406" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0085" class="citations"><div id="rf0085" class="citation"><div class="citation-content"><div class="label">16.</div><div>Lin, P. ∙ Dickason, T.J. ∙ Fayad, L.E. ...</div><div><strong>Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma</strong></div><em>Cancer.</em> 2012; <strong>118</strong>:1566-1573</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cncr.26433" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_16_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84863230289" target="_blank" aria-label="Open Scopus in new tab">Scopus (60)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21882178/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1002%2Fcncr.26433&amp;pmid=21882178" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0090" class="citations"><div id="rf0090" class="citation"><div class="citation-content"><div class="label">17.</div><div>Green, T.M. ∙ Young, K.H. ∙ Visco, C. ...</div><div><strong>Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone</strong></div><em>J Clin Oncol.</em> 2012; <strong>30</strong>:3460-3467</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2011.41.4342" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_17_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84867060272" target="_blank" aria-label="Open Scopus in new tab">Scopus (574)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22665537/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2011.41.4342&amp;pmid=22665537" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0095" class="citations"><div id="rf0095" class="citation"><div class="citation-content"><div class="label">18.</div><div>Johnson, N.A. ∙ Slack, G.W. ∙ Savage, K.J. ...</div><div><strong>Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone</strong></div><em>J Clin Oncol.</em> 2012; <strong>30</strong>:3452-3459</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2011.41.0985" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_18_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84867088456" target="_blank" aria-label="Open Scopus in new tab">Scopus (780)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22851565/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2011.41.0985&amp;pmid=22851565" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0100" class="citations"><div id="rf0100" class="citation"><div class="citation-content"><div class="label">19.</div><div>Horn, H. ∙ Ziepert, M. ∙ Becher, C. ...</div><div><strong>MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma</strong></div><em>Blood.</em> 2013; <strong>121</strong>:2253-2263</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2012-06-435842" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_19_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84878030010" target="_blank" aria-label="Open Scopus in new tab">Scopus (446)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23335369/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2012-06-435842&amp;pmid=23335369" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0105" class="citations"><div id="rf0105" class="citation"><div class="citation-content"><div class="label">20.</div><div>Cheson, B.D. ∙ Fisher, R.I. ∙ Barrington, S.F. ...</div><div><strong>Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification</strong></div><em>J Clin Oncol.</em> 2014; <strong>32</strong>:3059-3068</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2013.54.8800" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_20_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84903462466" target="_blank" aria-label="Open Scopus in new tab">Scopus (3738)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25113753/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2013.54.8800&amp;pmid=25113753" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0110" class="citations"><div id="rf0110" class="citation"><div class="citation-content"><div class="label">21.</div><div>Barrington, S.F. ∙ Mikhaeel, N.G. ∙ Kostakoglu, L. ...</div><div><strong>Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group</strong></div><em>J Clin Oncol.</em> 2014; <strong>32</strong>:3048-3058</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2013.53.5229" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_21_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84907202542" target="_blank" aria-label="Open Scopus in new tab">Scopus (1240)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25113771/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2013.53.5229&amp;pmid=25113771" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0115" class="citations"><div id="rf0115" class="citation"><div class="citation-content"><div class="label">22.</div><div>Khan, A.B. ∙ Barrington, S.F. ∙ Mikhaeel, N.G. ...</div><div><strong>PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement</strong></div><em>Blood.</em> 2013; <strong>122</strong>:61-67</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2012-12-473389" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_22_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84883710608" target="_blank" aria-label="Open Scopus in new tab">Scopus (192)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23660958/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2012-12-473389&amp;pmid=23660958" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0120" class="citations"><div id="rf0120" class="citation"><div class="citation-content"><div class="label">23.</div><div>Pelosi, E. ∙ Penna, D. ∙ Douroukas, A. ...</div><div><strong>Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study</strong></div><em>Q J Nucl Med Mol Imaging.</em> 2011; <strong>55</strong>:469-475</div><div class="external-links"><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21150862/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?pmid=21150862" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0125" class="citations"><div id="rf0125" class="citation"><div class="citation-content"><div class="label">24.</div><div>Benevolo, G. ∙ Stacchini, A. ∙ Spina, M. ...</div><div><strong>Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination</strong></div><em>Blood.</em> 2012; <strong>120</strong>:3222-3228</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2012-04-423095" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_24_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84868128326" target="_blank" aria-label="Open Scopus in new tab">Scopus (73)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22927246/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2012-04-423095&amp;pmid=22927246" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0130" class="citations"><div id="rf0130" class="citation"><div class="citation-content"><div class="label">25.</div><div><strong>A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project</strong></div><em>N Engl J Med.</em> 1993; <strong>329</strong>:987-994</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJM199309303291402" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_25_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-0027444652" target="_blank" aria-label="Open Scopus in new tab">Scopus (5299)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8141877/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJM199309303291402&amp;pmid=8141877" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0135" class="citations"><div id="rf0135" class="citation"><div class="citation-content"><div class="label">26.</div><div>Récher, C. ∙ Coiffier, B. ∙ Haioun, C. ...</div><div><strong>Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial</strong></div><em>Lancet.</em> 2011; <strong>378</strong>:1858-1867</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_26_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS0140-6736%2811%2961040-4&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_26_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS0140-6736%2811%2961040-4&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_26_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-82255186682" target="_blank" aria-label="Open Scopus in new tab">Scopus (302)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22118442/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2811%2961040-4&amp;pmid=22118442" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0140" class="citations"><div id="rf0140" class="citation"><div class="citation-content"><div class="label">27.</div><div>Fitoussi, O. ∙ Belhadj, K. ∙ Mounier, N. ...</div><div><strong>Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA</strong></div><em>Haematologica.</em> 2011; <strong>96</strong>:1136-1143</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.3324/haematol.2010.038109" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_27_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-79961096440" target="_blank" aria-label="Open Scopus in new tab">Scopus (79)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21546499/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.3324%2Fhaematol.2010.038109&amp;pmid=21546499" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0145" class="citations"><div id="rf0145" class="citation"><div class="citation-content"><div class="label">28.</div><div>Ziepert, M. ∙ Hasenclever, D. ∙ Kuhnt, E. ...</div><div><strong>Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era</strong></div><em>J Clin Oncol.</em> 2010; <strong>28</strong>:2373-2380</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2009.26.2493" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_28_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-77952477025" target="_blank" aria-label="Open Scopus in new tab">Scopus (484)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20385988/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2009.26.2493&amp;pmid=20385988" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0150" class="citations"><div id="rf0150" class="citation"><div class="citation-content"><div class="label">29.</div><div>Ketterer, N. ∙ Coiffier, B. ∙ Thieblemont, C. ...</div><div><strong>Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03–1B)</strong></div><em>Ann Oncol.</em> 2013; <strong>24</strong>:1032-1037</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_29_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1093%2Fannonc%2Fmds600&amp;cf=fulltext&amp;site=annonc-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_29_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1093%2Fannonc%2Fmds600&amp;cf=pdf&amp;site=annonc-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_29_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84875626098" target="_blank" aria-label="Open Scopus in new tab">Scopus (28)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23235801/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fannonc%2Fmds600&amp;pmid=23235801" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0155" class="citations"><div id="rf0155" class="citation"><div class="citation-content"><div class="label">30.</div><div>Pfreundschuh, M. ∙ Ho, A.D. ∙ Cavallin-Stahl, E. ...</div><div><strong>Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study</strong></div><em>Lancet Oncol.</em> 2008; <strong>9</strong>:435-444</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_30_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2808%2970078-0&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_30_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2808%2970078-0&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_30_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-42649113874" target="_blank" aria-label="Open Scopus in new tab">Scopus (178)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18400558/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2808%2970078-0&amp;pmid=18400558" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0160" class="citations"><div id="rf0160" class="citation"><div class="citation-content"><div class="label">31.</div><div>Pfreundschuh, M. ∙ Kuhnt, E. ∙ Trumper, L. ...</div><div><strong>CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group</strong></div><em>Lancet Oncol.</em> 2011; <strong>12</strong>:1013-1022</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2811%2970235-2&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2811%2970235-2&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-80053384016" target="_blank" aria-label="Open Scopus in new tab">Scopus (612)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21940214/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2811%2970235-2&amp;pmid=21940214" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0165" class="citations"><div id="rf0165" class="citation"><div class="citation-content"><div class="label">32.</div><div>Reyes, F. ∙ Lepage, E. ∙ Ganem, G. ...</div><div><strong>ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma</strong></div><em>N Engl J Med.</em> 2005; <strong>352</strong>:1197-1205</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa042040" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_32_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-20144369743" target="_blank" aria-label="Open Scopus in new tab">Scopus (299)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15788496/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa042040&amp;pmid=15788496" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0170" class="citations"><div id="or0010" class="citation"><div class="citation-content"><div class="label">33.</div>TLamy, GDamaj, EGyanet al. R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B cell lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02-03 trial from the Lysa/Goelams Group. In: 2014 ASH Annual Meeting, Orlando, Florida. Abstract 393.</div><div class="external-links"><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=TLamy%2C+GDamaj%2C+EGyanet+al.+R-CHOP+with+or+without+radiotherapy+in+non-bulky+limited-stage+diffuse+large+B+cell+lymphoma+%28DLBCL%29%3A+preliminary+results+of+the+prospective+randomized+phase+III+02-03+trial+from+the+Lysa%2FGoelams+Group.+In%3A+2014+ASH+Annual+Meeting%2C+Orlando%2C+Florida.+Abstract+393." target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0175" class="citations"><div id="rf0170" class="citation"><div class="citation-content"><div class="label">34.</div><div>Cunningham, D. ∙ Hawkes, E.A. ∙ Jack, A. ...</div><div><strong>Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles</strong></div><em>Lancet.</em> 2013; <strong>381</strong>:1817-1826</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_34_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS0140-6736%2813%2960313-X&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_34_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS0140-6736%2813%2960313-X&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_34_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84878112490" target="_blank" aria-label="Open Scopus in new tab">Scopus (436)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23615461/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2813%2960313-X&amp;pmid=23615461" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0180" class="citations"><div id="rf0175" class="citation"><div class="citation-content"><div class="label">35.</div><div>Schmitz, N. ∙ Nickelsen, M. ∙ Ziepert, M. ...</div><div><strong>Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002–1)</strong></div><em>Lancet Oncol.</em> 2012; <strong>13</strong>:1250-1259</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_35_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2812%2970481-3&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_35_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2812%2970481-3&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_35_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84870239168" target="_blank" aria-label="Open Scopus in new tab">Scopus (205)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23168367/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2812%2970481-3&amp;pmid=23168367" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0185" class="citations"><div id="rf0180" class="citation"><div class="citation-content"><div class="label">36.</div><div>Vitolo, U. ∙ Chiappella, A. ∙ Brusamolino, E. ...</div><div><strong>Rituximab dose-dense chemotherapy followed by intensified high-dose chemotherapy and autologous stem cell transplantation (HDC+ASCT) significantly reduces the risk of progression compared to standard rituximab dose-dense chemotherapy as first line treatment in young patients with high-risk (aa-IPI 2-3) diffuse large B-cell lymphoma (DLBCL): final results of phase III randomized trial DLCL04 of the Fondazione Italiana Linfomi (FIL)</strong></div><em>Blood.</em> 2012; <strong>120</strong>:688 (ASH Annual Meeting Abstracts)</div><div class="external-links"><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=U.VitoloA.ChiappellaE.BrusamolinoRituximab+dose-dense+chemotherapy+followed+by+intensified+high-dose+chemotherapy+and+autologous+stem+cell+transplantation+%28HDC%2BASCT%29+significantly+reduces+the+risk+of+progression+compared+to+standard+rituximab+dose-dense+chemotherapy+as+first+line+treatment+in+young+patients+with+high-risk+%28aa-IPI+2-3%29+diffuse+large+B-cell+lymphoma+%28DLBCL%29%3A+final+results+of+phase+III+randomized+trial+DLCL04+of+the+Fondazione+Italiana+Linfomi+%28FIL%29Blood1202012688%28ASH+Annual+Meeting+Abstracts%29" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0190" class="citations"><div id="rf0185" class="citation"><div class="citation-content"><div class="label">37.</div><div>Stiff, P.J. ∙ Unger, J.M. ∙ Cook, J.R. ...</div><div><strong>Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma</strong></div><em>N Engl J Med.</em> 2013; <strong>369</strong>:1681-1690</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1301077" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_37_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84886740979" target="_blank" aria-label="Open Scopus in new tab">Scopus (276)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24171516/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1301077&amp;pmid=24171516" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0195" class="citations"><div id="rf0190" class="citation"><div class="citation-content"><div class="label">38.</div><div>Le Gouill, S. ∙ Milpied, N.J. ∙ Lamy, T. ...</div><div><strong>First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: preliminary results of the GOELAMS 075 prospective multicenter randomized trial</strong></div><em>J Clin Oncol.</em> 2011; <strong>29</strong>:8003 ASCO Annual Meeting Abstracts Part 1</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/jco.2011.29.15_suppl.8003" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2Fjco.2011.29.15_suppl.8003" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0200" class="citations"><div id="rf0195" class="citation"><div class="citation-content"><div class="label">39.</div><div>Casasnovas, R.O. ∙ Ysebaert, L. ∙ Thieblemont, C. ...</div><div><strong>Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL)</strong></div><em>J Clin Oncol.</em> 2014; <strong>32</strong>:8503 ASCO Annual Meeting Abstracts</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/jco.2014.32.15_suppl.8503" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2Fjco.2014.32.15_suppl.8503" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0205" class="citations"><div id="rf0200" class="citation"><div class="citation-content"><div class="label">40.</div><div>Sehn, L.H. ∙ Hardy, E.L.G. ∙ Gill, K.K. ...</div><div><strong>Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC)</strong></div><em>Blood.</em> 2014; <strong>124</strong>:392 (ASH Annual Meeting Abstracts)</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.V124.21.392.392" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood.V124.21.392.392" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0210" class="citations"><div id="rf0205" class="citation"><div class="citation-content"><div class="label">41.</div><div>Coiffier, B. ∙ Thieblemont, C. ∙ Van Den Neste, E. ...</div><div><strong>Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte</strong></div><em>Blood.</em> 2010; <strong>116</strong>:2040-2045</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2010-03-276246" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_41_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-77957200763" target="_blank" aria-label="Open Scopus in new tab">Scopus (1167)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20548096/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2010-03-276246&amp;pmid=20548096" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0215" class="citations"><div id="rf0210" class="citation"><div class="citation-content"><div class="label">42.</div><div>Delarue, R. ∙ Tilly, H. ∙ Mounier, N. ...</div><div><strong>Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial</strong></div><em>Lancet Oncol.</em> 2013; <strong>14</strong>:525-533</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_42_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2813%2970122-0&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_42_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2813%2970122-0&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_42_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84876987456" target="_blank" aria-label="Open Scopus in new tab">Scopus (243)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23578722/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2813%2970122-0&amp;pmid=23578722" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0220" class="citations"><div id="rf0215" class="citation"><div class="citation-content"><div class="label">43.</div><div>Pfreundschuh, M. ∙ Schubert, J. ∙ Ziepert, M. ...</div><div><strong>Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)</strong></div><em>Lancet Oncol.</em> 2008; <strong>9</strong>:105-116</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_43_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2808%2970002-0&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_43_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2808%2970002-0&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_43_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-38549147027" target="_blank" aria-label="Open Scopus in new tab">Scopus (943)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18226581/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2808%2970002-0&amp;pmid=18226581" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0225" class="citations"><div id="rf0220" class="citation"><div class="citation-content"><div class="label">44.</div><div>Bonnet, C. ∙ Fillet, G. ∙ Mounier, N. ...</div><div><strong>CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte</strong></div><em>J Clin Oncol.</em> 2007; <strong>25</strong>:787-792</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2006.07.0722" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_44_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-33947543250" target="_blank" aria-label="Open Scopus in new tab">Scopus (220)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17228021/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2006.07.0722&amp;pmid=17228021" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0230" class="citations"><div id="rf0225" class="citation"><div class="citation-content"><div class="label">45.</div><div>Held, G. ∙ Murawski, N. ∙ Ziepert, M. ...</div><div><strong>Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma</strong></div><em>J Clin Oncol.</em> 2014; <strong>32</strong>:1112-1118</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2013.51.4505" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_45_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84901837261" target="_blank" aria-label="Open Scopus in new tab">Scopus (179)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24493716/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2013.51.4505&amp;pmid=24493716" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0235" class="citations"><div id="rf0230" class="citation"><div class="citation-content"><div class="label">46.</div><div>Pfreundschuh, M. ∙ Poeschel, V. ∙ Zeynalova, S. ...</div><div><strong>Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group</strong></div><em>J Clin Oncol.</em> 2014; <strong>32</strong>:4127-4133</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2013.54.6861" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_46_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84919756001" target="_blank" aria-label="Open Scopus in new tab">Scopus (67)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25403207/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2013.54.6861&amp;pmid=25403207" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0240" class="citations"><div id="rf0235" class="citation"><div class="citation-content"><div class="label">47.</div><div>Morrison, V.A. ∙ Hamlin, P. ∙ Soubeyran, P. ...</div><div><strong>Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper</strong></div><em>J Geriatr Oncol.</em> 2015; <strong>6</strong>:141-152</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_47_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2Fj.jgo.2014.11.004&amp;cf=fulltext&amp;site=jgo-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_47_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2Fj.jgo.2014.11.004&amp;cf=pdf&amp;site=jgo-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_47_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84925248601" target="_blank" aria-label="Open Scopus in new tab">Scopus (55)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25491101/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.jgo.2014.11.004&amp;pmid=25491101" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0245" class="citations"><div id="rf0240" class="citation"><div class="citation-content"><div class="label">48.</div><div>Tucci, A. ∙ Martelli, M. ∙ Rigacci, L. ...</div><div><strong>Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)</strong></div><em>Leuk Lymphoma.</em> 2015; <strong>56</strong>:921-926</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.3109/10428194.2014.953142" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_48_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84929083288" target="_blank" aria-label="Open Scopus in new tab">Scopus (130)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25110825/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.3109%2F10428194.2014.953142&amp;pmid=25110825" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0250" class="citations"><div id="rf0245" class="citation"><div class="citation-content"><div class="label">49.</div><div>Spina, M. ∙ Balzarotti, M. ∙ Uziel, L. ...</div><div><strong>Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma</strong></div><em>Oncologist.</em> 2012; <strong>17</strong>:838-846</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1634/theoncologist.2011-0417" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_49_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84862840453" target="_blank" aria-label="Open Scopus in new tab">Scopus (113)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22610154/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1634%2Ftheoncologist.2011-0417&amp;pmid=22610154" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0255" class="citations"><div id="rf0250" class="citation"><div class="citation-content"><div class="label">50.</div><div>Peyrade, F. ∙ Jardin, F. ∙ Thieblemont, C. ...</div><div><strong>Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial</strong></div><em>Lancet Oncol.</em> 2011; <strong>12</strong>:460-468</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_50_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2811%2970069-9&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_50_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2811%2970069-9&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_50_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-79955473473" target="_blank" aria-label="Open Scopus in new tab">Scopus (425)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21482186/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2811%2970069-9&amp;pmid=21482186" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0260" class="citations"><div id="rf0255" class="citation"><div class="citation-content"><div class="label">51.</div><div>Fields, P.A. ∙ Townsend, W. ∙ Webb, A. ...</div><div><strong>De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial</strong></div><em>J Clin Oncol.</em> 2014; <strong>32</strong>:282-287</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2013.49.7586" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_51_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84897019433" target="_blank" aria-label="Open Scopus in new tab">Scopus (82)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24220559/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2013.49.7586&amp;pmid=24220559" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0265" class="citations"><div id="rf0260" class="citation"><div class="citation-content"><div class="label">52.</div><div>Kridel, R. ∙ Dietrich, P.Y.</div><div><strong>Prevention of CNS relapse in diffuse large B-cell lymphoma</strong></div><em>Lancet Oncol.</em> 2011; <strong>12</strong>:1258-1266</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_52_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2811%2970140-1&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_52_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2811%2970140-1&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_52_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-82555179236" target="_blank" aria-label="Open Scopus in new tab">Scopus (79)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21933751/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2811%2970140-1&amp;pmid=21933751" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0270" class="citations"><div id="rf0265" class="citation"><div class="citation-content"><div class="label">53.</div><div>Savage, K.J. ∙ Zeynalova, S. ∙ Kansara, R.R. ...</div><div><strong>Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma</strong></div><em>Blood.</em> 2014; <strong>124</strong>:394 (ASH Annual Meeting Abstracts)</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.V124.21.394.394" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood.V124.21.394.394" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0275" class="citations"><div id="rf0270" class="citation"><div class="citation-content"><div class="label">54.</div><div>Tilly, H. ∙ Lepage, E. ∙ Coiffier, B. ...</div><div><strong>Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma</strong></div><em>Blood.</em> 2003; <strong>102</strong>:4284-4289</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2003-02-0542" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_54_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-10744224285" target="_blank" aria-label="Open Scopus in new tab">Scopus (293)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12920037/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2003-02-0542&amp;pmid=12920037" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0280" class="citations"><div id="rf0275" class="citation"><div class="citation-content"><div class="label">55.</div><div>Abramson, J.S. ∙ Hellmann, M. ∙ Barnes, J.A. ...</div><div><strong>Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma</strong></div><em>Cancer.</em> 2010; <strong>116</strong>:4283-4290</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cncr.25278" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_55_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-77957331593" target="_blank" aria-label="Open Scopus in new tab">Scopus (183)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20564149/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1002%2Fcncr.25278&amp;pmid=20564149" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0285" class="citations"><div id="rf0280" class="citation"><div class="citation-content"><div class="label">56.</div><div>Cheah, C.Y. ∙ Herbert, K.E. ∙ O'Rourke, K. ...</div><div><strong>A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma</strong></div><em>Br J Cancer.</em> 2014; <strong>111</strong>:1072-1079</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/bjc.2014.405" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_56_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84908481527" target="_blank" aria-label="Open Scopus in new tab">Scopus (99)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25072255/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fbjc.2014.405&amp;pmid=25072255" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0290" class="citations"><div id="rf0285" class="citation"><div class="citation-content"><div class="label">57.</div><div>Coutinho, R. ∙ Pria, A.D. ∙ Gandhi, S. ...</div><div><strong>HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era</strong></div><em>AIDS.</em> 2014; <strong>28</strong>:689-697</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAD.0000000000000133" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_57_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84898733980" target="_blank" aria-label="Open Scopus in new tab">Scopus (55)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24418826/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1097%2FQAD.0000000000000133&amp;pmid=24418826" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0295" class="citations"><div id="rf0290" class="citation"><div class="citation-content"><div class="label">58.</div><div>Seto, W.K. ∙ Chan, T.S. ∙ Hwang, Y.Y. ...</div><div><strong>Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study</strong></div><em>J Clin Oncol.</em> 2014; <strong>32</strong>:3736-3743</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2014.56.7081" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_58_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84911424291" target="_blank" aria-label="Open Scopus in new tab">Scopus (266)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25287829/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2014.56.7081&amp;pmid=25287829" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0300" class="citations"><div id="rf0295" class="citation"><div class="citation-content"><div class="label">59.</div><div>Meignan, M. ∙ Itti, E. ∙ Gallamini, A. ...</div><div><strong>Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation—where do we stand?</strong></div><em>Leuk Lymphoma.</em> 2009; <strong>50</strong>:1753-1756</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.3109/10428190903308056" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_59_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-71049138078" target="_blank" aria-label="Open Scopus in new tab">Scopus (42)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19863178/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.3109%2F10428190903308056&amp;pmid=19863178" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0305" class="citations"><div id="rf0300" class="citation"><div class="citation-content"><div class="label">60.</div><div>Maurer, M.J. ∙ Ghesquieres, H. ∙ Jais, J.P. ...</div><div><strong>Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy</strong></div><em>J Clin Oncol.</em> 2014; <strong>32</strong>:1066-1073</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2013.51.5866" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_60_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84901700388" target="_blank" aria-label="Open Scopus in new tab">Scopus (314)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24550425/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2013.51.5866&amp;pmid=24550425" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0310" class="citations"><div id="rf0305" class="citation"><div class="citation-content"><div class="label">61.</div><div>Thompson, C.A. ∙ Ghesquieres, H. ∙ Maurer, M.J. ...</div><div><strong>Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma</strong></div><em>J Clin Oncol.</em> 2014; <strong>32</strong>:3506-3512</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2014.55.7561" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_61_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84911476792" target="_blank" aria-label="Open Scopus in new tab">Scopus (144)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25267745/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2014.55.7561&amp;pmid=25267745" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0315" class="citations"><div id="rf0310" class="citation"><div class="citation-content"><div class="label">62.</div><div>Chien, S.H. ∙ Liu, C.J. ∙ Hu, Y.W. ...</div><div><strong>Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: a nationwide population-based study</strong></div><em>Int J Cancer.</em> 2015; <strong>137</strong>:658-665</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ijc.29433" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_62_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84929509382" target="_blank" aria-label="Open Scopus in new tab">Scopus (38)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25630766/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1002%2Fijc.29433&amp;pmid=25630766" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0320" class="citations"><div id="rf0315" class="citation"><div class="citation-content"><div class="label">63.</div><div>Gisselbrecht, C. ∙ Glass, B. ∙ Mounier, N. ...</div><div><strong>Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era</strong></div><em>J Clin Oncol.</em> 2010; <strong>28</strong>:4184-4190</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2010.28.1618" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_63_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-77957965500" target="_blank" aria-label="Open Scopus in new tab">Scopus (1285)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20660832/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2010.28.1618&amp;pmid=20660832" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0325" class="citations"><div id="rf0320" class="citation"><div class="citation-content"><div class="label">64.</div><div>Horwitz, S.M. ∙ Negrin, R.S. ∙ Blume, K.G. ...</div><div><strong>Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma</strong></div><em>Blood.</em> 2004; <strong>103</strong>:777-783</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2003-04-1257" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_64_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-9144266912" target="_blank" aria-label="Open Scopus in new tab">Scopus (208)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12907446/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2003-04-1257&amp;pmid=12907446" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0330" class="citations"><div id="rf0325" class="citation"><div class="citation-content"><div class="label">65.</div><div>Kewalramani, T. ∙ Zelenetz, A.D. ∙ Nimer, S.D. ...</div><div><strong>Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma</strong></div><em>Blood.</em> 2004; <strong>103</strong>:3684-3688</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2003-11-3911" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_65_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-1842829171" target="_blank" aria-label="Open Scopus in new tab">Scopus (372)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14739217/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2003-11-3911&amp;pmid=14739217" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0335" class="citations"><div id="rf0330" class="citation"><div class="citation-content"><div class="label">66.</div><div>Crump, M. ∙ Kuruvilla, J. ∙ Couban, S. ...</div><div><strong>Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12</strong></div><em>J Clin Oncol.</em> 2014; <strong>32</strong>:3490-3496</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2013.53.9593" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_66_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84911498561" target="_blank" aria-label="Open Scopus in new tab">Scopus (341)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25267740/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2013.53.9593&amp;pmid=25267740" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0340" class="citations"><div id="rf0335" class="citation"><div class="citation-content"><div class="label">67.</div><div>Thieblemont, C. ∙ Briere, J. ∙ Mounier, N. ...</div><div><strong>The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study</strong></div><em>J Clin Oncol.</em> 2011; <strong>29</strong>:4079-4087</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2011.35.4423" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_67_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-80755143466" target="_blank" aria-label="Open Scopus in new tab">Scopus (230)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21947824/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2011.35.4423&amp;pmid=21947824" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0345" class="citations"><div id="rf0340" class="citation"><div class="citation-content"><div class="label">68.</div><div>Gisselbrecht, C. ∙ Schmitz, N. ∙ Mounier, N. ...</div><div><strong>Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma</strong></div><em>J Clin Oncol.</em> 2012; <strong>30</strong>:4462-4469</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2012.41.9416" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_68_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84871731101" target="_blank" aria-label="Open Scopus in new tab">Scopus (232)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23091101/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2012.41.9416&amp;pmid=23091101" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0350" class="citations"><div id="rf0345" class="citation"><div class="citation-content"><div class="label">69.</div><div>Glass, B. ∙ Hasenkamp, J. ∙ Wulf, G. ...</div><div><strong>Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial</strong></div><em>Lancet Oncol.</em> 2014; <strong>15</strong>:757-766</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_69_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2814%2970161-5&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_69_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2814%2970161-5&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_69_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84901615992" target="_blank" aria-label="Open Scopus in new tab">Scopus (87)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24827808/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2814%2970161-5&amp;pmid=24827808" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0355" class="citations"><div id="rf0350" class="citation"><div class="citation-content"><div class="label">70.</div><div>Mounier, N. ∙ El Gnaoui, T. ∙ Tilly, H. ...</div><div><strong>Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial</strong></div><em>Haematologica.</em> 2013; <strong>98</strong>:1726-1731</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.3324/haematol.2013.090597" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_70_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84886992205" target="_blank" aria-label="Open Scopus in new tab">Scopus (129)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23753028/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.3324%2Fhaematol.2013.090597&amp;pmid=23753028" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0360" class="citations"><div id="rf0355" class="citation"><div class="citation-content"><div class="label">71.</div><div>Pettengell, R. ∙ Coiffier, B. ∙ Narayanan, G. ...</div><div><strong>Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial</strong></div><em>Lancet Oncol.</em> 2012; <strong>13</strong>:696-706</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_71_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2812%2970212-7&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_71_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2812%2970212-7&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_71_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84863113681" target="_blank" aria-label="Open Scopus in new tab">Scopus (108)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22652183/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2812%2970212-7&amp;pmid=22652183" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0365" class="citations"><div id="rf0360" class="citation"><div class="citation-content"><div class="label">72.</div><div>Dickinson, M. ∙ Hoyt, R. ∙ Roberts, A.W. ...</div><div><strong>Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy</strong></div><em>Br J Haematol.</em> 2010; <strong>150</strong>:39-45</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2141.2010.08162.x" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_72_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-77953527083" target="_blank" aria-label="Open Scopus in new tab">Scopus (71)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20507301/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1111%2Fj.1365-2141.2010.08162.x&amp;pmid=20507301" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0370" class="citations"><div id="rf0365" class="citation"><div class="citation-content"><div class="label">73.</div><div>Molina, T.J. ∙ Canioni, D. ∙ Copie-Bergman, C. ...</div><div><strong>Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03–2B</strong></div><em>J Clin Oncol.</em> 2014; <strong>32</strong>:3996-4003</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2013.54.9493" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_73_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84919343441" target="_blank" aria-label="Open Scopus in new tab">Scopus (72)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25385729/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2013.54.9493&amp;pmid=25385729" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0375" class="citations"><div id="rf0370" class="citation"><div class="citation-content"><div class="label">74.</div><div>Dunleavy, K. ∙ Pittaluga, S. ∙ Czuczman, M.S. ...</div><div><strong>Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma</strong></div><em>Blood.</em> 2009; <strong>113</strong>:6069-6076</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2009-01-199679" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_74_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-67650398258" target="_blank" aria-label="Open Scopus in new tab">Scopus (441)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19380866/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2009-01-199679&amp;pmid=19380866" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0380" class="citations"><div id="rf0375" class="citation"><div class="citation-content"><div class="label">75.</div><div>Hernandez-Ilizaliturri, F.J. ∙ Deeb, G. ∙ Zinzani, P.L. ...</div><div><strong>Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype</strong></div><em>Cancer.</em> 2011; <strong>117</strong>:5058-5066</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/cncr.26135" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_75_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-80053502780" target="_blank" aria-label="Open Scopus in new tab">Scopus (276)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21495023/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1002%2Fcncr.26135&amp;pmid=21495023" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0385" class="citations"><div id="rf0380" class="citation"><div class="citation-content"><div class="label">76.</div><div>Czuczman, M.S. ∙ Davies, A. ∙ Linton, K.M. ...</div><div><strong>A phase 2/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator's choice in relapsed/refractory DLBCL</strong></div><em>Blood.</em> 2014; <strong>124</strong>:628 ASH Annual Meeting Abstracts</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.V124.21.628.628" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24855206/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood.V124.21.628.628&amp;pmid=24855206" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0390" class="citations"><div id="rf0385" class="citation"><div class="citation-content"><div class="label">77.</div><div>Vitolo, U. ∙ Chiappella, A. ∙ Franceschetti, S. ...</div><div><strong>Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial</strong></div><em>Lancet Oncol.</em> 2014; <strong>15</strong>:730-737</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_77_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2814%2970191-3&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_77_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2814%2970191-3&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_77_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84901391325" target="_blank" aria-label="Open Scopus in new tab">Scopus (162)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24831981/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2814%2970191-3&amp;pmid=24831981" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0395" class="citations"><div id="rf0390" class="citation"><div class="citation-content"><div class="label">78.</div><div>Nowakowski, G.S. ∙ LaPlant, B. ∙ Macon, W.R. ...</div><div><strong>Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study</strong></div><em>J Clin Oncol.</em> 2015; <strong>33</strong>:251-257</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2014.55.5714" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_78_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84921764017" target="_blank" aria-label="Open Scopus in new tab">Scopus (315)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25135992/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2014.55.5714&amp;pmid=25135992" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0400" class="citations"><div id="rf0395" class="citation"><div class="citation-content"><div class="label">79.</div><div>Younes, A. ∙ Thieblemont, C. ∙ Morschhauser, F. ...</div><div><strong>Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study</strong></div><em>Lancet Oncol.</em> 2014; <strong>15</strong>:1019-1026</div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_79_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2814%2970311-0&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_79_2&amp;dbid=4&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=10.1016%2FS1470-2045%2814%2970311-0&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_79_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84904999787" target="_blank" aria-label="Open Scopus in new tab">Scopus (233)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25042202/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2814%2970311-0&amp;pmid=25042202" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0405" class="citations"><div id="rf0400" class="citation"><div class="citation-content"><div class="label">80.</div><div>Swerdlow, S.H.</div><div><strong>Diagnosis of "double hit" diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate Burkitt lymphoma: when and how, FISH versus IHC.</strong></div><em>Hematology Am Soc Hematol Educ Program.</em> 2014; <strong>2014</strong>:90-99</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/asheducation-2014.1.90" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_80_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84930994719" target="_blank" aria-label="Open Scopus in new tab">Scopus (125)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25696840/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fasheducation-2014.1.90&amp;pmid=25696840" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0410" class="citations"><div id="rf0405" class="citation"><div class="citation-content"><div class="label">81.</div><div>Oki, Y. ∙ Noorani, M. ∙ Lin, P. ...</div><div><strong>Double hit lymphoma: the MD Anderson Cancer Center clinical experience</strong></div><em>Br J Haematol.</em> 2014; <strong>166</strong>:891-901</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.12982" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_81_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84907599085" target="_blank" aria-label="Open Scopus in new tab">Scopus (308)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24943107/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1111%2Fbjh.12982&amp;pmid=24943107" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0415" class="citations"><div id="rf0410" class="citation"><div class="citation-content"><div class="label">82.</div><div>Petrich, A.M. ∙ Gandhi, M. ∙ Jovanovic, B. ...</div><div><strong>Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis</strong></div><em>Blood.</em> 2014; <strong>124</strong>:2354-2361</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2014-05-578963" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_82_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84907611124" target="_blank" aria-label="Open Scopus in new tab">Scopus (381)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25161267/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2014-05-578963&amp;pmid=25161267" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0420" class="citations"><div id="rf0415" class="citation"><div class="citation-content"><div class="label">83.</div><div>Intlekofer, A.M. ∙ Younes, A.</div><div><strong>Precision therapy for lymphoma—current state and future directions</strong></div><em>Nat Rev Clin Oncol.</em> 2014; <strong>11</strong>:585-596</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrclinonc.2014.137" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_83_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84910006341" target="_blank" aria-label="Open Scopus in new tab">Scopus (68)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25135367/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnrclinonc.2014.137&amp;pmid=25135367" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0425" class="citations"><div id="rf0420" class="citation"><div class="citation-content"><div class="label">84.</div><div>Dunleavy, K. ∙ Roschewski, M. ∙ Wilson, W.H.</div><div><strong>Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype</strong></div><em>Clin Cancer Res.</em> 2014; <strong>20</strong>:5182-5193</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-14-0497" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_84_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-84909594060" target="_blank" aria-label="Open Scopus in new tab">Scopus (38)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25320368/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1158%2F1078-0432.CCR-14-0497&amp;pmid=25320368" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0430" class="citations"><div id="rf0425" class="citation"><div class="citation-content"><div class="label">85.</div><div>Jardin, F.</div><div><strong>Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy</strong></div><em>Discov Med.</em> 2014; <strong>18</strong>:51-65</div><div class="external-links"><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25091488/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?pmid=25091488" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bb0435" class="citations"><div id="rf0430" class="citation"><div class="citation-content"><div class="label">86.</div><div>Dykewicz, C.A.</div><div><strong>Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients</strong></div><em>Clin Infect Dis.</em> 2001; <strong>33</strong>:139-144</div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1086/321805" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_86_2&amp;dbid=137438953472&amp;doi=10.1093%2Fannonc%2Fmdv304&amp;key=2-s2.0-0035879607" target="_blank" aria-label="Open Scopus in new tab">Scopus (491)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11418871/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1086%2F321805&amp;pmid=11418871" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div></div></div></section></div></section><div class="core-linked-content">
    

        

</div></div></div><div class="core-collateral-aside"><section id="core-collateral-figures"></section>
    

        


    

            

            

            <section id="core-collateral-metrics" class="publication-list__axel-section"><h2>Article metrics</h2><div><ul class="publication-list rlist publication-list--list plum-x--lazy-load publication-list--axel" data-plum-x-url="/pb/widgets/ux3/publicationList/plumx?widgetId=60784550-ac83-412a-a4dd-0b020b0cfaed&pbContext=%3Bctype%3Astring%3AJournal+Content%3Bcsubtype%3Astring%3AVolume+Supplement%3Bjournal%3Ajournal%3Aannonc%3BpageGroup%3Astring%3AArticle+View%3Barticle%3Aarticle%3Apii%5C%3AS0923753419471846%3Bwgroup%3Astring%3AMigrated+Websites%3Bpage%3Astring%3AShow+Full+Text%3Bissue%3Aissue%3Apii%5C%3AS0923753415X68001%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Aannonc-site%3Bproduct%3Aproduct%3Aelsevier%5C%3Aproduct%5C%3Aha%3BrequestedJournal%3Ajournal%3Aannonc" data-pb-mode-enabled="false"><li aria-label="loading articles" role="alert" class="js--loading plum-x--spinner hidden"></li></ul></div></section>

            

        
<section id="core-collateral-supplementary"></section>
    

        


    

            

            

            <section id="core-collateral-relatedArticles" class="axel-related-articles"><h2 id="relatedArticles" class="top axel-related-articles__title" data-title="Related articles">Related Articles</h2><div data-pb-widget-type="ux3-relatedArticles" data-widget-id="55d12544-88af-4b41-92cd-fa404a51ef23" data-widget-name="AtyponTempUX3RelatedArticlesWidget" data-article-pii="S0923753419471846" class="ux3DeferredOnScrollWidget axel-related-articles__body" data-show-more="true"></div></section>

            

        
</div></div><aside data-core-aside="right-rail"><div class="inner-wrapper">

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget literatumAd none adplaceholder widget-verticalAd" id="80e61381-d1dc-4a1f-98c4-59c9e22b2cf2">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-verticalAd "><div class="verticalAdContainer">
    <div class="verticalAdLabelContainer">
        <div class="verticalAdLabel">
                <img src="/templates/jsp/_style2/_marlin/images/bg_adVert.gif" alt="Advertisement"/>
        </div>
    </div>
    <div class="verticalAd">
        





        <div class="pb-ad">
            <div class="gpt-ad" data-adsize="sidebar"></div>
        </div>
    

    </div>
</div></div>
                </div>
                </div>

        


</div></aside><div class="core-authors-details" style="display:none"><section class="core-authors"><div id="au0010" property="author" typeof="Person"><div class="heading"><span property="givenName">H.</span> <span property="familyName">Tilly</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Centre Henri-Becquerel, Université de Rouen, Rouen, France</span></div></div><div class="core-author-link"><a href="/authored-by/Tilly/H" target="_blank">Search for articles by this author</a></div></div></div><div id="au0015" property="author" typeof="Person"><div class="heading"><span property="givenName">M.</span> <span property="familyName">Gomes da Silva</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Portuguese Institute of Oncology, Lisbon, Portugal</span></div></div><div class="core-author-link"><a href="/authored-by/Gomes+da+Silva/M" target="_blank">Search for articles by this author</a></div></div></div><div id="au0020" property="author" typeof="Person"><div class="heading"><span property="givenName">U.</span> <span property="familyName">Vitolo</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">A.O. Città della Salute e della Scienza di Torino, Turin, Italy</span></div></div><div class="core-author-link"><a href="/authored-by/Vitolo/U" target="_blank">Search for articles by this author</a></div></div></div><div id="au0025" property="author" typeof="Person"><div class="heading"><span property="givenName">A.</span> <span property="familyName">Jack</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">St James's University Hospital, Leeds, UK</span></div></div><div class="core-author-link"><a href="/authored-by/Jack/A" target="_blank">Search for articles by this author</a></div></div></div><div id="au0030" property="author" typeof="Person"><div class="heading"><span property="givenName">M.</span> <span property="familyName">Meignan</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Henri Mondor University Hospital, Créteil, France</span></div></div><div class="core-author-link"><a href="/authored-by/Meignan/M" target="_blank">Search for articles by this author</a></div></div></div><div id="au0035" property="author" typeof="Person"><div class="heading"><span property="givenName">A.</span> <span property="familyName">Lopez-Guillermo</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Hospital Clinic, Barcelona, Spain</span></div></div><div class="core-author-link"><a href="/authored-by/Lopez-Guillermo/A" target="_blank">Search for articles by this author</a></div></div></div><div id="au0040" property="author" typeof="Person"><div class="heading"><span property="givenName">J.</span> <span property="familyName">Walewski</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland</span></div></div><div class="core-author-link"><a href="/authored-by/Walewski/J" target="_blank">Search for articles by this author</a></div></div></div><div id="au0045" property="author" typeof="Person"><div class="heading"><span property="givenName">M.</span> <span property="familyName">André</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium</span></div></div><div class="core-author-link"><a href="/authored-by/Andr%C3%A9/M" target="_blank">Search for articles by this author</a></div></div></div><div id="au0050" property="author" typeof="Person"><div class="heading"><span property="givenName">P.W.</span> <span property="familyName">Johnson</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Cancer Research UK, University of Southampton, Southampton, UK</span></div></div><div class="core-author-link"><a href="/authored-by/Johnson/P+W" target="_blank">Search for articles by this author</a></div></div></div><div id="au0055" property="author" typeof="Person"><div class="heading"><span property="givenName">M.</span> <span property="familyName">Pfreundschuh</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Innere Medizin I, Universität des Saarlandes, Hamburg, Germany</span></div></div><div class="core-author-link"><a href="/authored-by/Pfreundschuh/M" target="_blank">Search for articles by this author</a></div></div></div><div id="au0060" property="author" typeof="Person"><div class="heading"><span property="givenName">M.</span> <span property="familyName">Ladetto</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy</span></div></div><div class="core-author-link"><a href="/authored-by/Ladetto/M" target="_blank">Search for articles by this author</a></div></div></div><div id="co9000" property="author" typeof="Person"><div class="heading"><span property="name">on behalf of the ESMO Guidelines Committee</span></div><div class="content"><div class="core-author-link"><a href="/authored-by/group/on+behalf+of+the+ESMO+Guidelines+Committee" target="_blank">Search for articles by this author</a></div></div></div></section></div></article><div data-extent="article-wrapper"><div class="core-container"></div></div><script id="contribution-meta" type="application/json">{
    "doi": "10.1093/annonc/mdv304",
    "isRetraction": "false",
    "isRetired": "false"
}</script><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><script id="book-title" type="application/json">{
    "bookTitle": ""
}
</script><template id="figure_nav_template"><a href="#" class="open-in-viewer btn btn-dark figure-pop-btn"><i aria-hidden="true" class="icon-export_citation"></i><span>Open in viewer</span></a></template><div id="figure-viewer" role="dialog" aria-modal="true" aria-label="Figure Viewer" class="showCaption showThumbstrip figure-viewer"><nav class="nav-bar figure-viewer__top"><a href="#" title="Close Figure Viewer" role="button" class="figure-viewer__close"><i aria-hidden="true" class="icon-tools_close"></i></a><div class="figure-viewer__title"></div></nav><div class="frames"><ul class="frames__list"></ul><a href="#" title="Previous Frame" class="frameButton previousFrameButton frames__prev"><!--span Previous Frame--><i class="icon-arrow_l"></i></a><a href="#" title="Next Frame" class="frameButton nextFrameButton frames__next"><!--span Next Frame--><i class="icon-arrow_r"></i></a></div><div class="caption"><div class="figure-viewer__caption-body"></div></div><div class="toolbar figure-viewer__toolbar"><span class="figure-viewer__counter"></span><a href="#" class="button toggle-caption-button figure-viewer__caption__ctrl"><i aria-hidden="true" class="icon icon-info"></i><span class="label">Hide Caption</span></a><a href="#" class="button download-options-button"><i aria-hidden="true" class="icon icon-gizmo-folder-in download-size-icon"></i><span class="label">Download</span></a><a href="#figures" class="button see-figures figure-viewer__see-figure__ctrl"><i aria-hidden="true" class="icon icon-gizmo-image_figure viewer-size-icon"></i><span class="label">See figure in Article</span></a></div><div class="thumbstrip"><a href="#" class="toggleButton thumbstrip__ctrl"><span>Toggle Thumbstrip</span></a><a href="#" title="Previous Thumbnails" class="thumbstripButton previousThumbstripButton thumbstrip__prev"><i aria-hidden="true" class="icon-arrow_l"></i></a><a href="#" title="Next Thumbnails" class="thumbstripButton nextThumbstripButton thumbstrip__next"><i aria-hidden="true" class="icon-arrow_r"></i></a><div class="thumbstrip__wrapper"><ul class="rlist figure-viewer__thumbslist"></ul></div></div><div class="download figure-viewer__download"><div class="pointer"></div><ul class="rlist downlad__wrapper"><li><a target="_blank" href="/specs/products/marlin/components/figure-viewer/images/facets-2015-0010-f10-standard.jpg" title="View high resolution image in a new tab" class="downloadThisButton"><i class="icon icon-gizmo-image_figure figure-viewer__download__viewer-size-icon"></i><span class="figure-viewer__download__text">Download Hi-res image</span></a></li><li class="hidden-xs hidden-sm"><a href="/action/downloadFigures?articleNumber=e00489" target="_blank" title="Doanload .PPT" class="downloadAllButton"><i class="icon icon-gizmo-ppt figure-viewer__download__viewer-size-icon figure-viewer__download__viewer-size-icon--ppt"></i><span class="figure-viewer__download__text"> Download .PPT</span></a></li></ul></div></div><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-subdirectory_arrow_left"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-subdirectory_arrow_left"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-haspopup="true" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-subdirectory_arrow_left"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--inverse"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-do="Digital Object" data-figures="Figures" data-metrics="Article Metrics" data-related="Related articles" data-supplementary="Supplementary materials"></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info & Affiliations</a></template></div>
                </div>
                </div>

        

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                            
                        
                        
                            
                            
                            
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget general-html-asset none noMargin widget-none  widget-compact-all" id="2d4f14e8-99bd-4905-926b-9fb341fe128f">
                
                
                    
                

                <div class="wrapped " id='NAV BAR STYLES'>
                    
                    <div class="widget-body body body-none  body-compact-all"><style>

/* Article List */ 

.navarticlecss h4.meta__title {
text-decoration:none!important;
font-size:14px!important;
line-height:19px!important;
margin-bottom:0px!important;
margin-top:0px!important;
}

.navarticlecss .meta__header {
display:none;
}

.navarticlecss .OALabel {
display:none!important;
}

/*
.navarticlecss .search__item__body {
padding-bottom:18px!important;
}
*/

.navarticlecss .search__item {
border:0px!important;
padding:0px!important;
background-color:transparent!important; 
}


.listDropZone h2 {
font-size:1rem!important;
margin-top:0px!important;
border-bottom:.0625rem solid #bdbdbd;
padding: 0 0 .3125rem!important;
margin-bottom:.625rem!important;
font-weight:400;
} 


.navarticlecss .publication-list .search__item
{
margin:0 0 0.5rem!important;
}



/* News DO */ 

.navdocss .search-result__toolbar-bottom {
display:none;
}

.navdocss .do-date {
display:none;
}

.navdocss .do-breadcrumb {
display:none;
}

.navdocss .search-result__count {
display:none;
}

.navdocss .do-search-result-cards.search-result__body {
margin-top: 0px!important;
}

.navdocss .do-item-description {
display:none;
}



/* Nav Video DO */ 

.navvideodocss .do-item-media--video {
display:none;
}

.navvideodocss .do-item-content {
padding:0px!important;
}

.navvideodocss .do-media-links {
display:none!important;
}

.navvideodocss .do-item-content h3 {
line-height:1.4rem!important;
font-size:14px!important;
}

.navvideodocss .do-card{
border:0px!important;
background-color:transparent; 
}

/* Nav CfP */ 

.navcfpdo .do-item-content .do-item-description {
   display:none;
}

.navcfpdo .do-breadcrumb {
display:none;
}

.navcfpdo .do-list-item .do-date {
   display:none;
}

.navcfpdo .do-item-content h3 {
    font-size: 14px!important;
}

.navcfpdo .search__item
{
border-bottom: 0px!important;
}

.navcfpdo .items-results--articles .search__item
{
padding:0px!important;
margin-bottom:7px;
}

</style><script defer src="https://static.cloudflareinsights.com/beacon.min.js/v52afc6f149f6479b8c77fa569edb01181681764108816" integrity="sha512-jGCTpDpBAYDGNYR5ztKt4BQPGef1P0giN6ZGVUi835kFF88FOmmn8jBQWNgrNd8g/Yu421NdgWhwQoaOPFflDw==" data-cf-beacon='{"rayId":"7d4ab435ba3129e4","token":"57a02315956f4b2e82817b3dfa99b1a2","version":"2023.4.0","si":100}' crossorigin="anonymous"></script></div>
                </div>
                </div>

        

    

        


    

            

            

            <div data-widget-id="540089d6-bb03-4a3b-94ea-8f0af9d845d5" data-widget-name="UX3HTMLWidget"><style>
.journal-logos:nth-of-type(2) img {
max-height: 45px !important;
}
.journal-logos:nth-of-type(3) img {
max-height: 45px !important;
}
.ux3 .journal-logos + .journal-logos {
margin-left: 24px;
}
.header__wrapper.clearfix .col-xs-6:first-of-type {
width: 55%;
}
.header__wrapper.clearfix .col-xs-6:nth-of-type(2) {
width: 45%;
}
@media screen and (max-width: 1000px) {
.ux3 .journal-logos + .journal-logos {
display: none;
}
.header__wrapper.clearfix .col-xs-6:first-of-type {
width: 50%;
}
.header__wrapper.clearfix .col-xs-6:nth-of-type(2) {
width: 50%;
}
}
</style></div>

            

        

    

        


    

            

            

            <div data-widget-id="925de97c-bf89-4bb2-a76a-0aa0a54f3b18" data-widget-name="UX3HTMLWidget"><style>/* GLOBAL HEADER and SEARCH ROW: */

.ux3 .header,.ux3 .quick-search .dropBlock [data-db-target-of]::before{background:#002F5F !important}.ux3 .quick-search__button::before{color:#002F5F !important}.ux3 .quick-search__button:focus,.ux3 .quick-search__button:hover{opacity:.85}.ux3 .quick-search__button:focus,.ux3 .quick-search__button:hover{background:#fff!important}
/* ARTICLE PAGE */

.article-header .author__search i,.article-header .author__search:hover span,.article-header .content-navigation:not(.js--sticky) a:focus i,.article-header .content-navigation:not(.js--sticky) a:hover i,.article__body h1,.article__body h2,.article__body h3,.article__body h4,.article__body h5,.article__body h6,.content-navigation__body__top,.figure-viewer__thumbslist .current .thumbnail__label,table th{color:#002F5F !important}.left-side-nav li a.active,.left-side-nav li a.js--active,.left-side-nav li a:hover{color:#002F5F !important;border-left-color:#002F5F !important}.content-navigation.js--sticky a:focus,.content-navigation.js--sticky a:hover{background-color:#002F5F !important}.article-header__info__email,.figure-viewer__close,.left-side-nav__ctrl,.upsell-box__banner{background:#002F5F !important}.figure-viewer__thumbslist .current .thumbnail{border-color:#002F5F !important}.article-header__overlay{background:linear-gradient(100deg,#002347 0,#002F5F 50%, #003872 100%)!important}</style></div>

            

        

    

        

</div></div>

            
                </div>
            

        

        </div>
    

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget sessionValidationWidget none  widget-none" id="454875d4-cdd3-43d7-8792-9ad9208efb7a">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-none "><script>
    $.ajax({
        url: "https://www.annalsofoncology.org/ssoSessionCheck",
        type: "GET",
        dataType: "jsonp",
        success: function (data) {
            if(data.RefreshSession) {
                location.reload();
            }
        },
        error : function (){
            console.warn("can't validate CSAS session.");
        }
    });
</script></div>
                </div>
                </div>

        

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget csasSsoUrls none  widget-none" id="50d01d29-5810-433b-8bff-c2b88479f2e2">
                
                

                <div class="wrapped " >
                    
                    <div class="widget-body body body-none "><div id="sso-urls-div" class="hidden ssoUrls">
        
            <iframe src="//acw.secure.jbs.elsevierhealth.com/SSOCore/update?acw=6477b4aa466c274651085a994fd13dc49e24gxrqa%7C%24%7C9AADB002FACFF6D552C86E427B175217A6FAB6282328DF213440D0E00536B88D6F950066B6AC63C03D714CA753324812FBB89B04BC9E94D33FBA44D1BD4E4F2EB0469A67597464825D387A21AFA2E514&utt=9a32-db4ca2d8291e61ba035883158588de3f96-y"></iframe>
        
            <iframe src="//acw.sciencedirect.com/SSOCore/update?acw=6477b4aa466c274651085a994fd13dc49e24gxrqa%7C%24%7C9AADB002FACFF6D552C86E427B175217A6FAB6282328DF213440D0E00536B88D6F950066B6AC63C03D714CA753324812FBB89B04BC9E94D33FBA44D1BD4E4F2EB0469A67597464825D387A21AFA2E514&utt=9a32-db4ca2d8291e61ba035883158588de3f96-y"></iframe>
        
            <iframe src="//acw.elsevier.com/SSOCore/update?acw=6477b4aa466c274651085a994fd13dc49e24gxrqa%7C%24%7C9AADB002FACFF6D552C86E427B175217A6FAB6282328DF213440D0E00536B88D6F950066B6AC63C03D714CA753324812FBB89B04BC9E94D33FBA44D1BD4E4F2EB0469A67597464825D387A21AFA2E514&utt=9a32-db4ca2d8291e61ba035883158588de3f96-y"></iframe>
        
    </div>


<!-- clear SSO URLs after all iFrames are rendered or after passing a time out-->
<script>
    setTimeout(clearSsoUrlsFun,10000);
    var iFramesList = document.getElementById("sso-urls-div").getElementsByTagName("iframe");
    var renderedIFramesCount = 0;
    var numberOfIFrames = iFramesList.length;
    var skipRefresh = false;
    for (var i = 0; i < iFramesList.length; i++) {
        var iFrame = iFramesList[i];
        iFrame.addEventListener("load", function() {
            renderedIFramesCount = renderedIFramesCount + 1;
            if (renderedIFramesCount >= numberOfIFrames)
            {
                clearSsoUrlsFun();
            }
        });
    }

    function clearSsoUrlsFun() {
        if (skipRefresh == false && numberOfIFrames > 0)
        {
            skipRefresh = true;
            $.ajax({
                url: "https://www.annalsofoncology.org/action/clearSsoUrls",
                type: "GET",
                dataType: "jsonp",
                error : errorCallingAjx
            });
        }
    }

    function errorCallingAjx(){
        console.log("can't delete sso urls .")
    }
</script></div>
                </div>
                </div>

        

    

        


    

            

            

            <div data-widget-id="a2356e73-3e47-40ff-8279-67800fd4773d" data-widget-name="UX3HTMLWidget"><script>
// open society logos in new window
$(document).ready(function() {
$(".journal-logos:nth-of-type(2) a").attr("target","_blank");
});
</script></div>

            

        










        <div data-widget-def="ux3-layout-widget" data-widget-id="637fb9ce-735b-43bf-a200-c13296f28a9b" class="ux3">
        
    

        


    

            

            

            <div data-widget-id="637fb9ce-735b-43bf-a200-c13296f28a9b" data-widget-name="ux3-layout-widget"><div class="footer clearfix">
    

        


    

        


    

            

            

            <div data-widget-id="c7617e63-9788-4e9b-9592-37f0c6bf7ae0" data-widget-name="UX3HTMLWidget"><div class='footer__bottom text-onDark'>
	<ul id='footerSiteLinks'>
		<li class='footerLink'>
			<a href='/home'>Home</a>
		</li>
		<li class='footerLink'>
			<a href="/developing-countries">Access for Developing Countries</a>
		</li>		
		<li class='footerHeading'>Articles &amp; Issues</li>
		<li class='footerLink'>
			<a href='/current'>Current Issue</a>
		</li>
		<li class='footerLink'>
			<a href='/inpress'>Articles in Press</a>
		</li>
		<li class='footerLink'>
			<a href='/issues'>List of Issues</a>
		</li>
		<li class='footerLink'>
			<a href='/content/supplements'>Supplements</a>
		</li>
		<li class='footerHeading'>For Authors</li>
		<li class='footerLink'>
			<a href='https://www.elsevier.com/journals/annals-of-oncology/0923-7534/guide-for-authors' target='_blank'>Author Information</a>
		</li>
				<li class='footerLink'>
			<a href='/pb/assets/raw/Health%20Advance/journals/annonc/Editable_figures_Guide_For_Authors_final-version_V2-1611939338513.pdf' target='_blank'>Editable Figure Guidance</a>
		</li>
		<li class='footerLink'>
			<a href='https://www.elsevier.com/journals/annals-of-oncology/0923-7534/open-access-options' target='_blank'>About Open Access</a>
		</li>
		<li class='footerLink'>
			<a href='/content/permission'>Permissions</a>
		</li>
		<li class='footerLink'>
			<a href='https://www.researcheracademy.com' target='_blank'>Researcher Academy</a>
		</li>
		<li class='footerLink'>
			<a href='https://www.editorialmanager.com/annonc/default2.aspx' target='_blank'>Submit a Manuscript</a>
		</li>
		<li class='footerHeading'>Journal Information</li>
		<li class='footerLink'>
			<a href='/aims'>About the Journal</a>
		</li>
		<li class='footerLink'>
			<a href='https://www.elsevier.com/journals/annals-of-oncology/0923-7534/open-access-options' target='_blank'>About Open Access</a>
		</li>
		<li class='footerLink'>
			<a href='/contact-us'>Contact Us</a>
		</li>
		<li class='footerLink'>
			<a href='https://www.sciencedirect.com/journal/annals-of-oncology/about/editorial-board' target='_blank'>Editorial Board</a>
		</li>
		<li class='footerLink'>
			<a href='https://www.elsmediakits.com/specialty-audiences/oncologyhematology/annals-oncology/annonc/2023
 ' target='_blank'>Info for Advertisers</a>
		</li>
		
		<li class='footerLink'>
			<a href='http://reprints.elsevier.com/' target='_blank'>Reprints</a>
		</li>
		<li class='footerLink'>
			<a href='https://www.esmo.org/'>About ESMO</a>
		</li>
		<li class='footerHeading'>Related Publications</li>
		<li class='footerLink'>
			<a href='https://www.esmoopen.com' target='_blank'>ESMO Open</a>
		</li>
		<li class='footerLink'>
			<a href='https://www.esmoiotech.org/' target='_blank'>Immuno-Oncology Technology </a>
		</li>
		<li class='footerLink'>
			<a href='https://www.editorialmanager.com/annonc/default2.aspx' target="_blank">Submit Your Manuscript</a>
		</li>
		<li class='footerLink'>
			<a href='/content/editors_choices'>Editor's Choice</a>
		</li>
		<li class='footerLink'>
			<a href='/content/review'>Reviews</a>
		</li>
		<li class='footerLink'>
			<a href='/content/ESMO_clinical_practice_guidelines'>ESMO Guidelines</a>
		</li>
		<li class='footerLink'>
			<a href='https://researcheracademy.elsevier.com/career-path/career-guidance/mindfulness-researchers-approach-stress-relief-research-life-balance'>Researcher Academy</a>
		</li>
		<li class='footerLink'>
			<a href='/content/supplements'>Supplements</a>
		</li>
				<li class='footerLink'>
			<a href='/audio'>Podcasts</a>
		</li>
		
		<li class='footerHeading'>Follow Us</li>
				<li class='footerLink'>
					<a href='https://www.facebook.com/esmo.org/' target='_blank'>Facebook</a>
				</li>
				<li class='footerLink'>
					<a href='https://twitter.com/Annals_Oncology' target='_blank'>Twitter</a>
				</li>
				<li class='footerLink'>
					<a href='https://www.linkedin.com/company/european-society-for-medical-oncology' target='_blank'>Linkedin</a>
		</li>
						<li class='footerLink'>
							<a href='https://www.annalsofoncology.org/content/rss' target='_blank'>RSS Feed</a>
		</li>
	</ul>
</div>
<style>.footer__bottom a {text-decoration: none;color: #005789;} .footer__bottom a:hover {text-decoration: underline;} ul#footerSiteLinks {column-count: 5; list-style: none; margin-top: 2em; margin-right: 20px; margin-bottom:40px;} ul#footerSiteLinks li {margin-bottom: 20px; color: #505050; text-decoration: none; font-size: 14px; } ul#footerSiteLinks li.footerHeading {text-transform: uppercase; color: #63666a; font-weight: bold; font-size: 13px;} @media screen and (max-width: 1100px) { ul#footerSiteLinks {column-count:2;}} @media screen and (max-width: 550px) { ul#footerSiteLinks {column-count:1;}}</style></div>

            

        

    

        


    

            

            
                <div class="align-center copy-right">
            

            <div data-widget-id="0c47df72-dc53-47d6-a894-88946220b838" data-widget-name="UX3HTMLWidget"><style>
 
button#cookieBtn {
   text-decoration: none;
   background-color: transparent;
   color: #005789;
   font-weight: bold;
   padding: 0;
   margin: 0;
   font-size: 14px;
}
 
button#cookieBtn:hover {
   text-decoration: underline;
}

</style>
<script>
// HIDE ONETRUST BACKGROUND AFTER USER PRESSES ESCAPE KEY
setTimeout(function(){ 
   $("#onetrust-pc-sdk").on("keydown", function(e) { 
      if (e.keyCode == 27) {  // ESC key
         setTimeout(function(){ 
            $(".onetrust-pc-dark-filter").css("display","none");
         }, 100); 
      }
   });
}, 5000);
</script>




<hr/>
<p align="center"><b>The content on this site is intended for healthcare professionals.</b></p>
<hr/><br/>

<div class="es-footer-cookie">
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the 
      <b><button id="cookieBtn" class="ot-sdk-show-settings" type="button" aria-label="Manage cookie consent preferences">Cookie Settings</button></b> for this site.<br />
</div>

    <!--Copyright © 2024 Elsevier Inc. except certain content provided by third parties.-->
	All content on this site: Copyright © 2024 Elsevier Inc., its licensors, and contributors. <br/>All rights are reserved, including those for text and data mining, AI training, and similar technologies. <br/>For all open access content, the Creative Commons licensing terms apply.
<br /><br />

<ul class="rlist--inline">
    <li><a href="https://www.elsevier.com/legal/privacy-policy" target="_blank">Privacy Policy</a>&nbsp;&nbsp;</li>
    <li><a href="https://www.elsevier.com/legal/elsevier-website-terms-and-conditions" target="_blank">Terms and Conditions</a>&nbsp;&nbsp;</li>
    <li><a href="https://www.healthadvance.com/accessibility" target="_blank">Accessibility</a>&nbsp;&nbsp;</li>
    <li><a href="https://service.elsevier.com/app/overview/healthadvance/" target="_blank">Help &amp; Contact</a></li>

</ul>
<br>
<a href="https://www.relx.com"><img src="/pb/assets/raw/Health%20Advance/images/relx-1554393210983.png" alt="RELX" rel="nofollow" target="_new"></a>
<br>
<br></div>

            
                </div>
            

        

    

        


    

            

            

            <div data-widget-id="50c9dc39-d4fb-48f7-9891-1192d9d27bd3" data-widget-name="UX3HTMLWidget"><style>
    .ux3 .admin-tool-bar input{
        width: 15%;
        padding: 0;
    }
    .ux3 .admin-tool-bar [type=button]{
        padding: 5px;
    }
    .ux3 .footer .copy-right{
        padding: 0;
    }
    
</style></div>

            

        

    

        


    

            

            

            <div data-widget-id="3c9b021b-bfb2-4fcd-9711-c919a04ed2a6" data-widget-name="UX3HTMLWidget"><style>
    /*This was added temporarily until the PB changelog tab issue got fixed. [LIT-444969 - c#4]*/
    [data-tab-id="changelogTab"] {
        display: none !important;
    }
    
    /*This was added temporarily until the PB changelog tab issue got fixed. [LIT-518839]*/
    @media (min-width: 769px) {
        .ux3 .quick-search .dropBlock [data-db-target-of],
        .quick-search .dropBlock [data-db-target-of] {
            width: 100vw !important;
        }
    }
</style></div>

            

        
</div></div>

            

        

        </div>
    

    

        


    

            

            

            <div data-widget-id="77cf9626-56c1-43c4-965f-6c77d9b11e9d" data-widget-name="UX3HTMLWidget"><!-- RESERVED FOR THE SESSION TIME OUT CODE WHEN IT'S REINSTATED DO NOT REMOVE THIS WIDGET --></div>

            

        

    

        


    

            

            

            <div data-widget-id="01ea3c0a-522b-45b3-a8ae-409a6e2b6711" data-widget-name="UX3HTMLWidget"><style>
    .stickied div.inner-wrapper {
    z-index: 0;
}
</style>

<script>
// move Download Full Issue button
$(".core-header-aside .article-header__download-full-issue").detach().appendTo("header .meta-panel");
 
// hide the Download Full Issue popup
$(".meta-panel > div:not(:empty) > div").css("display","none");
 
// add CSS - mostly spacing
$("body").append("<style>.meta-panel__right {margin-right: 20px;} @media (max-width: 1179px) {.meta-panel .meta-panel__right {display: block;} .meta-panel .meta-panel__right + .article-header__download-full-issue button.btn--download-issue {margin-top: 9px; min-height: 32px !important;} .article-header__download-full-issue .download-full-issue > span {font-size: 14px;}} .article-header__download-full-issue .download-full-issue:focus, .article-header__download-full-issue .download-full-issue:hover {background-color: #727272;}</style>");

</script></div>

            

        
        </div>
    </div>


































    



















        
        
        
        
            
                <script src="/products/marlin/ha/releasedAssets/js/main.bundle-22f2cd8553b460991db2.js"></script>
            
        

    




<script type="text/javascript">
    var pageData =  {"journal":{"specialty":"Oncology","issn":"0923-7534","name":"Annals of Oncology"},"page":{"loadTimestamp":"1728945612546","server":"healthadvance.com","environment":"prod","businessUnit":"ELS:RAP:JBS","noTracking":"","name":"fulltext:html","section":"Other journal branded sites","language":"en","type":"CP-CA","productName":"JB"},"visitor":{"departmentName":"ae:Journal Branded Solutions - Guests|ae:ScienceDirect Guests","accessType":"ae:ANON_GUEST|ae:ANON_GUEST","accountId":"ae:375335|ae:228598","accountName":"ae:Journal Branded Solutions - Guests|ae:ScienceDirect Guests","departmentId":"ae:388406|ae:291352","ipAddress":"73.4.14.22","loginStatus":"anonymous","userId":"ae:19319093|ae:12975512"},"content":[{"accessType":"article:free:openarchive","volumeNumber":"26","viewState":"fulltext","format":"MIME-HTML","id":"pii:S0923753419471846","coverDate":"201509","type":"XOCS-JOURNAL:SCOPE-FULL","title":"Diffuse large Bcell lymphoma DLBCL ESMO Clinical Practice Guidelines for diagnosis treatment and followupsupx2020sup","status":"S300"}]};
</script>

<script type="text/javascript">
    if(typeof pageDataTracker !== "undefined") {
        pageDataTracker.trackPageLoad();
    }
</script>
<script defer src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon='{"rayId":"8d2b11d87d468ff0","serverTiming":{"name":{"cfExtPri":true,"cfL4":true,"cfSpeedBrain":true,"cfCacheStatus":true}},"version":"2024.10.1","token":"57a02315956f4b2e82817b3dfa99b1a2"}' crossorigin="anonymous"></script>
</body>
</html>
